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3. ABSTRACT 
Personalised Medicine has the potential to impact cancer prevention, diagnosis, 
treatment and prognosis. Today efficient, affordable and available early BRCA1/2 
screening techniques are now feasible and can provide results to inform treatment. 
However BRCA1/2 testing, undertaken close to cancer diagnosis, can represent an 
added burden for patients during a highly stressful time. This study aimed to 
investigate BRCA1/2 gene testing experiences and the impact these have on 
treatment decisions in women with hereditary breast cancer.  
In-depth interviews with 17 women explored genetic knowledge, test timing and 
impact of results on treatment choices. Secondary data analysis has been conducted 
using 5 interview recordings, obtained from a previous study. Inductive analysis, 
based on Grounded Theory, has been assisted by the Framework Approach. 
Comparative methods have produced rich qualitative data that illustrates diverse 
genetic testing experiences, opinions and treatment decisions.  
Personalised treatment to maximise survival was identified as a significant factor in 
patient support and uptake of early BRCA1/2 testing. Participants propose that ‘it 
makes sense’ to obtain early genetic information. Genetic status can be used to 
inform and assist ‘tailored treatment’ decisions, including risk-reducing interventions. 
 
 
Clinical progression towards early genetic testing to inform treatment for newly 
diagnosed hereditary breast cancer appears to be acceptable and feasible. The offer 
of a genetic test at the time of diagnosis is new in the field of cancer genetics, we 
need to optimise the way in which this technique is used to provide health advantage 
for patients and clinicians.  Future study should focus on the acceptability of the 
integration of personalised medicine techniques, within current clinical pathways.   
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4. INTRODUCTION  
Hereditary Breast Cancer & the BRCA Genes 
Breast cancer is the most common female cancer (Ferlay et al., 2013).  Excluding 
age, family history is one of the most significant factors in determining risk (Antoniou 
and Easton, 2006).  In a general population 1 in 450 people will carry a BRCA1/2 
mutation (CGHFBG, 2001); correspondingly between 5 and 10% of breast cancers 
are BRCA1/2 related (Claus et al., 1996). Typically these tumours are more invasive 
and respond less predictably than sporadic cancers, furthermore they are associated 
with a high recurrence risk (Shuen and Foulkes, 2011).   
BRCA mutations are the most common cause of hereditary breast cancer (Miki et al., 
1994, Wooster et al., 1995) and within a hereditary population women who present 
with breast cancer and an extensive family history will most probably have a BRCA 
mutation (Eccles and Pichert, 2005).  For these women, the option for early genetic 
testing is now clinically feasible with results available within 3 weeks to inform 
treatment (Wevers et al., 2014).   
The current research agenda requires evidence to improve hereditary cancer 
outcomes (Eccles et al., 2013, NICE, 2013b).  Early genetic testing, carried out close 
to diagnosis, can bring significant benefit; informing treatment and risk-reduction 
decisions to improve patient outcomes (Wevers et al., 2012a, Metcalfe et al., 2014).  
Closely related to this, a reduced threshold for predictive BRCA testing has been 
provided in the 2013 national clinical guidelines (SIGN, 2013, NICE, 2013b), 
however there is no current guidance for early testing.   
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BRCA1/2 testing undertaken close to the time of a cancer diagnosis can represent 
an added burden for patients during a highly stressful time (Wevers et al., 2012b).   
At the outset of this project, little was known of the hereditary breast cancer genetic 
testing patient experience.  Correspondingly this research study was developed, 
primarily to explore opinions about genetic testing. 
 
Study Overview 
This qualitative, in-depth interview study aimed to investigate BRCA1/2 gene testing 
experiences and the impact these have on treatment decisions in women with 
hereditary breast cancer.   Data has been obtained to represent the experience and 
opinions of 17 patients under the care of NHS Tayside Clinical Genetics Department.  
Grounded Theory has formed the basis for inductive analysis. Comparative 
techniques have been adopted to produce rich qualitative data that illustrates diverse 
genetic testing experiences, opinions and treatment decisions.  
 
Research Interest & Study Relevance 
My interest in hereditary breast cancer was captured in 2009 whilst working as a 
research nurse for Breast Cancer Campaign Tissue Bank. At this time I observed a 
situation that was evolving within the field of Breast Cancer and Clinical Genetics.  
The availability of new genetic technologies and techniques created the option for 
providing genetic information, for the highly penetrant BRCA1/2 genes, before 
starting targeted breast cancer treatment.   
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At the outset of this project, early genetic testing for women with a hereditary breast 
cancer diagnosis was rarely undertaken and while early testing remains relatively 
uncommon in 2015, it is becoming more usual.  It is anticipated, that for women with 
a hereditary breast cancer diagnosis, early testing to inform treatment will become 
routine practice. Subsequently this research study was conceived, to create 
understanding and develop theory relating to the patient experience of genetic 
testing in NHS Tayside.   
 
It is expected that the results of this research will assist Clinical Genetics and the 
extended Breast Care Team in NHS Tayside to develop evidence-based care for 
high risk breast cancer patients.  The study findings will be presented locally; 
national dissemination will occur by conference presentation1 and peer review 
publication. 
 
Thesis Structure  
This report aims firstly, in the literature review chapter, to define relevant theory and 
to answer questions relating to the main issues that surround early BRCA1/2 gene 
testing for the hereditary breast cancer patient.  Literature detailed throughout has 
been accessed during the project which spanned 5 years, and commenced in 2010.  
During this period the hereditary breast cancer and early genetic testing landscape 
have evolved considerably; furthermore the related clinical and technological 
advances have resulted in improved patient outcomes.  Literature obtained early in 
the project assisted the development of the research questions and the study aims 
and objectives.   
                                            
1 Abstract accepted for British Association of Cancer Research (Breast Cancer Conference) 2015. 
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Subsequent literature searches have provided further evidence for the clinical 
relevance and patient acceptance of early genetic testing. While this evidence has 
been used within the literature review chapter, to frame the main issues, these 
theory have not informed the data analysis or thematic development.  
However these later theory have been used deductively to corroborate the study 
findings, correspondingly they are included in the discussion chapter. 
 
The chapters that follow the literature review detail the study aims and objectives, 
methodology, including limitations, and ethical issues.  Additional information to 
assist the reader has been provided in footnotes and appendices, referenced 
throughout the report. The study findings chapter uses an abundance of verbatim 
quotations to illustrate participant opinion.  Findings are presented systematically 
using the 4 main analytic categories that evolved inductively from the data.  Each 
category is reported and begins with a summary of the key findings, thereafter detail 
is provided using the inductively developed sub-categories.  Reference to Figure 12: 
BRCA Test Topic, Analytic Categories & Sub-Categories (pg 124) is recommended 
to assist the reader’s progress through the study findings chapter. 
 
The discussion chapter presents the findings in accordance with the 5 study 
objectives, using associated headings. Published theory, including factors that 
influence patient decisions and opinions, are woven throughout discussion text.  In 
concluding, 5 key questions, relating to the study objectives, have been answered 
using theory derived from this data analysis.    
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5. LITERATURE REVIEW 
5.1 Why Offer Early Genetic Testing? 
Approximately 5-10% of breast cancers are caused by highly penetrant genes (Claus 
et al., 1996).  The biology and response of BRCA-related breast cancer differs from 
that of sporadic cancers (CGHFBG, 2001).  Tumours are often larger, more 
aggressive and response to conventional treatment less predictable (Shuen and 
Foulkes, 2011).   
 
The option to offer early genetic testing is today a clinically feasible option with 
results available within 3 weeks to inform treatment (Wevers et al., 2012b, Trainer et 
al., 2010b).  Personalised BRCA breast cancer treatment and risk-reduction 
interventions have been used with demonstrable improvements in patient outcomes 
and survival (Metcalfe et al., 2014, Narod et al., 2013, Cooper et al., 2013). 
 
Social, ethical and clinical debate have not slowed the molecular genetic 
technological advances that have resulted in efficient and affordable genetic 
screening techniques for BRCA1 and BRCA2, the results of which can be 
incorporated into increasingly personalised care (McGowan et al., 2014, Ginsburg 
and Willard, 2009). Early genetic testing, at the time of diagnosis, to inform and 
personalise treatment for women with breast cancer and relevant risk factors, such 
as a strong family history (Meiser et al., 2008) or a triple negative tumour (Robertson 
et al., 2012), is now a feasible option.  However the impacts for the patient group 
must be considered (Ardern-Jones et al., 2005, Wevers et al., 2012b).   
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Acceptability of Early Testing 
Recent evidence suggests that knowledge of BRCA1/2 gene mutation status at 
diagnosis can influence surgical and potentially, chemotherapy, radiotherapy and 
endocrine therapy choices for women with breast cancer (Weitzel, 2003, Haffty, 
2002, Schwartz, 2004, Pierce, 2000, Smith and Isaacs, 2011).  Current treatment 
pathways can provide increasingly personalised care for women with a BRCA1/2 
mutation, a mutation of uncertain significance or no mutation in the presence of 
hereditary breast cancer.  Thus genetic testing at the time of diagnosis is 
increasingly being considered as an option for and by these patients (Schwartz, 
2005, Francken et al., 2013, Smith and Isaacs, 2011, Euhus and Robinson, 2012). 
Regardless of this, concerns regarding the impact of genetic testing immediately 
post-diagnosis remain (Francken et al., 2013, Schwartz et al., 2005).   
 
The option for a BRCA1/2 genetic test, to establish hereditary or genetic nature of 
their cancer, does not come without significant psychological burden for patients and 
their families.  This is particularly relevant when testing is proposed at or close to 
cancer diagnosis, an already highly stressful time (Glanz, 1992, Wevers et al., 
2011b, Eijzenga, 2014, Bombard et al., 2014).  The decision to offer genetic testing 
at diagnosis is not an easy one.   
 
A study that focused on BRCA status for women with ovarian cancer reported that 
acceptance of treatment focused early genetic testing is based on the option to 
receive targeted cancer treatment (Meiser et al., 2012a).  Participants conveyed that 
this benefit outweighed perceived disadvantages.  Of significance, the women in a 
later study (Meiser et al., 2012b) also supported early testing, even if the only 
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purpose was to obtain genetic information for family benefit, including three 
participants who had no children.  Perceived advantages and disadvantages of 
treatment focused genetic testing are shown in Figure 1. 
 
Figure 1: Early Genetic Testing Patient Opinions 
 
 
Source / Adapted from (Meiser et al., 2012a) 
 
Despite concerns, patient and professional acceptance of early genetic testing is 
high (Burcher et al., 2013, Meiser et al., 2012b, Wevers et al., 2012b).    Acceptance 
is exemplified in the following quote regarding whether patients require time or 
assistance to consider the option of an early genetic test: 
(there is) “no decision to make” p156 (Meiser et al., 2012a). 
 
A study conducted in Australia concluded that women aged below 50 want to be 
informed about ‘Treatment-Focused Genetic Testing’ at or around the time of 
diagnosis, when treatments are being discussed and before a final decision is made.  
Advantages
Ease your mind
More information 
Better treatment 
options
Bigger picture for 
oncologist
Disadvantages
Dealing with 
results
Own cancer risk
Impact on 
relationships
Lifestyle decisions 
for family
Mixed 
Feelings About 
Results
Worry while 
waiting for results
Tackle results 
when they come
Bittersweet: relief 
and upset
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The primary reason for these women seeking genetic information is to guide initial 
cancer treatment and future risk management (Meiser et al., 2012b).  Similar findings 
are reported in a Dutch study (Wevers et al., 2012b); women state gaining certainty, 
about the risk of developing further breast cancer, is the prime reason for 
undertaking early genetic testing.  Associated with this is a desire to choose the most 
appropriate treatment to reduce future surgeries and cancer treatments.    
 
An earlier publication by Meiser (Meiser et al., 2012a) reported that post-diagnosis 
vulnerability increased patient acceptance of treatment focused early genetic testing.  
The possibility of obtaining information that will tailor treatment and improve survival 
is described as one of the highest priorities.  However at the time of diagnosis 
women may feel overwhelmed by a life-threatening diagnosis and treatment options 
(Meiser et al., 2012a).  A small number of patients chose to withdraw from early 
genetic testing for this reason (Watts et al., 2012).  To ensure that all high risk 
patients who meet early testing criteria are offered BRCA1/2 testing at a time that 
suits them Watts (2012) recommends a process that enables patients, who do not 
wish to proceed before primary cancer treatment, to receive a  genetics referral at a 
later date. Similarly, some women describe not wanting to wait for genetic results 
before having initial treatment, even when personalised treatment will be available 
very soon after receiving genetic results.   For these women delayed personalised 
treatment can follow initial cancer treatment (Wevers et al., 2012b). 
 
Information Delivery  
The method of delivering genetic test information to patients has been explored in a 
qualitative study (Meiser et al., 2012b).  The majority of participants wanted early 
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genetic testing to be discussed before cancer management decisions were made 
and some preferred genetic testing to be discussed at the time of diagnosis.  The 
following dialogue supports the option for integrating genetic testing with treatment 
planning: 
“at the start, as part of being diagnosed” E105 (Meiser et al., 2012a). 
 
In the study a range of healthcare professionals were proposed to introduce genetic 
testing, though no clear majority emerged from the more popular choices of surgeon, 
oncologist or breast care nurse (Meiser et al., 2012b).  Face-to-face consultation was 
the overwhelming preference for information delivery2.  This direct method allows for 
spontaneous questioning and a more personalised approach that enables a family 
member or close friend to support the patient.   
 
A prospective study is currently underway to further explore how to discuss early 
genetic testing (Watts et al., 2012).  The study aims to provide evidence for safe and 
effective clinical genetics care pathway, for treatment focused genetic testing 
especially for newly diagnosed younger women. 
 
                                            
2 Supplementary written information was viewed as essential by most participants MEISER, B., 
GLEESON, M., WATTS, K., PEATE, M., ZILLIACUS, E., BARLOW STEWART, K., SAUNDERS, C., 
MITCHELL, G. & KIRK, J. 2012b. Getting to the Point: What Women Newly Diagnosed With Breast 
Cancer Want to Know About Treatment-Focused Genetic Testing. Oncology nursing forum, 39, E101-
E111..  This allows patients to take in the information in their own time and consider questions.  
Different formats of written information have been proposed, either a leaflet, DVD or website with 
each containing the same information.  Some felt that the DVD or website were not required.  Most 
women were satisfied with a leaflet as a source of supplementary information.  Additionally most 
reported that the leaflet improved their understanding, particularly in relation to the purpose of early 
genetic testing. 
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Responses to Early Testing 
An early study of expedited genetic assessment proposed that treatment focused 
testing is indicated for high risk women who would consider risk-reducing mastectomy 
and oophorectomy (Meiser et al., 2008).  More recent studies have established that 
knowledge of carrier status before primary breast cancer treatment influences 
treatment choices (Wevers et al., 2012a), and suggest that women with newly 
diagnosed breast cancer benefit from the knowledge that they carry a BRCA mutation 
(Metcalfe et al., 2014).   
 
Confirmation of a BRCA1/2 mutation is predictive for establishing contralateral breast 
cancer risk and is of crucial importance when deciding whether contralateral 
prophylactic mastectomy is indicated (Rhiem et al., 2012, Graeser et al., 2009).  
Following rapid genetic testing and counselling Wevers et al (2012 & 2014) report an 
increasing trend in the uptake of bilateral mastectomies at the time of first surgery 
(Wevers et al., 2012b, Wevers et al., 2014).   
 
Bilateral mastectomy (Metcalfe et al., 2014) and personalised regimen using targeted 
adjuvant therapies (EBCTCG, 2011, Cooper et al., 2013, Shuen and Foulkes, 2011) 
are justified for women identified with a BRCA1/2 mutation.   Survival data for women 
with BRCA1/2 mutation supports the use of early genetic testing to establish status 
prior to exploiting the unique biology of BRCA-related tumours, with specific 
chemotherapy (Narod et al., 2013) and new adjuvant agents such as platinum based 
agents (Byrski et al., 2012) and adjuvant PARP inhibitors (Smith et al., 2014). 
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Personalised cancer treatments and strategies to stop future cancers are 
fundamental to the value of early genetic testing for women with a diagnosis and 
family history of breast cancer. 
 
5.2 Genetic Care: An Overview 
A High Risk Population 
The number of people with a mutation in either BRCA gene is small however the 
impact of a genetic fault for the individual, their family and health care is significant 
(Stratton, 1997, Chappuis et al., 1999).  Research has established that 
approximately 2 in 1,000 people carry a BRCA gene mutation (Antoniou et al., 2002) 
and it is estimated that 1 in 20 women diagnosed in the UK with breast cancer have 
a fault in either BRCA1 or BRCA2 (CancerResearchUK, 2012).   
 
These two highly penetrant single gene mutations confer a significant lifetime risk for 
developing breast cancer (Antoniou et al., 2002).  For women carrying a BRCA1 
gene mutation the lifetime risk for breast cancer is reported between 65 and 85% 
and estimates for BRCA2 vary between 40 and 85% (Antoniou et al., 2003).  
Importantly BRCA1/2 mutation carriers are more likely to develop early onset and 
bilateral breast cancer (Ford and Easton, 1995, Antoniou et al., 2003, Claus et al., 
1996). 
 
Personalising Medicine 
The consequences for individuals with BRCA gene mutations have resulted in these 
genes being the focus of substantial scrutiny and the development of molecular 
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techniques for identifying mutations.  The impact of a mutation in relation to patient 
outcome and survival is now understood (Nilsson et al., 2014). Current work and 
clinical guidelines are focusing on developing and providing personalised treatments 
(Couch et al., 2014, NICE, 2013a).  
 
The concept of personalised medicine3 has gained increasing global acceptance 
over the last two decades (Jackson and Chester, 2014, Couch et al., 2014, Daly, 
2004).  Whilst many governments, health care agencies and the public support a 
shift towards personalised medicine the accessibility, regulation, funding and 
education are challenges to overcome before progression can be made (Chan and 
Ginsburg, 2011, Weldon et al., 2012).  Fully personalised medical care requires an 
individual’s clinical, environmental, genetic and genomic information to inform 
medical decisions and tailor interventions; optimising disease prevention and 
treatment (Ginsburg and Willard, 2009). 
 
In the UK clinical genetics has evolved from a small peripheral clinical service to an 
established multi-disciplinary service (Bleiker et al., 1997, Meiser et al., 2008, Grant 
et al., 2006). However numerous challenges exist today for the NHS clinical genetics 
service, particularly related to the provision of genetic counselling and testing 
services for patients with cancer or a family history of cancer (Burns, 2009, Evans et 
al., 2014, Skirton et al., 2014). 
 
                                            
3 Personalized medicine uses individual genetic and environmental information to prevent, diagnose 
and treat disease. 
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Genetic information will have significant impacts for the individual and their family, 
triggering psychosocial, financial and direct health consequences.  Genetic and 
genomic tests cannot provide absolute predictions because a gene mutation alone 
cannot predict outcome; clinical interpretation that incorporates age and relevant 
lifestyle risk factors, and an understanding of test specificity and sensitivity is key 
when translating results and counselling patients (Hamburg and Collins, 2010, Gryn 
and Kim, 2014, O'Daniel et al., 2010).  
 
Personal genomic information is not currently available via the NHS and access to 
genetic testing is restricted to those patients with the greatest clinical need4.  The UK 
regulatory body, the Medicines and Healthcare Products Regulatory Agency (MHRA) 
and legal system provides protection to the British public from unscrupulous 
companies offering un-validated gene testing (HousesofParliment, 2012).   
 
While there are barriers and opposition from some religious groups, to advancing 
Personalised Medicine many patients are requesting personalised care which takes 
a holistic approach to physical and mental health (Cornetta and Brown, 2013).  The 
                                            
4 Direct-to-customer ancestry-related and un-interpreted raw genetic data is available from private 
companies such as 23andMe. ENNIS, C. 2012. Genetic screening: curiosity killed the CATG The 
Guardian, 11/10/2012.   
Previously 23andMe offered health-related genetic reports, their most popular service, until in 2013 
the American Food and Drug Administration (FDA) halted 23andMe from advertising and selling 
health-related reports.  The FDA accused the company of misleading customers: DNA test kits did not 
have proven reliability therefore false results could result in individuals seeking treatment for diseases 
they do not have.  Until the health-related DNA kit receives FDA approval as a medical device 
23andMe will not be able to offer such a service. FUNG, B. 2013. Bowing again to the FDA, 23andMe 
stops issuing health-related genetic reports. The Washington Post, 6/12/2013.   
Outwith the UK problems with un-regulated tests have resulted in unnecessary medical procedures 
and significant distress for patients. HAMBURG, M. A. & COLLINS, F. S. 2010. The Path to 
Personalized Medicine. New England Journal of Medicine, 363, 301-304.  
Myriad Genetics, another private Bio-technology company, continues to offer worldwide private 
genetic testing.  Myriad provide risk assessment and medical management recommendations for 8 
cancers including breast cancer however the provision of this service appears to be in conjunction 
with the patient’s physician. 
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psychology  and personal experience of seeking genetic information requires 
carefully planned intervention that assist patients to make decisions and understand 
emotional reactions (McDaniel, 2005).  Positive patient expectations, acceptance 
and willingness to receive and act on results are key to the future of personalised 
medicine (Cornetta and Brown, 2013).  
 
Recently it has been proposed that behavioural and psycho-cognitive aspects are 
added to the 4P approach to oncology medicine (Pravettoni and Gorini, 2011).  The 
4P approach aims to create Predictive, Personalised, Preventative and Participatory 
models for patient care (Hood and Friend, 2011).  This addition acknowledges the 
psychological impact of Personalised Medicine and is proposed with the aim of 
empowering the patient, a move from passive recipient to active decision maker.   It 
is anticipated that the addition of a behavioural component    yielded from 
personalised medicine has the potential to impact disease prevention, diagnosis, 
prognosis and treatments (Song et al., 2011, Jackson and Chester, 2014, Chan and 
Ginsburg, 2011). Table 1 details the proposed opportunities following complete 
adoption and integration of personalised medicine (PersonalizedMedicineCoalition, 
2014).  However the addition of lifestyle assessments and interventions will further 
impact disease and patient outcomes (Howell et al., 2014). 
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Table 1: The Potentials for Personalised Medicine  
Opportunity Example 
Shift emphasis in medicine from reaction to 
prevention 
Molecular markers to define disease risk or 
presence before clinical symptoms e.g. BRCA1 
gene detection with subsequent prophylactic 
surgery or increased screening and 
chemoprevention. 
Direct the selection of optimal therapy and 
reduce trial-and-error prescribing 
Individual response to drugs varies due to 
genetic variation in enzymes or 
presence/absence of cell receptors e.g.  HER2 
receptors present in breast tumour tissue, 
instigate Herceptin therapy with the aim of 
reducing tumour recurrence. 
Help avoid adverse drug reactions Genetic variations in drug-metabolising 
enzymes can cause slow elimination and toxicity 
with effects ranging from unpleasant to fatal e.g. 
warfarin anticoagulant therapy. 
Increase patient adherence to treatment Effective treatment with few side effects or 
confirmed genetic risk for a conditions will 
incentivise therapy compliance. 
Improve quality of life Blood test for molecular marker to replace 
invasive diagnostic procedures e.g. lung cancer. 
Reveal additional or alternative uses for 
medicines and drug candidates 
Genetically defined patient population 
responses e.g. specific genetic mutation. 
Help control the overall cost of health care  Target treatment to reduce costs e.g. early 
cancer diagnosis saving adjuvant 
chemotherapy, adverse event management and 
supportive care costs. 
Source / Adapted from (PersonalizedMedicineCoalition, 2014) 
 
The Personalised Medicine debate is acutely focused on highly penetrant genetic 
disorders (Jackson and Chester, 2014) and Genome-wide association studies 
(Lenfant, 2013) because it is within this area that the greatest benefit for the 
individual and healthcare can be realised.  High penetrance confers a high lifetime 
risk for developing a condition5.   The risk for individuals with these genetic mutations 
is rarely amplified by environmental or lifestyle factors and for the majority of these 
                                            
5 A disorder with 95% penetrance will affect 95% of individuals who have the mutation, i.e. the 
affected population will have a 95% chance of developing the disorder. 
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conditions the impact of the disorder is significant.  Conversely low penetrance 
genes confer a low risk for developing the disease and risk is augmented with 
exposure to environmental factors (Shields and Harris, 2000)6.   The highly penetrant 
BRCA1/2 genes have helped to facilitate research that aims to identify genomic 
information can be utilised for optimum patient benefit (Couch et al., 2014).  Within 
the high penetrance paradigm genetic information identifies patients who will benefit 
from more intense screening and prevention therapies, including targeted 
treatments.   
 
A 2010 publication (O'Daniel et al., 2010) reported results of a study that examined 
the opinions of experienced genetics health care professionals in relation to genomic 
testing, its apparent value, psychosocial impact and effect upon health behaviours.  
Fourteen participants undertook genomic testing, interviews and surveys.  Motivation 
to (participate in the study and) acquire individual genomic information differed from 
a general population: professional curiosity and interest were reported by most 
participants and not a need to change unhealthy behaviours.  Good health 
behaviours with a small ‘margin for improvement’ (p397) were reported. A small 
proportion of first responses to the personal genomic information were light-hearted 
with ‘science nerd’ (p392) qualities although the majority were positive and regarded 
the results as interesting however they did not indicate that the information was 
needed for health decisions.  
 
                                            
6 Using an example of sporadic lung cancer: cancer risk for low-penetrance genes, such as p53, is 
increased with exposure to carcinogens (e.g. tobacco). 
SHIELDS, P. G. & HARRIS, C. C. 2000. Cancer Risk and Low-Penetrance Susceptibility Genes in 
Gene-Environment Interactions. Journal of Clinical Oncology, 18, 2309-2315. 
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Participants’ perceived risk for disease both before and after the test was based 
upon family history; only 2 participants reported that genomic information influenced 
health risks after receiving results.  The researchers in the O’Daniel study (2010) 
conclude that low risk results explain the low importance or impact of the results.   
 
Genetic testing differs from genomic testing, it provides single gene information while 
genomics provide gene-wide or complete DNA sequence results.  One participant 
confirmed that their health risk perception would change had single gene testing 
revealed a positive result.  Corresponding health behaviour including information 
seeking was largely unchanged 3 months after receiving results, despite the majority 
of participants indicating pre-test that they may change health behaviour.    The 
majority of participants report and the authors of the O’Daniel publication (2010) 
conclude that genomics will have more importance and significant potential in the 
future.   While the characteristics of the participant group differ from a general 
population these findings are valid and assist understanding the value and health 
impacts of genetic and genomic information.  
 
Individual Responses to Personalised Medicine 
An individual’s perceived risk of developing a disease and not scientific risk 
influences their behaviour, decision-making and emotional response (Lerman et al., 
2002).  From an individuals’ first thought about obtaining genetic information, to their 
response to the results and proposed risk management interventions, the individual 
will require to make potentially life changing decisions (Finch et al., 2013, DeFrank et 
al., 2013).   
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The spectrum of diseases for which genetic testing is available ranges from 
progressive conditions, with no available treatment, to conditions for which 
preventative treatment can remove most of the risk for developing the disease.   
The psychology of genetic disease is recognised. McDaniel (McDaniel, 2005) reports 
that the experience begins with knowledge of the inherited condition within a family 
and that the testing experience is based in the meaning of the condition, or the 
individual’s response to the genetic test results.   
 
The decision to proceed with genetic testing is complex and emotionally laden.  The 
individual’s experience of caring for or loosing close family members, as a result of 
the condition for which genetic testing is under consideration, may further compound 
the psychosocial impact of decision making.  A recently published review of 
psychosocial reactions to predictive genetic test results indicates three areas of 
impact:  
 altered social relationships 
 important life decisions such as career 
 reproductive choices and self-concept (Grubs et al., 2014).   
These authors however provide reassurance that negative consequences, for 
example severe depression impacting on all aspects of life, for the participants were 
not as severe as initially predicted.  Graceffa and colleagues (Graceffa et al., 2009) 
caution against genetic testing without psychological support for individuals who 
have specific psychological traits, such as prior mental health problems. 
Genetic identification of an individuals’ risk for developing a condition or disease may 
create potential isolation, stigma and exclusion impacting for a wide range of social 
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relationships ranging from employer, financial institutions and companies, health 
care professionals, family members and spouse / future spouse.   
 
Stigma and isolation have particular relevance in the case of highly penetrant defects 
which confer a significant lifetime risk for developing the condition, such as BRCA1 
which confers up to an 80% lifetime risk.  Furthermore an individual may be looked 
upon or treated as if they have developed the disease, or that their destiny is to even 
develop the disease when gene penetrance or the risk of developing the condition is 
not understood (Novas and Rose, 2000)7.  An example highlighting such difficulties 
is described by Kitzman and Sweeny; sensitive genetic information may not be 
communicated to a potential partner; with fear of rejection or previous personal 
experience are cited as reasons for non-disclosure  (Klitzman and Sweeney, 2011)8. 
 
Diverse family relationships will be impacted by the knowledge of a genetic condition 
and in relation to genetic inheritance past and future.  Contribution to another 
individual’s risk for developing a disease affects relationships between parents, 
                                            
7 Consider Huntington’s Disease: the individual identified as a carrier and would not be expected to 
develop the disease however an insurer may decline to provide life insurance because they do not 
appreciate the individual has a very low risk for developing the disease. Conversely a highly penetrant 
BRCA defect:  where a woman who has received breast cancer specific genetic information then 
undertakes risk reducing bilateral mastectomy surgery to minimise her chance of developing breast 
cancer has arguably increased her lifespan however suffers social stigma associated with 
mastectomy. 
   
8 Outwith the scope of this project but worth a brief mention are the following social impacts that relate 
to molecular genetics: 
 The growing belief that many ‘undesirable conditions’ have a basis in a genetic mutation.  
This psychosocial impact may create added stress for an individual undertaking genetic 
testing or following the receipt of results that confirm the presence of a mutation.  On a more 
positive note it is however often easier to gain research funding for ‘undesirable’ diseases  
 Does genetic information reduce the individual to cellular matter?  This question relates to 
human identity or the notion of being human, a personal and global level 
 Governance for molecular genetic science to ensure that individuals are protected, for 
example to ensure that inadvertent identification of genetic mutation through diagnostic 
screening tests does not occur. 
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siblings, partners and children (MacDonald et al., 2010, McDaniel, 2005).  
MacDonald (2010) explores the impact on family relationships citing the potential for 
genetic information to sub-divide families.  Conversely the family social network may 
be enhanced, in response to genetic counselling and the identification of new family 
members, or the current family structure may be enriched in respect of new found 
genetic inheritance (Novas and Rose, 2000).   
 
Graceffa et al (2009) relates coping mechanisms used during the pre-symptomatic 
genetic test process with psychological mechanisms used by individuals during Post 
Traumatic Stress Disorder.  The use of avoidance, in order to prevent thoughts about 
the disease was used by a high proportion of participants in their study, particularly 
before test results were received.  Avoidance affects relationships when the 
individual avoids close emotional relationships.  Emotional numbness, a symptom of 
avoidance, will be characterised by the individual performing routine activities that 
require little engagement.  Later when thinking about the testing process, flashbacks 
may occur when the individual may be flooded with emotion or correspondingly they 
may be incapable of feeling or expressing the emotions relating to their 
psychological response to genetic testing (Graceffa et al., 2009).  These authors 
report depression as a common response to unresolved emotional pain.  Extreme 
psychosocial responses were only reported by female participants.   
 
Emotional responses including anger, sadness and guilt are recognised reactions to 
carrying and passing a genetic mutation to family members (McDaniel, 2005).   
Depression and anxiety following positive results can be related to guilt and concern 
for family members (Graceffa et al., 2009). Regardless of cause depression and 
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anxiety will affect an individual’s quality of life.  Graceffa (2009) reports a negative 
impact on general well-being following positive genetic test results.  Furthermore the 
authors propose that loss of social functioning and reduced self-esteem, may be in 
response to fear of disease or becoming a burden for the family. 
 
Psychological response to a negative results include regret about not living life to the 
full while living with a high risk of developing an inherited disease (McDaniel, 2005).  
This is frequently likened to ‘Survivor guilt’ (Valverde, 2006, McDaniel, 2005, 
Graceffa et al., 2009, Cummings, 2000).  Survivor guilt in this context is a 
psychological reaction that occurs in response to the confirmation that an individual 
does not carry a genetic mutation, while other family members are affected.  This 
guilt can relate to relief or joy, that is felt when results are revealed or later when the 
individual feels a new sense of freedom, then subsequently has to deal with the 
reality of a disease that affects other family members (Graceffa et al., 2009).   
 
Psychological support is recommended both before and long-term after genetics 
testing, irrespective of the result (Graceffa et al., 2009).  Efforts have been made to 
predict outcomes to genetic testing, with complex pre- and post-test assessment  
and counselling in use for Huntington’s Disease (Grubs et al., 2014), to ensure that 
individuals are fully informed about testing and receiving their results.  
 
In the last 10 years a multi-disciplinary team in Wales have conducted several 
studies that revealed the psychological and emotional responses to cancer genetic-
specific information.  In response to the findings they developed a measure of coping 
tool: GRACE (Phelps et al., 2010).  The tool acknowledges 2 main coping styles (as 
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reported by Miller (Miller, 1995) although terminology differs) and is based on 11 
areas of concern or stress and 8 coping strategies, that were identified in their earlier 
work, these are presented in Table 2.  These stressors and coping strategies are 
commonly reported across genetic testing (regardless of clinical area / indication) 
and psychological support text (Graceffa et al., 2009, Dougall et al., 2009, Smith et 
al., 2008).    
 
Table 2: GRACE Tool Stressors & Coping Strategies 
11 Stressors 8 Coping Strategies & Examples 
Not understanding the risk assessment process Acceptance: Accepted nothing I can do 
Having to wait to find out my risk Distraction: Did things to take my mind off it 
Completing the Family History Questionnaire Positive appraisal: Focused on the positive 
aspects 
Asking family members about cancer in the 
family 
Planning: Made and followed a plan of action 
How I would cope if found to be at increased 
risk 
Information seeking: Searched for more 
information about it 
How family members would react if found to be 
at increased risk 
Social support: Sought support from family and / 
or friends 
Being eligible for genetic testing Emotional expression: Talked or wrote about it / 
what I felt 
Possible decisions about surgery Role model: Though of positive role models 
Being able to get increased screening  
The impact on my lifestyle if found to be at 
increased risk 
 
The implications for family members if at 
increased risk 
 
Source / Adapted from (Phelps et al., 2010, Bennett et al., 2012) 
 
The team have recently presented the results of a randomised study, that used the 
tool to explore patients concerns and coping before and during cancer genetic risk 
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assessment (Bennett et al., 2012)9.  The greatest concern for participants was future 
consequences of being at high risk, both on a personal and family level.  A range of 
coping strategies were reported for each concern however all strategies were 
employed in response to all concerns at baseline and 1 month follow-up.  Emotional 
strategies (positive appraisal, acceptance, social support) were used most often 
during the risk assessment period, when the patient waited and little could be done 
to change the concerns. The authors propose that genetic counsellors use the 
GRACE tool to focus counselling.   
 
Genetic mutations alone do not predict disease outcomes. To quote one Harvard 
psychology professor “actual outcome depends on a tangle of other circumstances” 
(paragraph 14) (Pinker, 2009).  The majority of ‘other circumstances’ are arguably 
health behaviours and these are the source of much debate.  Increasing availability 
of genetic information, through single gene or genome testing, can provide 
individuals with disease susceptibility knowledge however positive health behaviours 
are required to moderate future health-problems.   
 
Much of the early patient research relating to the psychological aspects of single 
gene testing has been carried out with the hereditary breast and ovarian cancer, 
hereditary colon cancer and Huntington’s Disease populations. However research 
with a specific health behaviour focus is primarily focused on hereditary cancer 
populations, where positive lifestyle change can alter risk for developing disease 
(Beery and Williams, 2007).   Publications in 2010 and 2012 reinforce the findings in 
                                            
9 In using the Grace Tool the patient scores their frequency of worry from 0 (not at all) to 3 (very much 
so) for each of the worries then indicates which of the coping strategies they have used (either done 
or thought about) for each.   
36 
Beery and Williams earlier systematic review and make the observations, that where 
genetic information confirms a low risk for developing the condition of interest health 
behaviour will be largely unchanged, and correspondingly, where risk is high positive 
health behaviours will be adopted (McBride et al., 2012, McBride et al., 2010).   
These findings relate primarily to screening behaviours for highly penetrant genetic 
conditions and not to exposure health behaviours (e.g. smoking, exercise, healthy 
diet) which have limited effect on development of highly penetrant disease. 
Irrespective of the study population, research shows, a wide variation in health 
behaviour change in response to personalised genetic and genomic information 
(Schneider and Schmidtke, 2014). Within the global population the most common 
causes of ill health and mortality are related to unhealthy behaviours such as 
smoking, high alcohol consumption, over-eating and under exercising.  Within 
populations with a genetic mutation that confers an increased risk for disease, the 
complex interaction of such unhealthy behaviours further compound individual risk 
(Boyle, 2012, Guinan et al., 2013b, Bao et al., 2013, Hu, 2011). 
 
Nevertheless, the previous 20 year increase, current and projected rise in breast 
cancer incidence is not unexpected (Howell et al., 2014).  Healthy lifestyle choices in 
the three key areas (weight control, regular exercise and modest alcohol intake) 
could cut breast cancer risk by approximately 30% (Howell et al., 2014).  Exposure 
to these and other modern lifestyle risk factors may be attributed to the increase in 
breast cancer risk found in high risk families: in a UK study population women born 
after 1960 had a 40% risk for breast cancer by age 40 while those born in 1940 had 
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a 22% risk by age 40 compared to only 8% in the group born before 1930 (Evans et 
al., 2008)10.   
 
One investigation, that presented participants with hypothetical genetically-linked 
disorders, reported a higher risk for developing a disorder correlated with greater 
intention to adopt recommended health behaviours. However there was no evidence 
to suggest the genetic information is a stronger motivator than family-history based 
risk information (Hicken and Tucker, 2002).  Expectations that genetic information 
will motivate positive health behaviours have been explored for several decades. 
Reports suggest that genetic risk information, may be the least useful health risk 
information, when health behaviour change is required (Marteau and Weinman, 
2006).    
  
The potential use of genetic testing as a motivational tool within complex diseases 
has been studied using the paradigm of smoking cessation (Sanderson and Wardle, 
2005).  This study reported that 65% of participants would be motivated to stop 
smoking following the receipt of a positive genetic test result however 39% would be 
discouraged to stop should they receive a negative result.  Similar findings have 
been reported in hereditary breast and ovarian cancer studies with patients 
undertaking prophylactic surgery in response to positive BRCA genetic test results 
(Tercyak et al., 2007, Schwartz et al., 2003, Watson et al., 2004). 
 
                                            
10 The authors report similar parity and age of onset for menarche and menopause across the age 
groups.  
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The previously described work of O’Daniel et al  (O'Daniel et al., 2010) reported 
minimal change to lifestyle or health behaviours in response to genetic information 
however the research population, genetic health care professionals, differs 
considerably from a general patient population.  There is concern that genetic risk 
information may discourage positive health behaviours  (McBride et al., 2010, Grant 
et al., 2011, Graves et al., 2014, McBride et al., 2012) and this is particularly relevant 
when considering direct-to-consumer genetic testing (Bloss et al., 2011), for example 
when results indicate a low risk for cardiovascular disease and subsequently 
motivation to adopt a healthy diet or stop smoking is decreased.  A modest 27% 
change in health behaviour is reported in a study that investigated health behaviour 
and anxiety in a direct-to-customer genetic test population (Egglestone et al., 2013).   
Personalised genetic information and kinship networks have been proposed to  
encourage health behaviour change (McBride et al., 2010).  Exploitation of familial 
networks may increase the motivating effect of genetic information, while shared risk 
and peer pressure can promote continued focus. 
 
The ethical issues that relate to gene testing have a long history and are far-
reaching.   Much of the early debate relates to predictive testing for hereditary adult-
onset disease such as Hereditary Breast and Ovarian Cancer (HBOC), 
Cardiomyopathy and Huntington’s Disease (HD).  When consideration is given to 
genetic testing, often for healthy, individuals who have a family history of adult onset 
disease the ethical debate encompasses much of the lifespan. Individuals who carry 
a gene mutation that predisposes them to adult onset disease have concerns about 
passing the mutation to their children, this is particularly so with an autosomal 
dominant pattern of inheritance, for example HBOC or HD, where each child has a 
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50% chance of inheriting the mutation (Donnelly et al., 2013, Decruyenaere et al., 
2007).   Child bearing decision making is one of the frequently cited reasons for 
undertaking genetic testing for hereditary cancer (Pasacreta, 2003). Questionnaire 
studies that explore reproductive decisions report between 12% (HBOC) and 35% 
(HD) participants choosing not to have children in response to their confirmation of a 
genetic mutation that conferred a high risk for adult onset disease (Fortuny et al., 
2009, Decruyenaere et al., 2007).    
 
Disclosure of information, to relatives, that creates worry causes ethical discord, for 
example cancer risks (Hallowell et al., 2003).  The study participants described 
experiencing conflict, associated with their responsibility to care for family members, 
when the genetic information would be portrayed (by or for the relative) as a new or 
increased health risk.   Not talking about the result to avoid upset for the family 
member, has been described as increasing isolation for the individual with the gene 
mutation (Foster et al., 2004), and negative health implications may result when a 
family member is not informed of their potential genetic risk (Pho et al., 2000).  
Appropriate health screening and prophylactic choices that are available to at risk 
individuals may not be considered or available when the risk is unknown.  
 
Moral and ethical considerations relating to informing a relative of risk, when the 
individual tested has no contact or when privacy for the individual tested is 
requested, will have psychological impacts for the individual tested, the family and 
the geneticist or genetic counsellor. Decisions about revealing genetic information to 
family members are described in a qualitative interview study of 37 individuals and 
19 partners, facing HBOC and HD (Forrest et al., 2003).  Disclosure was identified 
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as difficult for some participants.  There main difficulties are identified, these are 
presented in Figure 2. Many participants identify that the family are responsible for 
informing relatives about a potential genetic risk.  However health care professionals 
are thought by some to legitimise or back-up uncertain risk information.  It is notable 
that regardless of who in the family receives the genetic information the majority 
assume the role of informing children of potential risk is primarily that of the parents.  
Difficulties may arise when informing a niece or nephew. 
 
Figure 2: Genetic Disclosure Difficulties 
 
 
Source / Adapted from (Forrest et al., 2003) 
 
Disclosure is considered a process, and not a single, act with two styles: 
‘pragmatism’ and ‘prevarication’ (pg 321) (Forrest et al., 2003). Pragmatic individuals 
take an active and practical approaches. Prevaricators search for normal ‘family life’ 
opportunities where ‘the right moment’ is identified for disclosure (pg 321); this can 
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take a long time.  Problems may arise when both styles of disclosure exist within the 
family and one member may feel rushed into sharing the information. 
 
The best time to tell is presented when the first important disease-related life 
decision needs to be made, for example when a child forms a serious relationship / 
considering having children or when cancer screening / prophylactic intervention can 
start.  Another key time identified is when a child is considered old enough to 
understand the information (e.g. early teenage years).  The authors acknowledge 
that genetic health care requires understanding of subtle family issues, to assist 
people to come to terms with the emotional and ethical issues relating to a genetic 
disorder (Novas and Rose, 2000).  
 
Personalised Medicine Challenges 
Personalised Medicine approaches are being integrated within oncology. Ethical and 
social challenges, of oncology specific personalised medicine, have recently been 
published in a study that explored the perspectives of 117 institutional and 
professional stakeholders. This research report, by McGowan et al (2014), 
demonstrates recent integration and discusses the associated ethical challenges.  
The authors conclude with 4 significant ethical concerns (displayed in Figure 3). 
McGowan focuses on targeted oncology therapies and healthcare costs for up-
scaling pharmacogenomic testing.  While these concerns exist currently within the 
oncology paradigm the authors propose they will extend into new clinical areas, as 
PM approaches evolve and integrate (McGowan et al., 2014).  
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Figure 3: Personalised Medicine - the Ethical & Social Concerns  
Source / Adapted from (McGowan et al., 2014) 
 
A more recent review of ethical, legal and social challenges (Joly et al., 2014) 
expanded the McGowan et al (2014) findings to provide patient safeguards.  Key 
challenges include: 
1. Protection for individuals and sub-populations to ensure that they are not 
discriminated against 
2. Emerging healthcare roles 
3. Clinical translation of results and therapies 
4. Direct-to-consumer testing. 
Similarly a manuscript published in 2013 identifies additional obstacles for 
personalised medicine and makes recommendations, these are detailed in Figure 4.  
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Figure 4: Recommendations for Personalised Medicine 
 
Source / Adapted from  (Cohen, 2013) 
 
A study that explored patient and staff perceptions of privacy and equality during 
diagnostic genetic testing revealed differing patient and staff opinions. The authors 
concluded that genetics staff require additional ethics training, and that counselling 
should consider the patient from a global perspective (Nyrhinen et al., 2007)11.  
                                            
11 UK confidentiality laws forbid doctors from disclosing genetic test results to other interested parties, 
this includes relatives.  The responsibility for communicating genetic information, to potentially 
affected family members, lies with the individual tested.  HALLOWELL, N., FOSTER, C., EELES, R., 
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Clinicians are responsible for the identification of suitable patients for gene testing, 
however this role requires knowledge and patient advocacy skills when gene testing 
is challenged, for example due to resource allocation.   Additionally advocacy will be 
required where barriers to care provision result, for example within personalised 
medicine gene specific drug treatment is frequently more costly than standard care 
however patient benefit is also greater.  Collaboration and teamwork with associated 
clinical specialities are crucial to the success of the genetics.  It is essential that 
these colleagues support and acknowledge the evolving role of the genetics for 
patient care benefit. 
 
The provision of emotional support, risk information and risk reduction treatments are 
frequently a source of ethical dilemma for health care professionals (Burke and Press, 
2006).  A survey of genetic service health care professionals revealed the most 
common ethical problems correspond to patient’s emotional reactions, informed 
consent, uncertain test results and limited resources (Abad-Perotín et al., 2012).  The 
clinician shares the patient’s burden to ensure autonomy and informed choice are 
provided for the patient and at risk members of the family.   Reassuringly these authors 
report that such ethical dilemmas occur very infrequently.   
                                            
ARDERN-JONES, A., MURDAY, V. & WATSON, M. 2003. Balancing autonomy and responsibility: the 
ethics of generating and disclosing genetic information. Journal Of Medical Ethics, 29, 74-79. 
The General Medical Council (GMC) acknowledges that some patients may refuse to share genetic 
information and recognises that in exceptional cases disclosure, that where possible does not identify 
the index patient, may be justified. GENERALMEDICALCOUNCIL. 2009. Confidentiality guidance: 
Genetic and other shared information [Online]. London: GMC. Available: http://www.gmc-
uk.org/guidance/ethical_guidance/confidentiality_67_69_genetic_and_other_shared_information.asp 
[Accessed 11/02/15 2015].   
These exceptional cases must be weigh-up potential harm both to the patient and patient–doctor 
relationship from disclosing the index patient’s information and that caused by non-disclosure to the 
relative.  The role of the genetics health care professional extends to adopting a proactive stance to 
support individuals to share genetic information with relatives. At times this role will include facilitation 
of family communication however the principles of privacy and autonomy should not be compromised. 
SUTHERS, G. K., ARMSTRONG, J., MCCORMACK, J. & TROTT, D. 2006. Letting the family know: 
balancing ethics and effectiveness when notifying relatives about genetic testing for a familial 
disorder. Journal Of Medical Genetics, 43, 665-670. 
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5.3 Breast Cancer & Genetics: The Size of the Problem 
Excluding age, family history or genetic inheritance is one of the most fundamental 
factors in determining breast cancer risk  (Antoniou and Easton, 2006).   
Approximately 5-10% of all breast cancers are associated with a hereditary 
predisposition (Lynch et al., 1984, Claus et al., 1996).     
 
A Case for Breast Cancer Genetics 
BRCA1/2 mutations occur in around 2 in 1000 of the general population (ABCSG, 
2000)12.  This incidence is confirmed by a large scale re-analysis study that included 
52 epidemiological studies and just under 15,000 patients.  This study reported just 
over 0.1% of the general population or 1 in 450 women carry a fault in either the 
BRCA1 or BRCA2 gene (CGHFBG, 2001).   
 
Reports, previous and current, estimate that mutations in the two highly penetrant 
BRCA genes, account for between 5 and 10% of breast cancer in the general 
population (Kiberstis and Roberts, 2014, Claus et al., 1996).  The variations in these 
estimations indicate that additional genes (Couch et al., 2014, Shuen and Foulkes, 
2011, Smith et al., 2006b, Begg et al., 2008, Ponder et al., 2005)13 and modifiable 
                                            
12 Breast cancer incidence supplementary information is provided in Appendix A.  
 
13 The identified breast cancer susceptibility genes are categorised into three groups:  
 high-penetrance alleles e.g. BRCA1, BRCA2 and TP53  
 rare medium-penetrance alleles e.g. CHEK2 and ATM 
 common low-penetrance alleles e.g. FGFR2 and TOX 
WOOSTER, R. 1995. Identification of the breast cancer susceptibility gene BRCA2. Nature, 378, 789, 
MIKI, Y. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. 
Science, 266, 66, WALSH, T., CASADEI, S., COATS, K. H., SWISHER, E., STRAY, S. M., HIGGINS, 
J., ROACH, K. C., MANDELL, J., LEE, M. K., CIERNIKOVA, S., FORETOVA, L., SOUCEK, P. & 
KING, M.-C. 2006. Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High 
Risk of Breast Cancer. JAMA: The Journal of the American Medical Association, 295, 1379-1388, 
STRATTON, M. R. & RAHMAN, N. 2008. The emerging landscape of breast cancer susceptibility. Nat 
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lifestyle factors may be involved (King et al., 2003, Nkondjock and Ghadirian, 2004, 
Guinan et al., 2013a, Colditz and Bohlke, 2014). 
 
Individuals with an affected first-degree relative (i.e. mother or sister) have a two-to 
threefold increased risk of developing breast cancer over the general population 
(Malone et al., 1998, Kerlikowske et al., 1992, Pharoah et al., 1997), this risk further 
increases where two or more relatives have been affected and where the relative 
was diagnosed below age 50 (CGHFBG, 2001).    Up to 15% of invasive breast 
cancer is diagnosed in women with at least 1 first-degree relative (mother, sister or 
daughter) who has / had breast cancer (Møller et al., 2007).  
 
 Approximately 80% of patients with familial breast cancer do not have BRCA1/2 
gene mutations (Thompson and Easton, 2004). Estimates do however vary, Moller  
reports that family history investigation exposes fewer than 50% of BRCA1/2 
mutation carriers (Møller et al., 2007) while other investigations state that the 
presence of mutations in the BRCA1/2 genes, account for between 10-40% of 
hereditary breast cancer (Walsh et al., 2006, Shuen and Foulkes, 2011, Antoniou et 
al., 2003).  Given that BRCA1/2 gene mutations are not indicated in the majority of 
hereditary breast cancer cases, it is reasonable to conclude that familial breast 
cancer requires further exploration. Nevertheless women with a significant family 
history who present with breast cancer are most likely have a highly penetrant 
BRCA1/2 mutation (Eccles and Pichert, 2005) and the majority of women with 
                                            
Genet, 40, 17-22, GUDMUNDSDOTTIR, K. & ASHWORTH, A. 2006. The roles of BRCA1 and 
BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene, 25, 5864-5874, 
ibid.  
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BRCA1/2 mutations have in their family a history of BRCA-related cancers (Francken 
et al., 2013).  
 
In the last 2 decades over 1800 distinct variants of BRCA1 mutation and in excess of 
2000 in BRCA2 variants have been identified and the associated risk for developing 
cancer calculated, reported in (Couch et al., 2014)14. Whole genome information is 
not available for the vast majority of patients, genetic information specific to 
hereditary breast cancer can be used to assess risk, plan preventative measures 
and predict responses to treatment (Vig and Wang, 2012, Couch et al., 2014). 
 
BRCA1/2 mutations are by far the most common cause of hereditary breast cancer 
(Miki et al., 1994, Wooster et al., 1995), accounting for approximately 20-25% of 
familial breast cancer and in families with four or more breast cancers BRCA1/2 
account for the majority of cases (Ford et al., 1998, Peto et al., 1999, Easton, 1999, 
ABCSG, 2000, Eccles et al., 2000).   Correspondingly, the majority of women with 
hereditary breast cancer will not be found to have a BRCA1/2 mutation (Thompson 
and Easton, 2004, Eccles and Pichert, 2005).  For these women genetic testing may 
reveal a BRCA mutation of uncertain significance or no mutation.  BRCA gene 
variants of uncertain (or unknown) significance are DNA alterations for which there is 
insufficient data to categorise the alteration as harmful, indicating increased cancer 
risk15 (Cheon et al., 2014).   For women who present with a triple negative tumour 
                                            
14 Predictive genetic testing (prior to breast cancer diagnosis) has been available for approximately 20 
years however at that time was expensive and the waiting time for results was lengthy.   In the early 
years accuracy of testing was poor and targeted screening was required in order to locate known 
mutations within a family or founder group such as the Ashkenazi Jewish or Dutch populations.  
 
15 Further genetic investigation will be proposed to establish cancer risk where a previously 
unidentified or rare variant is identified.    It is proposed that the majority of uncertain significance 
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around 20% will not reveal a BRCA1/2 mutation (Lakhani et al., 2002).  Personalised 
treatment and risk reduction pathways for these patients will rely on genetic risk 
predictions and tumour biological characteristics (Boyle, 2012, Huzarski et al., 2013, 
Rhiem et al., 2012).  
 
BRCA1/2 related breast cancer diagnosis is more likely where the patient is from a 
known high risk group (Antoniou et al., 2003, Thompson and Easton, 2004, Jackson 
et al., 2014): 
 member or descendent of an ethnic group with a known founder BRCA1/2 
mutation such as Ashkenazi Jewish (Struewing et al., 1997, Roa et al., 1996), 
Icelandic and Polish origins (Hodgson, 2007) 
 family history of the following cancers: breast, ovarian, prostate, thyroid, 
sarcoma, endometrial, adrenocortical, brain or pancreas (Cybulski et al., 
2014, Marsh and Zori, 2002, BreastCancerLinkageConsortium, 1999). 
 
In families where a BRCA1/2 mutation is present there will be mutation-positive and 
mutation-negative members. In the largest prospective study of mutation-negative 
                                            
results will not confer increased risk ECCLES, D. M., MITCHELL, G., MONTEIRO, A. N., 
SCHMUTZLER, R., COUCH, F. J., SPURDLE, A. B. & GOMEZ-GARCIA, E. B. 2015. BRCA1 and 
BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical 
significance. Ann Oncol..  Additionally the proportion of uncertain results are reducing; MYRIAD 
reported uncertain significance in 12.8% of BRCA1/2 tests in 2002, this rate fell by 77.3% to 2.9% of 
tests in 2012 EGGINGTON, J., BURBRIDGE, L., ROA, B., PRUSS, D., BOWLES, K., ROSENTHAL, 
E., ESTERLING, L. & WENSTRUP, R. Current variant of uncertain significance rates in BRCA1/2 and 
Lynch syndrome testing (MLH1, MSH2, MSH6, PMS2, EpCam).  Presented American College of 
medical genetics and genomics annual meeting, 2012..  International collaborative groups, such as 
ENIGMA, which facilitate the collection and (re-) classification of rare and previously unidentified 
variants aim to improving clinical knowledge and patient management SPURDLE, A. B., HEALEY, S., 
DEVEREAU, A., HOGERVORST, F. B., MONTEIRO, A. N., NATHANSON, K. L., RADICE, P., 
STOPPA-LYONNET, D., TAVTIGIAN, S., WAPPENSCHMIDT, B., COUCH, F. J. & GOLDGAR, D. E. 
2012. ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an 
international initiative to evaluate risk and clinical significance associated with sequence variation in 
BRCA1 and BRCA2 genes. Hum Mutat, 33, 2-7.   
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women, from families with BRCA1/2 genetic mutation, the data indicated that breast 
cancer risk for mutation-negative women is similar to the general population risk, 
with a slight increase, where there is a family history of breast cancer in a first 
degree relative (Korde et al., 2011). 
 
Diagnosis, Recurrence, Prognosis & Treatment 
The likelihood of breast cancer diagnosis increases with age, doubling about every 
10 years until the menopause, when the rate of increase slows dramatically 
(Aaronson et al., 2010).  Women with a family history of breast cancer are most likely 
to be diagnosed with breast cancer over the age of 50, despite the risk of diagnosis 
being greater when they are under 50 (CGHFBG, 2001). The lifetime risk by age 70 
for developing breast cancer with a mutation in the highly penetrant BRCA1 or 
BRCA2 genes is 45 to 88% (Antoniou et al., 2003, Walsh et al., 2006, Ford et al., 
1998).  Age of diagnosis with a BRCA1/2 related breast cancer is attributed at the 
rate of approximately 33% of cases in the 20-29 age group, decreasing markedly 
with age to 2% of cases in the age 70-79 range (Claus et al., 1996).   
 
The risk for BRCA1 and BRCA2 are similar however it has been reported that for 
BRCA2 breast cancer risk is lower in the under 50 age group (Ford et al., 1998).  
The presence of a BRCA1/2 mutation increases the risk for early onset and bilateral 
breast cancer (Korde et al., 2011).  In addition women with a BRCA1/2 mutation face 
an approximate 15-60% risk of ovarian cancer (Ford et al., 1998, Struewing et al., 
1997, Easton et al., 1995, Ford et al., 1994). 
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A critical review of evidence, published in 2010, states that BRCA mutation carriers 
have a significant risk of contralateral recurrence and at 10 years recurrence occurs 
in 20-40% of carriers (Bordeleau et al., 2010).  The risk for BRCA1 mutation carriers 
of contralateral cancer is reportedly higher than for BRCA2 mutation carriers 
(Graeser et al., 2009).  However a longitudinal study, carried out by the Rotterdam 
Family Cancer Clinic, reports high contralateral recurrence risk as the only clinical 
outcome difference when BRCA2 mutation related cancers are compared with non-
BRCA sporadic cancers (Brekelmans et al., 2007).  
 
Prognosis for BRCA1/2 mutation carrier is not clearly defined (Robson et al., 2004).  
Studies cite similar (Liebens et al., 2007, Pierce et al., 2010, Rennert et al., 2007, 
Bordeleau et al., 2010), worse  (Foulkes et al., 1997, Chappuis et al., 1999) and 
improved prognosis (Marcus et al., 1996) when compared to sporadic breast 
cancers.  Significant for prognosis, the patient has an increased risk of developing 
ovarian cancer where BRCA1/2 mutation is detected (Easton et al., 1995, Peto et al., 
1999, Miki et al., 1994). 
 
A meta-analysis and review of survival patterns, conducted by Lee et al in 2010, 
advises 5-year recurrence and overall survival are reduced in BRCA1 mutation 
carriers but both are improved in BRCA2 mutation carriers when compared with non-
hereditary breast cancer patients: this is attributable to distinctive BRCA1 and 
BRCA2 carcinogenic pathways (Euhus and Robinson, 2012, Lee et al., 2010).   
 
Approximately 80% of BRCA1 mutation-related breast cancers are triple-negative 
(ER, PR, HER2) while 75% of BRCA2 associated tumours are hormone responsive 
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or receptor positive (Peto et al., 1999, Schwartz et al., 2008) (Lakhani et al., 2002, 
Lips et al., 2013).   Triple negative breast cancer has a poorer prognosis than 
tumours with positive receptor status (DeRuijter et al., 2011). When combined with 
the 70-80% chance of a triple negative breast cancer, the overall the risk of 
recurrence is higher and prognosis is worse for women with a BRCA1 mutation 
related breast cancer (Stratton, 1997, Eccles and Pichert, 2005, Stoppa-Lyonnet et 
al., 2000).   
 
The Rotterdam Family Cancer Clinic reported, an identical clinical course and overall 
prognosis for 103 BRCA2 mutation carriers when compared with non BRCA1/2 and 
sporadic breast cancer (Brekelmans et al., 2007).  A recently published, international 
population-based cohort study, concludes that outcome for BRCA2 mutation carriers 
is related to more unfavourable biological tumour characteristics rather than mutation 
status (Goodwin et al., 2012). 
 
The benefit of treatment tailored to genetic status and tumour characteristics was 
identified in the mid-2000s however the challenge that lay ahead was to identify the 
most appropriate treatment specific for BRCA1/2 related breast cancer (Daly, 2004).    
Evidence-based clinical guidance for the treatment of BRCA1/2 related breast 
cancer until the mid-2000s was poor (Eccles and Pichert, 2005, Liebens et al., 
2007).  
 
Clinical Guidelines 
Women in the UK from families with a strong history of breast and / or ovarian 
cancer have, since the late 1990s, been able to access specialist family history 
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breast clinics (Saunders et al., 1999)16.  Family History Breast Cancer Clinics 
(FHBCC) offer multi-disciplinary care and screening from genetics, radiography, 
medicine, surgery and nursing services. Women attending the FHBCC have a 
moderate to high risk of developing breast cancer.  The NHS Tayside FHBCC works 
to Scottish Government Guidelines. Table 3 details stratification and management 
for women with a family history of breast cancer.   
 
Within a family history surveillance programme breast cancer occurs at a rate of 6 
per 1000 annual examinations; an eleven year study (1995-2006) of the NHS 
Tayside FHBCC surveillance programme reported cancer detection in 5.8 per 1000 
screening examinations (Reis et al., 2009).  Of these 74% were detected at 
screening with 78.5% detected at an early stage (Reis et al., 2009).   
 
Improvements over the last 10 years in scientific knowledge, molecular genetic  
techniques, clinical genetics and cancer services have enabled gene testing to be 
incorporated into routine clinical practice for patients with an indicative family history 
or clinical features that suggest BRCA1/2 gene mutation (Eccles and Pichert, 2005). 
Today predictive testing is accurate, faster and cheaper than in previous decades 
however the UK clinical guidelines threshold for testing exclude many women  
(NICE, 2013b, ScottishGovernment, 2013).  
 
  
                                            
16 UK breast care services supplementary information is provided in Appendix B. 
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Table 3: Management of Women with a Family History of Breast Cancer 
 Moderate Risk High Risk 
Stratification 1 first degree relative with breast 
cancer diagnosed < age 40 OR 1 first 
degree relative with male breast cancer 
(any age) 
2 first or 1 first & 1 second degree 
relative with breast cancer diagnosed < 
age 60 OR ovarian cancer at any age 
on the same side of the family 
3 first or second degree relatives with 
breast or ovarian cancer in the same 
side of the family where 1 is a first 
degree relative of the proband17 
OR of the proband’s father 
Bilateral breast cancer is equivalent to 
2 affected relatives 
First degree = mother, sister, daughter 
Second degree = Grandmother, 
granddaughter, aunt, niece. 
Families with 4 of more relatives with 
breast cancer < age 60 OR ovarian 
cancer at any age, in 3 generations 
Families where one individual has had 
breast and ovarian cancer 
Families where there is an estimated 
20% likelihood of BRCA1/2 or p53 
mutation 
Individuals with a lifetime risk of 
developing breast cancer of ≥30%. 
Individual being assessed should be a 
first degree relative of an affected 
family member or a second degree 
relative through an unaffected male  
Affected individuals should be first 
degree relatives of each other or 
related through unaffected males. 
Surveillance Start age 40 or 5 years younger than 
the youngest age of cancer onset in 
family 
Mammogram 2 yearly < age 40; annual 
mammogram age 40-50  
Mammography should not usually 
commence before 35, all women in this 
group should be offered mammography 
by age 40 
Breast examination where possible, 
may be appropriate before age 35 
when family history of early onset 
cancer. 
Start age 35 or 5 years younger than 
the youngest age of cancer onset in 
family 
Mammogram 2 yearly < age 40; annual 
mammogram age 40-50;  18 monthly 
age 50-70 
Mammography should usually start age 
35, & should not be offered below age 
30 
Breast examination should be offered, 
particularly to women considered too 
young for mammography who have 
come from families where onset of 
cancer < age 35 
Genetic testing should be offered in 
these families, if a sample is available 
from an affected relative.  Where 
mutation testing cannot be offered the 
possibility that the woman may be at 
sufficiently high risk to be offered MRI 
should be considered. 
Source / Adapted from Chief Medical Officer & Public Health Directorate 2009 publication: 
Cancer Genetics Services in Scotland - Management of Women with a Family History of 
Breast Cancer (Burns, 2009). 
                                            
17 Proband:  individual being investigated. Usually the first affected family member to bring the genetic 
disorder to medical attention.  Source NATIONALHUMANGENOMERESEARCHINSTITUTE. 2014. 
Proband [Online]. National Institutes of Health. Available: 
http://www.genome.gov/glossary/index.cfm?id=164 [Accessed 9/6/14 2014]. 
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Clinical guidelines identify individuals who are most likely to benefit from BRCA1/2 
gene testing (ScottishGovernment, 2013, NICE, 2013c, NICE, 2013b).  Patients who 
present with a significant or 10% risk of carrying a BRCA1/2 mutation should be 
referred to Clinical Genetics for detailed assessment (Schwartz et al., 2008).  Table 
4 summarises clinical guidance for Clinical Genetics referral. 
 
Table 4: Candidates for Genetic Referral 
Early breast or ovarian cancer onset, before age 40 
Multiple affected relatives: 
 2 or more 1st line with diagnosis before age 50 (including the patient) 
 3 or more 1st line  
Multiple primary cancers in the patient, particularly if breast and ovarian 
Male breast cancer 
Pathological features: 
 Medullary or pseudo-medullary breast cancer 
 Triple negative breast cancer (especially before age 50) 
Ashkenazi Jewish descent or other founder mutation ethnic group 
Known BRCA1/2 mutation in 1st or 2nd degree relative 
Breast cancer and family history of any of the following cancers: 
 Prostate, thyroid, sarcoma, endometrial, adrenocortical, brain or 
pancreatic. 
Source / Adapted from (Schwartz et al., 2008) 
 
The UK National Institute for Health and Clinical Excellence (NICE) 2006 guidance 
for the care of women with familial breast cancer stated that “genetic testing is 
appropriate for only a small proportion of women from high risk families” (pg 7) 
(NICE, 2006).  The Scottish Intercollegiate Guidelines Network publication 
‘Treatment for Primary Breast Cancer’ recommends that high risk patients be 
referred to a genetics service (SIGN, 2013).   There is no current guidance for 
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genetic testing in patients with a family history of breast cancer and a current 
diagnosis of breast cancer.  
 
Recently published NICE guidelines for Familial Breast Cancer (NICE, 2013b) 
demonstrate an increased acceptance of the role for genetic testing for women with 
a family history of breast cancer:   
 the threshold for genetic testing for familial breast cancer reduced from 20 to 
10 % risk estimation  
 women who have been given a diagnosis of breast cancer within the past 
month and who have a family history of breast cancer, may be offered 
immediate ('fast track', 'rapid' or ‘early’) genetic testing as part of a research 
trial (NICE, 2013b).   
However current UK guidelines do not provide recommendations for testing at the 
time of diagnosis out-with the remit of clinical research.  This may relate to local 
genetic laboratory or genetic counsellor service provision or to the current cost / 
payment structure within the NHS.  The provision of testing via clinical research 
removes the responsibility from local NHS organisations. 
 
In response to publication of the draft 2013 NICE guideline the Scottish Genetics 
Laboratory Consortium extended their threshold for BRCA testing, this change 
meant that the risk estimation level to trigger genetic testing fell from 20 per cent to 
10 per cent however this guidance has yet to be incorporated into a SIGN 
publication.  In the UK, genetic testing can now be performed for individuals at high-
risk of carrying BRCA1/2 mutations (NICE, 2013b).   
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While the NICE Guideline reduced the testing threshold it recommends that research 
is required, to provide evidence-based practice, for rapid testing at the time of 
diagnosis. Genetic testing at diagnosis is now performed faster than before and 
results can be available before treatment is commenced (Schwartz et al., 2004, 
Wevers et al., 2011b, Meiser et al., 2008, Trainer et al., 2010a).  A BRCA1/2 
mutation may alter treatment plans on account of the increased risk of breast cancer 
recurrence, tumour grade and biological receptor status (Trainer et al., 2010a, 
Ardern-Jones et al., 2005, Couch et al., 2014, Smith and Isaacs, 2011)18 .   
 
In 2006, the UK national guidelines did not provide specific guidance for the 
treatment of hereditary or BRCA-related breast cancer (NICE, 2006, SIGN, 2005). 
By 2007 risk-reducing strategies for patients at risk of developing breast cancer 
(including recurrence) took into account ‘state-of-the-art’ genetic testing that had 
been identified and agreed by international groups, though at the time the strategies 
were largely non-evidence based (Schwartz et al., 2008). 
 
Current UK clinical guidelines detail diagnostic and treatment pathways based on 
tumour and but not BRCA characteristics (SIGN, 2013, NICE, 2013b, NICE, 2013a, 
NICE, 2013c)19.  BRCA-related breast cancer treatment options are provided in 
Appendix E. 
 
 
 
                                            
18 An overview of the characteristics of a BRCA-related breast cancer is provided in Appendix C. 
 
19 Breast cancer treatment information is provided in Appendix D. 
57 
5.4 Why Do Women Seek Breast Cancer Related Genetic 
Information? 
There are known differences in the reasons for women attending cancer genetics 
services.  Women attending for predictive genetic counselling and testing do so to 
establish their own risk.  Women with a cancer diagnosis attend cancer genetics 
clinics to learn of the reason/s that they have cancer and to help improve the 
chances for family members by knowing their risk for developing cancer (Julian-
Reynier et al., 1998).  
 
Distinct reasons for seeking information are supported by the authors of a study that 
reports different risk perception between cancer survivors and unaffected HBOC 
family members (Mellon et al., 2008).  Unaffected relatives have a higher perception 
of cancer risk, while survivors have more cancer worries.  Factors impacting cancer 
risk perception and cancer worry are detailed in Figure 5. 
 
Responsibility is significant in both obtaining information and decision making in 
regard of cancer-specific genetic information.  A Canadian qualitative study 
(Etchegary et al., 2009) reports that seeking genetic risk information is experienced 
by most as a responsibility.  The authors present 3 dimensions of genetic 
responsibility: 
 for self 
 for others 
 to assist others to know.  
Each dimension carries implications for test decisions: family relationships, family 
members’ desire to know (or not) and to take action (or not) with respect to their own 
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genetic risk.  A series of studies conducted by a team from The Netherlands report 
similar reasons, or dimensions of genetic responsibility, for patients seeking cancer 
genetic-specific information however the work offers an alternative focus, rapid 
genetic counselling and testing.  They report that the key reasons for women 
undertaking genetic testing are to establish knowledge about future cancer risks and 
choice of preventative surgery, for their increased cancer risk (Wevers et al., 2014).  
 
Figure 5: Perception & Cancer Worry 
 
 
Source / Adapted from (Mellon et al., 2008) 
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Is Coping Style a Factor? 
Coping style theory is based upon early behavioural theory; Bowens Theory (Bowen, 
1978).  Within this, Differentiation of Self is a process that enables individuals to 
separate emotion and thought.  When faced with a challenging situation, for example 
cancer diagnosis or genetic testing, a range of techniques such as information 
seeking or avoidance will be used to reduce anxiety (Bartle-Haring et al., 2008). 
 
Coping style will influence whether an individual seeks genetic information and how, 
after testing, they respond.  Two main coping styles have been identified in relation 
to cancer screening and management:  
 monitoring or information seeking  
 blunting or avoiding (Miller, 1995).    
Information seeking is characterised by addressing threatening information.  These 
individuals typically have high levels of worry and anxiety regarding their cancer risk 
however they will be knowledgeable about their health situation.  Patients who adopt 
an information seeking style require high levels of psychosocial support however it is 
worth noting that these individuals are more inclined to take a passive role in 
decision making, deferring to competent individuals such as their doctor.  Conversely 
individuals who adopt an avoiding coping style do not seek information, and they will 
be satisfied with the minimal amount of information however they will tend to adopt 
an active role in decision making.  Patients who use avoidance techniques generally 
report low stress levels however because of this they are often given more 
information because they appear to cope well.   
 
60 
A study, conducted in the UK, that  used the previously described GRACE tool 
(Phelps et al., 2010) to explore patient coping during cancer genetic testing, 
identified that patients use a range of coping styles throughout the process (Bennett 
et al., 2012).  Furthermore the authors report that the majority of participants are not 
consistent in their coping response and use a variety of approaches. While they 
report that a minority of individuals, who lack flexibility and consistently, use a limited 
or more fixed range of coping strategies. 
 
Coping style and reaction to genetic testing has been explored in a genetic testing 
study that explores the experience of patients with hereditary colorectal cancer 
(Shiloh et al., 2008).  This publication reports that regardless of coping style 
participants were interested in genetic testing to inform risk reduction and disease 
treatment.  More recent work recommends that genetic information should presented 
in an individualised manner that targets the individuals coping style (Vig and Wang, 
2012). 
 
Genetic Information to Maximise Survival? 
A study by Wevers et al (Wevers et al., 2012b) cites 15 reasons, reported by  26 
women who had received rapid genetic counselling and testing, for seeking this 
information at the time of diagnosis. The most frequently stated reason (73%) is to 
obtain certainty about the risk of getting breast cancer again, this is followed by 
(69%) the desire to take preventative action for the unaffected breast and (50%) to 
choose surgical treatment of the affected breast.  These reasons can be viewed as 
maximising survival. 
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A recently published study (Jeffers et al., 2014)  explored the motivation of women 
with hereditary breast and ovarian cancer for undertaking BRCA1/2 gene testing.  
The publication describes “Maximising Survival”, a theme that is common from 
testing until 2 years after the test. While the study focused its exploration on 
understanding the experiences of women who receive BRCA1/2 positive results, the 
survival theme is relevant for a broader population who undertake genetic testing. 
An American study published in 1994 explored the attitudes of patients with a first 
degree relative who had breast cancer to genetic testing; 75% reported that they 
would definitely want to receive genetic testing for BRCA1 when a suitable test was 
available (Lerman et al., 1994).  Reasons that the women reported for wanting 
genetic information are: to learn about their children’s risks (76%), to increase use of 
screening (71%), to be reassured (70%), to inform or assist with childbearing 
decisions (48%) and to adopt healthy lifestyle behaviours (50%). This study did not 
relate to post-diagnosis testing though it did support the results of a later survey 
(Andrykowski et al., 1997) that a high uptake of genetic testing should be anticipated 
within the population who have a family history of breast cancer.   
 
5.5 Psychological Impact of Breast Cancer Genetic Testing 
 Expectations & Waiting for Results 
The Lerman study (Lerman et al., 1994) reported  patients’ expectations about the 
impact of BRCA test results.   A positive BRCA1/2 result was anticipated to leave 
80% expecting to feel depressed and 77% very anxious, 32% expected a positive 
result to negatively impact their quality of life and 1 of the 121 participants reported 
that she would consider suicide.  For negative BRCA1/2 test results participants 
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expected to feel less anxious (83%), 83% expected this to improve their quality of 
life, 82% would feel more in control, feel less depressed (68%) however 45% would 
still worry and 25% would feel guilty.  However studies report that individuals who 
receive results of uncertain significance experience prolonged uncertainty and 
confusion (Culver et al., 2013). 
 
The uptake of genetic testing is variable and there are many reasons for declining 
testing.  In one study that examined the barriers to participating in genetic 
counselling and testing during breast cancer treatment (Schlich-Bakker et al., 2007) 
participants who declined, genetic counselling and testing or withdrew early in the 
process (22%), did so because they do not consider the test to be relevant for 
themselves.   Participants who reported anxiety, about the impact of the result on 
their health or future health decisions (14%), declined to proceed or postpone testing 
after the genetic pedigree completion (genetic family tree).  A further 7% stopped the 
process before receiving results because they feared the genetic test result and / or 
a relative objected.   The publication stated that distress, HBOC knowledge, prior 
genetic testing (in family members) and perceived cancer risk were not reasons for 
declining the offer of BRCA gene mutation testing or withdrawal from genetic 
counselling and testing.  
 
Notably these authors state that 81% of the participants supported testing during 
breast cancer treatment or would prefer an earlier offer for gene testing.  They 
conclude by stating that patients who decline or withdraw from the genetic 
counselling and testing process would benefit from tailored health and risk education 
to facilitate their making an informed decision (Schlich-Bakker et al., 2007). 
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Insecurity concerning genetic status is a common psychological stress whilst 
awaiting genetic results (Bennett et al., 2012).  The period whilst waiting for results is 
associated with extreme stress; the stress predominately relates to thoughts about 
personal destiny (Valverde, 2006). In an attempt to minimise this fear-related 
psychological trauma techniques such as bargaining can be used by the individual 
(Valverde, 2006).  Bargaining involves the individual making assurances, for 
example ‘if I do not have a BRCA1/2 gene mutation I will take more exercise’.  
Health related behaviour is commonly used within bargaining when faced with 
insecurity and psychological stress. However Lerman et al (2002) report, little 
evidence for genetic testing promoting changes in health or risk-reducing behaviours 
(Lerman et al., 2002).   Self-help coping interventions prove useful in reducing 
anxiety and avoidance behaviour, whilst waiting for genetic test results (Phelps et al., 
2013, Bennett et al., 2007).  
 
Does Testing Increase Distress? 
A literature review conducted in the last 10 years concluded that genetic testing does 
not increase psychological distress in breast cancer patients (Schlich-Bakker et al., 
2006).   However the authors report that, the diagnosis of breast cancer adds to 
cancer-specific distress before genetic counselling and after genetic test results.   
Clinicians are advised to be sensitive, to a possible increase in general and cancer-
specific distress, following a recent diagnosis.  
 
Later work, conducted by a Dutch research team, reported that the 102 participants 
in their prospective study of breast cancer patients approached for BRCA genetic 
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counselling and testing, at the start of radiotherapy, did not experience additional 
short-term psychological distress (Schlich-Bakker et al., 2007).   
 
However other studies report conflicting results.  One study reported that  
approximately a quarter of patients who undertake predictive testing for BRCA1/2 
gene mutations experience cancer related worry (Watson et al., 2004).  For women 
who test positive, worry and mental health issues are at their highest 1 month after 
receiving the test result, and younger women (<50 years) experience the highest 
level of worry at this time (Watson et al., 2004).  
 
Participants in the Audrain study (Audrain et al., 1997), who reported the high levels 
of general distress in response to BRCA1/2 genetic testing were less likely to be 
married, more pessimistic and described feeling a lack of control over developing 
breast cancer. Similarly women with the most cancer-specific distress were younger, 
non-white and also reported low control over developing breast cancer.  
Correspondingly this study advises that interventions are implemented, to reduce the 
moderate levels of general and cancer-specific distress experienced by women with 
HBOC who self-refer for genetic counselling and BRCA gene testing  (Audrain et al., 
1997).   
 
A follow-on study of long-term impacts, conducted by the Watson team, reported that 
40% of the female BRCA1/2 carriers had difficulties with life and / or health 
insurance.  Distress was no different for BRCA1/2 carriers and non-carriers 3 years 
after the genetic test however a number of non-carriers, albeit a minority, despite 
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recommendations were not engaged in breast cancer screening programmes (Foster 
et al., 2007).  
 
Significant levels of psychological distress that range from anxiety to depression are 
described in response to BRCA genetic testing.  These symptoms can be prompted 
by the testing process (Tercyak et al., 2001) or by family history experiences of 
breast cancer.  This team recommend that, psychosocial support forms an integral 
part of genetic counselling for all women undergoing BRCA1/2 testing. 
  
More recently authors recommend, that psychological support measures are 
employed for patients aged below 50 years  (Watson et al., 2004).  Additional 
counselling is recommended and support may be required throughout the testing 
process, for certain groups who have been identified as requiring additional 
psychosocial support:  younger patients, single women with little support, those who 
are less optimistic, patients who use an avoiding coping style, highly distressed 
individuals and those with low quality of life (Schlich-Bakker et al., 2007). 
  
In response to distress, at the time of genetic counselling and testing initiated close 
to the time of diagnosis (Wevers et al., 2012a), the uptake of psychosocial 
counselling is reported for 1/3 of women.  Notably more women who tested BRCA1/2 
positive, than negative, attended psychosocial counselling provided by a social 
worker or psychologist.  However many of the reasons for the counselling were 
related to general coping with cancer and were not specific to rapid genetic 
counselling and testing.  Where issues related to genetic testing the most frequently 
reported reasons for attending counselling are cancer recurrence, risk-reducing 
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treatments such as prophylactic surgery and body image. Short-term psychosocial 
distress was reported by half of the participants; increased levels of distress related 
to genetic testing was identified, significantly this was in addition to the distress 
associated with their breast cancer diagnosis. 
 
5.6 Psychosocial Impact of Breast Cancer Genetic Testing 
Responses to BRCA Gene Testing 
The decision to undertake BRCA genetic testing is not always easy.  One study 
explored relationship support and psychological reactions to testing (Manne et al., 
2004). The majority of participants discussed the BRCA test decision and results 
with their partners.   Most partners were supportive.  However where little or no 
support was provided greater distress and relationship strain was reported 6 months 
after receiving BRCA results.  The study concluded that partner support is important 
particularly for women receiving results of uncertain significance.   
 
Genetic test results can have a life-changing affect.  Loneliness and isolation are 
described in response to a breast cancer diagnosis for women with a BRCA1/2 
mutation, this international paper reports on Social Separation (Kenen et al., 2006).  
Proposed reasons for emotional estrangement or pulling away are associated with a 
philosophical existence dilemma: increased cancer risk associated with genetic 
mutation may be interpreted as chronic illness or disability. Loss of identity is 
alternatively proposed as the catalyst for estrangement.  
 
67 
Participants in the Kenen study (2006) report feeling different and a sense of not 
belonging.  The characteristic use of silence or verbal discretion are associated with 
social separation.  Pretending to be attached was used as a tactic in certain public 
situations to disguise feelings of separation.  Within the Kenen (2006) study 
population cancer diagnosis plays a significant part in loneliness however this is 
amplified when BRCA1/2 mutation is identified.  The knowledge of a genetic 
mutation added complex feelings of responsibility and a need to make further health 
/ life changing decisions.  Participants described feeling ‘out-of-sync’ with their peers 
when making decisions such as increased screening or prophylactic surgeries (while 
their peers discuss social events).  The urgency to make significant health and life 
decisions make these participants feel isolated and that peer’s activities and 
decisions are frivolous or carry less importance.  The authors propose that support 
groups (face-to-face and virtual) are of value for reducing social separation in women 
with a breast cancer and BRCA mutation diagnosis (Kenen et al., 2006). 
 
Subtle complications that result from BRCA1/2 gene testing as described in a recent 
publication (Grubs et al., 2014).  An individual’s response to testing can alter social 
relationships with family friends, colleagues and clinicians.  Genetic test results can 
influence on self-concept, career, financial and reproductive choices.  Notably a 
positive mutation status can bring about a sense of urgency which alters or speeds 
up life plans.  However for some women this change is not positive and 
discrimination may lead to unemployment, social isolation and reduced self-esteem.  
 
While the presence of a highly penetrant genetic mutations confers an increased risk 
for disease, modifiable behaviours can play a role in risk reduction (Boyle, 2012, 
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Guinan et al., 2013b). The impact upon health behaviours is reported in a study of 
women who initiated BRCA1/2 testing (Dorval et al., 2008).  However the authors 
conclude that an established high-risk for breast cancer prior to BRCA1/2 testing 
does not provide sufficient motivation for women to assume healthy lifestyle 
behaviours including stopping smoking, taking exercise and undertaking breast 
screening measures, unless they have already had cancer.   
 
It is unclear what modifiable factors have clinical significance for reducing risk in the 
presence of a highly penetrant BRCA1/2 gene mutation.  A recent meta-analysis 
reviewed 9 modifiable factors in relation to BRCA and breast cancer risk reduction 
(Friebel et al., 2014).  Modifiable factors that were analysed: 
 Reproductive elements - age at first live birth, breastfeeding, number of 
children and exposure to oral contraceptives 
 Screening & prophylactic elements - exposure to mammogram and tamoxifen 
 Lifestyle elements - exposures to alcohol, coffee and smoking.  
Notably a healthy diet and exercise were not included in their analysis. 
 
Within the Friebel (2014) review limited evidence is reported for modification of 
breast cancer risk in the presence of a highly penetrant BRCA mutation although a 
probable association exists with late age at first birth.  Later age provides a 
protective effect for BRCA1 mutation carriers while more evidence is required for the 
BRCA2 population. A possible risk modifying protective association is reported in the 
presence of a BRCA1 mutation and further evidence is required for BRCA2 for (high) 
alcohol consumption and breastfeeding.  Smoking is associated with increased 
breast cancer risk for BRCA2 mutation carriers.  The authors advise that current data 
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relating to alcohol and smoking may not be suitable for clinical translation; study 
limitations include small sample sizes, convenience samples and retrospective 
assessments.  Large prospective randomised trials and clinical risk assessment tools 
are required, to clearly identify which modifiable factors confer the greatest risk (and 
benefit) for the high-risk BRCA population, to provide actionable health behaviour 
information for cancer risk reduction. 
 
While a BRCA1/2 mutation is the fundamental cause for developing breast cancer 
the effect of modifying lifestyle risk factors such as physical activity, body weight, 
alcohol and smoking should be discussed in breast cancer genetics counselling 
session (Albada et al., 2014). An early study identified modifiable lifestyle factors that 
could reduce breast cancer risk for women with a highly penetrant BRCA gene 
mutation.  High calorie intake, early age of maximum body mass index (BMI), rapid 
weight gain between 18 and 30 years are all associated with increased breast 
cancer risk for this population (Nkondjock et al., 2006).  A calorie restricted diet is 
proposed with particular attention to prevent rapid weight gain in young adulthood.   
Further work by this team recommended a high quality, healthy diet as a 
preventative strategy for reducing BRCA-associated breast cancer risk (Nkondjock 
and Ghadirian, 2007).  This message is reiterated by an associated research team 
who additionally propose a diet rich in fruit and vegetable variety to reduce risk for 
this population (Ghadirian et al., 2009). 
 
Smoking and alcohol exposure are well known modifiable health behaviours that 
increase risk for many diseases.  They may have additional significance within the 
realm of highly penetrant genetic mutations, confounding risk and in the presence of 
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disease worsening prognosis.  Image 1 highlights a specific challenge for health 
professionals though the challenge is relevant when considering all lifestyle 
behaviours that alter risk and prognosis. 
 
Image 1: Challenging Health Behaviours 
 
Source (Marteau and Lerman, 2001) 
 
An early study that identified that smoking may reduce breast cancer risk in 
BRCA1/2 mutation carriers (Brunet et al., 1998).  This controversial finding rapidly 
became the subject of further discussion and strong advice not to encourage women 
with a BRCA1/2 mutation to smoke (Baron and Haile, 1998). Indeed a large 
prospective study followed 426 high risk families over a 5 year period.  This study 
concluded that smoking may increase breast cancer risk particularly in families with 
the most penetrant BRCA1/2 mutations (Couch et al., 2001). 
 
Alcohol was proposed as a protective factor for women who carry a BRCA1/2 gene 
mutation (McGuire et al., 2006).  However study results on the whole do not support 
the proposal.  The exception being that BRCA2 mutation carriers who consume 
moderate levels of alcohol may be offered a possible risk reduction.  A more recent 
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case-analysis study has however proposed that alcohol may offer a protective 
function for BRCA1 mutation carriers (Moorman et al., 2010).  Reassuringly the 
authors do not propose or advise the use of alcohol as a risk reduction measure and 
advise further research to investigate this controversial finding. 
 
Three large prospective studies are currently recruiting participants and collecting 
modifiable lifestyle data from women with BRCA1/2 mutations.  These studies may 
provide much needed data on which to base counselling for factors that may improve 
cancer risks for women with a highly penetrant BRCA mutation 
(Guinan et al., 2013a, Pasanisi et al., 2014, Pettapiece-Phillips et al., 2015). 
 
Acceptance of a BRCA test result and associated breast cancer risk may take time 
and support (Valverde, 2006). In a study conducted in the late 1990s (Metcalfe et al., 
2000) approximately half of the participants reported negatively impacted 
relationships, in response to genetic testing that confirmed a positive result (Julian-
Reynier et al., 2000). 
 
Survivor guilt can result when a negative BRCA result is received.  A report written 
by a genetic counsellor, after her BRCA gene test revealed a negative result, 
maintains that survivor guilt is not  an adequate description (Valverde, 2006) and that 
‘identity loss’ (pg 462) provides a clearer description for response to a negative 
genetic test result.  After 30 years of worry about developing breast cancer she 
describes a 2 year period spent redressing her life view, self-identity and health 
behaviours.  The impact of this negative result left Valverde asking ‘why me?’ and 
questioning the importance of her life.   
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Valverde (2006) received a negative result however her sister received a positive 
genetic test result.  Associated with these results is period of readjustment related to 
the relationship with her sister.  Valverde describes coping with an overwhelming 
feeling loneliness and fear related to being the only one left when the affected 
members of her family die.  For her sister there is hope that her children will have a 
close aunt to care for them should she die, unlike when Valverde’s mothers 
generation died leaving daughters with no mother or senior female relatives.   
 
Following genetic testing women describe a range of family connectivity, from 
improved cohesiveness to social isolation (Douglas et al., 2009) that includes 
emotional separation (or hostility) and feelings of vulnerability, despite having the 
support of at least one family member.  The impact of BRCA testing on family 
relationships and dynamics is explored in a qualitative study (Douglas et al., 2009).  
The impact is three-fold: 
1. A special family role is adopted by the individual tested, this role can be 
challenging 
2. Family discussions change 
3. Connections with family members change 
Five key factors that influence altered family relationships after genetic testing are 
shown in Figure 6. 
 
A study published in Psycho-oncology reports that over a third of family relationships 
are positively affected by genetic testing:  families become closer, communication 
and support improved, appreciation for the relative undertaking testing increases and 
when results are negative a sense of relief is brought to the whole family (van 
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Oostrom et al., 2007).    Conversely negative effects of the genetic test result in 
unwanted changes in relationships for approximately one fifth, difficult situations for 
13% and conflicts for 4% of the 271 participants.    
 
Figure 6: Reactions to BRCA Testing: Factors that Alter Family Relationships  
 
Source / Adapted from (Douglas et al., 2009) 
 
Reported BRCA1/2 gene testing adverse effects are guilt, enforced secrecy and 
difficult communication.  The authors detail 2 predictors for adverse familial 
outcomes:  
 Disengaged – rigid family functioning 
 Enmeshed – chaotic family functioning 
Open familial communication should be promoted to ensure optimum disclosure of 
risk, support and interactions (van Oostrom et al., 2007). 
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A review published in Ethics in Medical Genetics (Grubs et al., 2014) reports 
negative changes to social relationships after genetic testing exposes a BRCA1/2 
mutation.   Women describe emotional un-availability for close family because they 
are pre-occupied by their genetic status  (Metcalfe et al., 2000).  In addition the 
obligation to disclose a BRCA1/2 mutation to family members is often seen as a 
burdensome.   
 
BRCA Disclosure  
The motivation to share BRCA1/2 gene information is multi-factorial.  Studies report 
responsibility for family as a motivator for undertaking BRCA testing (Hallowell et al., 
2003, Etchegary et al., 2009, Wevers et al., 2011a).  This responsibility can be a 
source of psychological distress, although sharing genetic information with family 
members is likely to result in the provision of emotional support (Hughes et al., 2002) 
that in turn alleviates distress (van Oostrom et al., 2007, Manne et al., 2004).  
Communal coping is a supportive strategy that aids coping when faced with a shared 
threat (Lewis et al., 2006). 
 
Additional factors that impact BRCA1/2 gene disclosure are age (of the proband and 
the relative), relevant cancer diagnosis, the number of daughters in the family and 
the presence of any cancer related psychological disturbance impacting close 
relationships.  These researchers conclude that the personal and emotional 
characteristics of the proband impact upon disclosure of BRCA1/2 gene information 
to family members (Julian-Reynier et al., 2000). 
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Three roles predominantly adopted by women: maintaining of family relationships, 
promoting (and sometimes controlling) healthy behaviour and support seeking are 
discussed within a paper that explores the ethical dilemmas experienced by women 
who undertook HBOC genetic testing (Foster et al., 2004).  When these roles are 
well established, and strong supportive relationships exist, the communication of 
difficult genetic information is reported to bring ethical dilemmas that conflict with the 
care giving responsibility.  These tensions create barriers to communication. One 
example illustrates the participant being selective about which relative they will 
inform about the genetic risk, giving consideration to age, feelings and the right not 
to know (Foster et al., 2004). 
 
A large survey-study reported that 97% of participants report their BRCA result to at 
least one relative, significantly the test result does not influence disclosure (Cheung 
et al., 2010).  Disclosure of HBOC risk is a complex issue for women to face after 
genetic status and cancer risks are revealed (Forrest et al., 2003, Foster et al., 
2004).   Ethical dilemmas oppose moral obligations to disclose and protect family 
members (Clarke et al., 2008). 
 
A French multi-centre study reports disparities of BRCA1/2 gene status disclosure 
within families.  The authors report that siblings are most frequently notified, with 
sisters (87%) then brothers (79%), followed by mother (71%), children (70%) and 
father (69%) (Julian-Reynier et al., 2000). Notably, women are more often informed 
of genetic testing than men despite conveying a risk for male relatives (Julian-
Reynier et al., 2000).  This may indicate the tested woman perceives the results as 
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having more value for female relatives or that her relationship with the female 
relatives resulted in easier communication.   
 
Similar findings have been illustrated by Hallowell (2003) with participants facing a 
greater burden when considering for example revealing the risk to their brothers.   
Furthermore sisters are reported to gain support when sharing BRCA1/2 test results 
with each other (Hughes et al., 2002).  When 2 or more sisters are mutation carriers 
they may benefit from communal coping strategies (Lewis et al., 2006, Koehly et al., 
2008).  The Koehly (2008) study examined the shared BRCA experience of sisters; 
reporting that sisters have similar levels of cancer risk perception and cancer worry.  
These authors report positive association with relatives (sisters) providing support, 
this results in low levels of anxiety and depression. Sharing and mutual support from 
a sister/s can facilitate acceptance, coping and adaption following the receipt of 
information that confirms a highly penetrant genetic mutation (Koehly et al., 2008).  
Hughes (2002) does however state that emotionally distant relatives may act as a 
barrier to effective sibling communication and support. 
 
A study of HBOC and family communication reports that adoption, divorce, 
remarriage, family conflicts and large age difference between siblings can obstruct 
the processes of obtaining and providing information (Green et al., 1997).  A survey 
study of 1,103 participants from broad ethnic and socio-economic backgrounds 
explored factors that impact family communication of BRCA test results.  The 
authors report that older age and Asian race are negatively associated with results 
communication (Cheung et al., 2010).   However greater knowledge of HBOC and 
higher socio-economic status correlate with superior communication of results.   
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These authors conclude that these predictors are adopted by genetics services to 
improve family communication of cancer risks, for example where a patient is 
assessed as having low knowledge of HBOC education.  Such assessments should 
be undertaken with an aim of improving communication within the family. 
A study that explored communication of BRCA test results to offspring, following 
genetic testing, reported 62% of patients informed children aged between 8 and 21 
years (Tercyak et al., 2013).  However results are more likely to be disclosed when 
negative or uncertain / uninformative compared with positive results.  Children over 
the age of 13 were more informed than younger children. 
 
A qualitative interview study reports maternal concern for protecting and educating 
children about HBOC risk.  Most parents participating felt relief and a fulfilled sense 
of parental duty after telling their children.  Age appropriate genetic information is 
recommended by the parents.  Notably an ‘immunizing effect of disclosure’ (pg 303) 
was viewed as preparing the child for possible family cancer diagnosis, while parents 
who chose not to tell were advised to disclose results in the future.  
Recommendations are made for genetic counsellors to take an active role in 
advising parents how to deliver genetic information to children (Patenaude et al., 
2013). 
 
An earlier study describes 3 phases of disclosure (Clarke et al., 2008), these are 
displayed in Figure 7.   While the study relates to parent and child disclosure it is 
predicted that similar phases and responses occur with all disclosure. Pre-disclosure 
the parent considers in relation to her offspring: cancer risk, loss of potential goals, 
potential genetic discrimination related to finance / insurance and life partner and the 
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child’s emotional responses.  Increased poignancy is reported when participants talk 
about their daughters.  Participants report being ‘caught off guard’ (pg 801) prior to a 
planned disclosure. For example, genetics was discussed by a 14-year old in relation 
to a school project however the mother lied when asked about ‘bad genes’ (pg 801) 
in the family; the lie was justified as protection.   
 
The possibility that your offspring will carry the BRCA1/2 gene mutation is the 
greatest fear for parents (Clarke et al., 2008).  The psychological impact of this fear 
and responsibility pre-disclosure creates significant conflict and distress however 
these lessen after disclosure.  The focus changes to supporting the child and 
whether / when they should undertake BRCA1/2 gene testing.   
 
 
 
Figure 7: Phases of Disclosure 
 
 
Key: relevant text for the broader family relationships are highlighted (bold) 
Source / Adapted from (Clarke et al., 2008) 
•Consider impact of genetic result for offspring
•Moral obligation to tell
•When to tell raises ethical dilemma, 
particularly as child approaches adulthood
•Consquence of not telling: 'gate-keeping'
Pre-disclosure
•Risk being 'caught off guard' 
Planned or 
spontaneous 
disclosure
•Parent or carrier: ? test child, fear child's 
mutation status, conflict after disclosure
•Perceived for child: life impacts, ? test
Disclosure 
Impacts
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6. AIMS & OBJECTIVES 
Aims 
This project aims to investigate experiences and opinions relating to genetic testing 
and the impact these have on treatment decisions in women who have a family 
history of breast cancer and who have undergone genetic testing for the BRCA1/2 
genes following diagnosis.   
 
Objectives  
 To identify the factors influencing genetic test and breast cancer treatment 
decisions  
 To explore the experiences of genetic testing for women with a family history 
and subsequent diagnosis of breast cancer 
 To evaluate the impact that genetic testing has on breast cancer treatment 
decisions  
 To compare experiences of women tested before and after breast cancer 
treatment to determine whether the timing of the genetic test impacts the 
experience  
 To identify plausible and acceptable approaches to improving breast cancer 
patient management following genetic testing. 
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7. METHODOLOGY 
As a qualitative researcher it is essential to acknowledge and define: 
 stance and external influences  
 theoretical approach, methodologies and philosophies used throughout the 
research.   
 
7.1 Stance & External Influences 
I am graduate nurse with over 20 years of registered practice, I have worked 
clinically within the National Health Service (NHS) and other healthcare 
organisations; primarily in the acute hospital settings.  However the majority of my 
career has been spent working in clinical research within the NHS, university and 
commercial research settings.   
 
This research was not commissioned by any organisation or department.  Financial 
assistance has been obtained from University of Dundee Staff Wavier Scheme, NHS 
Tayside Breast Endowment Fund, NHS Tayside Clinical Genetics Endowment Fund 
and the Scottish Research Nurse & Coordinators Network.   
 
Project supervision and research support have been provided by key members of 
the NHS Tayside Clinical Genetics Department and the Centre for Research into 
Cancer Prevention and Screening University of Dundee.  Input from three highly 
knowledgeable clinicians and researchers is acknowledged: Dr Jonathan Berg, 
Professor Annie Anderson, Ms Jacqueline Dunlop. 
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7.2 Approach 
This work broadly takes a Grounded Theory approach (Glaser and Strauss, 1967, 
Glaser and Strauss, 1999, Strauss and Corbin, 1998) where theory are discovered 
or emerge from dialogue, topics, categories and themes that exist within the data: 
Inductive theory development.  Grounded Theory research is frequently used within 
nursing and healthcare research (Dunne, 2011, Gelling, 2011); it is an established 
methodology for providing insight and understanding of the patient experience 
(Hernandez, 2010).   The use of an accessible methodology, familiar to colleagues 
(particularly those within the breast care team) was a fundamental factor in selecting 
this research approach. For this reason Grounded Theory was selected in 
preference to a generic thematic analysis approach. 
 
Two content analysis approaches, Discourse (Crowe, 2005) and Content analysis 
(Elo et al., 2014), were considered for this project.  Both approaches are ideally 
suited to conversation and transcription analysis (Silverman, 2000). However 
because these approaches focus on the use and context of language (within the 
phenomenon) they were rejected.  Furthermore, these approaches are better suited 
to observational research that is conducted in the environment where the (clinical) 
interaction occurs.   
 
The use of Interpretive Phenomenological Analysis (Smith et al., 2009, Larkin et al., 
2011), an approach ideally suited to understanding the patient experience, was 
considered.  This approach, like Grounded Theory, uses a ‘bottom up’ approach 
where the researcher develops theory from the data, rather than testing current 
theory.  Similarly, the use of interview and transcription data is applicable to this 
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approach.   While this approach was considered to be more appropriate than the 
previously described content analysis approaches, Grounded Theory was 
considered to be more widely accessible to the researcher and clinical colleagues.   
 
An Interpretivist approach (Ormiston et al., 2014a) has been employed with the aim 
of producing in-depth qualitative data that illustrates the diverse experiences and 
opinions from the patient group.  Relationships between the categories and themes 
have been evaluated using a constant comparative or substantive approach (Glaser 
and Holton, 2004).  This data analysis approach facilitated the generation of 
categories and themes that have been explored and refined to develop knowledge 
(of the patient experience) and theory.   
 
An alternative Positivist approach (Bryman, 2012) was considered; this approach 
uses existing formal theory to develop or test hypothesis and themes that emerge 
from data (Polgar and Thomas, 1995, Glaser and Strauss, 1999, Sarantakos, 
1998a).  At the outset of this study, the patient experience of early BRCA gene 
testing was unexplored; formal theory was not available to test, correspondingly a 
Positivist approach was rejected.  Furthermore (and significantly), patient\ 
experiences where neither known nor anticipated. Thus the development of a priori 
hypothesis20 and themes (to test) would have relied upon researcher imposed, pre-
conceived opinions that could restrict the study scope and (adversely) impact theory 
development. 
 
                                            
20 A priori hypothesis is based on assumptions and generated before research begins. 
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Whether a literature review should be undertaken has been the source of much 
debate by Grounded Theorists (Dunne, 2011) and healthcare researchers (Heath, 
2006, McCallin, 2003).  In simple terms purists, such as Strauss and Corbin (Strauss 
and Corbin, 1998), argue against conducting a review of literature which may 
contaminate data collection and theory development while the more pragmatic, 
including Glaser, assume “theoretical sensitivity” (p11, section 3.1) (Glaser and 
Holton, 2004) and propose that a “respectful yet critical stance” (p115) (Dunne, 
2011) is adopted.    
 
A wealth of published literature relating to breast cancer and predictive BRCA1/2 
genetic testing was available; this provided background theory and knowledge to 
inform the potential scope of study (Dunne, 2011, McCallin, 2003).  To further defend 
the use of relevant literature, established qualitative researchers recommend a 
review of existing theory to frame the research question (Creswell, 2003, McCallin, 
2003)  and prior to developing new concepts and theory (Stern, 2010).  Employing a 
pragmatic, reflective approach permits the researcher to acknowledge and engage 
with related theory and prior experience whilst developing new concepts (McCallin, 
2003); for example the critical use of existing literature can promote creative thought 
to develop new theory.  Since it is particularly suited to a new or emerging field, such 
as early genetic testing, this pragmatic approach to literature has been adopted.    
 
As previously described, analysis approaches that have been applied are founded 
within inductive, interpretive and constructive scientific methods (Ormiston et al., 
2014b, Bryman, 1988, Blaikie, 2007).  This Interpretivist approach creates 
representations and interpretations from participants’ narratives.  However 
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understanding has been taken from the narratives and interpretation of the data and 
not from related literature or published theory.   
 
Grounded theory proposes that data collection, development of topics and themes 
continues until saturation; where new data does not present additional meaning.  
Theoretical Saturation has been adopted and is fundamental to the sampling plan 
(Carter and Henderson, 2005, Strauss and Corbin, 1998, Bryman, 2012).  
 
Throughout the study (design, documents and thesis) the term ‘opinion’ is used in 
preference to the term ‘attitude’.  An opinion is a point of view or belief, how a person 
thinks about something; opinion is subjective and based on emotion or an 
individual’s consideration of fact or an event (OxfordEnglishDictionary).    Attitude is 
a demonstration of opinion or how a person acts in a given situation 
(OxfordEnglishDictionary).  Opinions are more accessible through interview however 
it is acknowledged that the two are closely related and that attitude may be guided 
by opinion.  
 
Experience and opinions of BRCA gene testing have been explored with the aim of 
uncovering the factors that influence uptake of the test and response to test results.  
Coding topics, analysis categories and sub-categories have been developed by the 
researcher to assist analysis.  The investigation focuses on whether a progression 
towards BRCA gene testing at the time of diagnosis to inform treatment decisions 
would be acceptable and feasible.  
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Where a participant had undertaken early genetic testing their experience has been 
fully explored. However the majority of participants recruited to the study undertook 
BRCA genetic testing after diagnosis.  In order to investigate opinions relating to 
early genetic testing participants were asked hypothetically how they would respond 
to an offer of genetic testing at the time of diagnosis.   While this required 
participants to consider hypothetical situations it was determined that they would 
base their response on opinions that had been formed during their genetic test and 
breast cancer experiences.   
 
Throughout the project it has been assumed that an external reality exists 
independent of peoples beliefs about or understanding of the reality: the 
Philosophical stance taken is based in Realism (Ormiston et al., 2014b).   
 
In relation to knowledge and how it is acquired or Epistemology (Truncellito) a 
Pragmatic Inductive stance (Ormiston et al., 2014b, Glaser and Strauss, 1999, 
Ritchie and Spencer, 1994) has been adopted: individuals gather evidence from 
experiences then build knowledge based on the evidence.  Furthermore this 
epistemologic stance acknowledges that the participant’s and researcher’s prior 
experiences and knowledge cloud their judgement and the researcher’s analysis 
(Ormiston et al., 2014b). This research is concerned with experiences and 
knowledge; it is acknowledged that the participants’ narrative of their experience and 
knowledge are therefore clouded.  Facts, values and opinions will cloud experience 
or knowledge. Additionally, time will play a role in clouding the experience or 
knowledge; it has been assumed that where the experience occurred more recently 
the participant will have better recall of the event and their emotional response to the 
86 
event.  It is recognised that recall bias may occur, particularly where participants 
undertook genetic testing experience some time ago. However in defence, this 
exploratory study aims to illustrate a broad patient experience, furthermore a rich 
narrative, indicating good recall, was provided by all participants.   
 
Theories of truth have been considered: Coherence and Correspondence Theories 
of Truth (Dowden and Swartz, Ormiston et al., 2014b) have been adopted.  The 
Coherence Theory of Truth relies on an account or narrative being supported by 
more than one additional account for verification; where a participant has provided 
alternative statements that support an account or opinion the account has been 
adopted as true.  Additionally where a narrative or statement is supported by another 
independent account, for example by another participant’s narrative, the account has 
been adopted as true; Correspondence of Truth (Ormiston et al., 2014b).   
 
Inconsistencies and contradictions exist within the narratives, where these occur the 
Pragmatic Theory of Truth has been adopted; it has been assumed that the 
participant believes the statement to be true because it is useful or helpful to them.   
To assist synthesis, during analysis, generalisations have been made where 
categories and themes recur.  Where generalisations have occurred, either 
throughout one or several narratives, effort has been made to illustrate theory using 
dialogue from each participant with the aim of providing equal voice to all 
participants.  Proportional participant representation has been attempted throughout 
the presentation of study findings. However the small sample size has inevitably lead 
to greater representation for some participants.  
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Validity and Reliability 
The researcher’s objective perspective and reflections are woven throughout the 
analysis although true representations of the participants’ narrative have been 
retained as the principal method for communicating the constructed topics, 
categories, themes and theory.  Furthermore this technique, exemplified by the use 
of verbatim quotations, has been adopted to enhance internal reliability and validity 
with the central aim of minimising researcher bias.  
 
Additional techniques have been employed to reduce researcher effects and improve 
internal validity, reliability and objectivity (Sarantakos, 1998b, Silverman, 2000):  
1. A neutral and professional stance has been adopted when engaging with 
participants with the aim of creating an interactive, non-judgemental 
relationship between myself (the researcher) and the participants. This neutral 
position has been maintained throughout the research, in order to produce 
objective findings.  For study participants, and the audience, the purpose of 
the research has been clearly presented.  Furthermore my status as nurse 
and researcher has been revealed with the aim of communicating 
professional biases and values.  For (potential) participants, this was detailed 
in the invitation letter and participant information sheet, additionally 
participants were advised during the informed consent discussion prior to 
consent and enrolment. Neutrality assisted candid discussion of the genetic 
test patient experience; had the research been conducted by a member of the 
clinical genetics team this neutrality may not have been achieved.  
2. Throughout the study, during data collection and analysis, a reflective and 
reflexive stance (Sarantakos, 1998b) has been adopted with the aim of 
88 
moderating potential researcher bias (Ormiston et al., 2014b) and providing 
flexibility to the data collection. However adherence to the interview schedule 
(Appendix G) has occurred primarily to reduce researcher bias. 
Comprehensive verbatim transcriptions that include subtle utterances, and 
reflective research notes have been produced by the researcher, close to the 
time of interviews.  This complete written record of interviews ensured 
accurate representation of participant narratives; this is fundamental in 
reducing researcher bias. Furthermore these transcriptions and high quality 
audio files are source data from which summary data matrices have been 
created. Reflective notes, also taken during analysis, are clearly identified and 
distinct from participant dialogue.  The use of reflective notes assisted 
researcher objectivity and thematic development. 
3. As a novice qualitative researcher the use of supportive (anonymised) 
discussions, following interviews, with member/s of the clinical genetics team 
acted as debrief sessions and assisted the reflective process.  Additionally 
study progress meetings with experienced researchers and members of the 
clinical team occurred predominantly during analysis; thematic development 
was assisted by these study findings discussions. 
 
Sharing interview recordings and transcriptions with participants was identified as a 
method to increase validity.  Participants were advised that copies of their data were 
available.  However no participant requested to receive the interview transcription or 
audio file therefore it was deemed that this technique could offer little benefit to the 
project.  For this technique to prove valuable participants would be required to read 
and / or listen to their data, then confirm accuracy. However participants did request 
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results from the study; a lay report will be produced although this is not intended to 
increase study reliability or validity. 
 
7.3 Research Design 
Following a review of qualitative and quantitative methodologies, qualitative 
methodology was identified as the most suitable method for investigating patient 
experience. Quantitative methodology was rejected because it was anticipated that 
the patient experience data would be broad ranging and that numeric coding 
techniques would be inadequate for capturing meaning. 
   
A detailed assessment of qualitative methodologies was conducted to identify an 
appropriate approach to explore patient experience and opinion.  This evaluation 
focused on four methodologies: questionnaire, focus groups, semi-structured and in-
depth interviews.  Particular consideration was given to the study population and the 
potentially sensitive issues that relate to the patient experience.  The advantages 
and disadvantages of the methodologies examined are detailed in Appendix F / 
Table 15: Qualitative Methodologies - Advantages & Disadvantages.   
 
In-depth interviews were judged to be the most appropriate methodology because 
they would yield rich data that would illustrate the diverse experiences and range of 
opinions of this patient group.  Semi-structured and structured interview 
methodologies were rejected; they were considered less applicable to the 
investigative nature of the study.  Fixed questions and / or pre-determined ordering 
of the interview schedule would reduce reflexivity to adapt the interview schedule 
(Sarantakos, 1998b) to the participant narrative; impacting data depth and quality.   
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In-depth interview methodology is particularly applicable for exploring sensitive 
topics, such as the issues that surround breast cancer and genetic testing.  
Furthermore a Grounded Theory approach combined with interview methodology 
(Hernandez, 2010) is most appropriate to inquiry that seeks to understand opinions, 
motivations, decisions and the impact of decisions (Lewis and Nicholls, 2014).  
Additionally in-depth interview methodology is suitable for a small number of 
participants: it was anticipated that study population would not exceed 20.   
 
A mixed methodologies design, combining questionnaires and in-depth interviews, 
was evaluated with the aim of collecting a large amount of scoping data prior to 
conducting in-depth interviews that would yield richly descriptive data from a smaller 
number of participants21.  However the use of questionnaires was rejected primarily 
because they would not capture sufficient detail to facilitate understanding of the 
patient experience or opinion.  Furthermore, available open-code (free to use) 
validated questionnaire tools relevant to this field of enquiry could not be identified, 
further excluding the use of questionnaires.  The process of developing a validated 
questionnaire that could gather useful qualitative patient experience data, to address 
the study aims was considered to be out-with the study scope and timescale.  
Significantly the pilot or validation process would require peer and patient input; early 
genetic testing is a new phenomenon, correspondingly the researcher and Clinical 
Genetics colleagues judged the engagement of hereditary breast cancer patients or 
breast care colleagues to be inappropriate.    
 
                                            
21 Study proposal approved by sponsor and submitted to Tayside Committee for Medical Research 
Ethics (Ref: 11/ES/0045).  Favourable ethical opinion was not received. 
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While exploring mixed methodologies focus groups were considered, as an 
alternative to questionnaire methodology, with a comparable aim of scoping data in 
advance of conducting in-depth interviews.  Focus groups function as a group 
interview; the researcher initiates questioning then participants interact, discussing 
the topic, while the researcher facilitates and observes (Polgar and Thomas, 1995).  
Focus groups could have been used to collect general genetic testing patient 
experience data, prior to conducting in-depth interviews (ideally with the same 
participants) to yield the personal opinion (and / or potentially sensitive) data. Focus 
group methodology is popular within healthcare research however it was rejected 
primarily for issues of data collection; accurate recording would require sensitive 
(and potentially expensive) equipment that was not readily available to the 
researcher.  Furthermore, as a novice researcher, it is important acknowledge 
limitations; the role of focus group facilitator was judged to exceed my skill and 
experience. In-depth interviews were subsequently retained however mixed 
methodology research, utilising questionnaire or focus group methods, was rejected. 
 
Formal qualitative research training was undertaken by the researcher following 
protocol development, Sponsor approval, submissions for Research Ethics and NHS 
permissions and prior to conducting any interviews22.  As a result of undertaking 
qualitative research training, reflexivity was identified as an essential element for the 
success of the project (Koch and Harrington, 1998).  The study protocol had been 
                                            
22 The courses attended were run by the Social Research Association and Liz Spencer who is known 
for her role in developing the Framework Approach.   
Additionally, informal training was undertaken and focused on the following: 
 Reading; In-depth Interview theory and techniques 
 Listening to anonymized interview recordings 
 Reading anonymized interview transcripts 
 Discussions and interview technique practice sessions (including reflective note taking) with 
experienced qualitative researchers.  
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submitted and approved prior to completion of this research training.  However had 
this training identified potential issues or conflicts relating to the choice of in-depth 
interview methodology, this would have been reconsidered; this did not occur. 
Furthermore the extra knowledge acquired during training reinforced the decision 
and choice of In-depth interview methodology.   
 
In-depth interviews explored key topics: 
 knowledge of genetic testing  
 views on timing for genetic testing following a breast cancer diagnosis  
 impact of test results on treatment choices.  
For sampling and recruitment purposes the study population has been divided into 
three test result subgroups and two timing categories.  While it has been anticipated 
that equal distribution (between the groups and categories) would not be reached, 
the study aimed to sample participants from each. 
 
A qualitative approach has been used throughout.  Reflexivity to adapt the interview 
schedule (Appendix G) to fit the participant’s experience is vital for sensitive and 
appropriate data collection.  This reflexivity permitted the researcher to add topics 
that were revealed during another participant’s interview and / or topical events to 
the discussion, for example when a celebrity received genetic testing for the BRCA 
gene this could be discussed in relation to the participant’s experience.   
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In-depth interviews were audio recorded23.  Interview recordings have been used to 
compile a comprehensive verbatim record or transcription of the interview, soon after 
the interview had been conducted. Supplementary reflective notes were taken by the 
researcher following interview and transcription.   
 
In-depth interviews had been conducted with a similar population, and using the 
same interview schedule, during an earlier NHS Tayside Department of Clinical 
Genetics investigation.  This earlier work, conducted in 2009-10 by Richard Watson 
(BMSc) and Jonathan Berg (East of Scotland REC Ref: 09/S1402/25) is 
acknowledged as a catalyst for developing this work.  As detailed in Silverman 
(Silverman, 2000) secondary data analysis makes use of previously produced 
relevant data. Relevant permissions were sought and obtained prior to accessing the 
previously generated anonymised interview data to supplement the interview data 
collected during this current research. 
 
Ritchie and Ormiston (2014) state the appropriateness of previously produced data 
and its use within the scope of the new research requires careful consideration.  The 
value of this previously generated data is unquestionable: it provided data from the 
group of patients with confirmed BRCA gene mutations and reduced the number of 
new interviews that were required.   Notably the offer and uptake of genetic testing 
close to diagnosis remains uncommon, furthermore the identification of a BRCA 
                                            
23 Recording and verbatim transcribing of the interviews took place only with explicit written informed 
consent.  The digital audio recording device was located close to the researcher and participant.  The 
participant was advised that the device would be turned on at the start of the interview, this occurred 
after the informed consent discussion and confirmation that the participant was happy to start the 
interview.  Participants were free to stop the interview at any time, additionally they were free to 
refuse to discuss any item without affecting their relationship with the researcher or any current or 
future care. 
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mutation after breast cancer diagnosis affects only a small number of patients within 
NHS Tayside.  Therefore it was important to make use of all potential participants 
and data.   Ethically it was considered to be more appropriate to make use of 
previously generated valuable data than to contact these participants for a second 
interview.  
 
A review of the interview schedule that had been used in the previous interviews 
occurred.  The schedule was confirmed to be appropriate and relevant to the aims of 
this study.  Subsequently, it was determined that the same interview schedule would 
be adopted for the new study, for consistency and to ensure comparable data.  The 
(previous) schedule had been developed by the NHS Tayside Clinical Genetics 
Team.  
 
Regrettably only 5 of the original 16 interviews contained complete audio data, 
furthermore the associated transcripts were incomplete. Consequently, these 
recordings were used to complete the 5 previously generated transcriptions, 
providing comprehensive verbatim transcripts for use in secondary data analysis.   
These 5 interviews were of exceptional value and contributed all the data for 
participants with a confirmed BRCA1/2 mutation.  The remaining 11 interview 
recordings were lost and only transcripts existed; the accuracy and quality of the 
transcripts could not be checked (Ritchie and Ormiston, 2014) therefore these would 
only be used if after 20 interviews saturation of themes did not occur. 
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7.4 Sample Design 
The research population have been selected to in order to explore the research 
questions:  
 What are the experiences of genetic testing, for mutations in the BRCA1/2 
genes, for women with a diagnosis and family history of breast cancer?  
 What is the impact of testing for a BRCA1/2 gene mutation before or during 
breast cancer treatment compared with testing after treatment from the 
perspective of women with a diagnosis and family history of breast cancer?  
 
The research team included a NHS Tayside Clinical Genetic Counsellor.  A role 
undertaken by this individual was to facilitate participant recruitment; identifying 
potential participants from the NHS Tayside Clinical Genetics Department database.  
Prior to performing this delegated role the Genetic Counsellor was trained according 
to the study sampling plan and eligibility criteria. 
   
Primary Research Question 
The primary aim has been to explore diverse patient experience and opinions 
following breast cancer diagnosis and BRCA1/2 genetic testing. For recruitment, 
interviewing (data collection) and analysis purposes the population has been divided 
by gene test result into 3 sub-groups: 
 Identified mutation in BRCA1/2 genes 
 Detected no mutation in BRCA1/2 genes  
 Detected BRCA1/2 variant of uncertain significance. 
Standardised recruitment, matching the characteristics or number of participants in 
the three sub-groups, was not planned or attempted.  The researcher was informed, 
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by the Genetic Counsellor, of the participant’s BRCA1/2 status prior to conducting 
the interview.  This knowledge was deemed necessary, to facilitate sensitive 
exploration of the participant’s response to the genetic test result.   
 
In 2012 the NHS Tayside Clinical Genetics Department had a potential group of 32 
participants with an identified BRCA1/2 mutation. However the previously conducted 
study (09/S1401/25) had invited 29 and recruited 16 of this potential 32 participants.  
The sampling plan included the use of supplementary anonymised interview data 
from the previously conducted 2010 study (09/S1401/25)24.  The 3 remaining 
potential participants with BRCA1/2 gene mutation had undertaken gene testing 
since 2011.  These and any newly identified (by NHS Tayside Clinical Genetics 
Department) eligible patients during this study would be invited to participate.  
 
It was proposed that a minimum of 10 anonymised interviews (09/S1401/25), 
transcriptions and supporting data would be required for analysis; this would 
continue until no new themes emerged or theoretical saturation is reached.  However 
only 5 complete recordings and transcripts were available; these would be added to 
the data set for analysis.   
 
In 2012 the NHS Tayside Clinical Genetics Department had a potential group of 
around one hundred patients with breast cancer who underwent BRCA1/2 gene 
                                            
24 Consideration was given to inviting these 16 participants to take part in this study. However 
following discussions with the East of Scotland Research Ethics Service, it was determined that it 
would be ethically appropriate to maximize the use of the valuable anonymised data and not to invite 
the women to take part in a similar study.  Additionally the remaining 13 who had not responded to or 
declined the invitation (and reminder) for the previous study were considered for invitation to this 
study however it was deemed unethical to contact them with a similar study.  Additionally it would be 
highly likely that these patients would decline or not respond to an invitation to this study.    
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analysis during the preceding ten years with results that identified no BRCA1/2 gene 
mutation or BRCA1/2 variant of uncertain significance. These and any newly 
identified eligible patients (during this study) would be invited to participate.  It was 
however anticipated that a number of the potential patients would not be eligible as 
would no longer be living in Tayside and some would have died. 
 
Secondary Research Question 
The secondary research question aimed to explore experiences and opinions 
relating to the time that the genetic test was undertaken.  To answer the second 
research question Purposive Sampling has been employed.  Potential participants 
were selected for comparison based on the time that gene testing occurred:  
 Category A: tested after breast cancer treatment  
 Category B: tested before or during breast cancer treatment. 
As for the primary question, no attempt was made to standardise recruitment by 
category.  The researcher was informed by the Clinical Genetics Counsellor of the 
test timing category prior to conducting the interview.   
 
Knowledge of the patient experience and impact of testing for the BRCA1/2 gene, 
from the perspective of patients from each Category, was identified as fundamental 
to understanding (and improving) the patient experience and breast cancer outcome. 
At the outset, it was acknowledged that equal distribution between these Categories 
could not be achieved.   The majority of patients with breast cancer who undertook 
gene testing (at the time of this research) did so after cancer treatment (Category A).  
This reflected clinical practice.  In 2012 the NHS Tayside Clinical Genetics patient 
population had an approximate ratio of 10:1 (Category A:B). 
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A recruitment strategy was implemented that aimed to create a sample that was 
more equally distributed between the Categories. Recruitment would be biased 
towards patients tested before or during breast cancer treatment (Category B) to 
ensure that data would be available to illustrate and represent the experiences and 
opinions from these patients (Category B).  Additionally this recruitment strategy 
would ensure that all eligible NHS Tayside Clinical Genetics patients who had gene 
testing before or during breast cancer treatment (Category B) were sampled / invited 
to participate.  This sub-population would be similar to those patients who, it is 
anticipated in the near future, may benefit from early BRCA1/2 gene analysis at the 
time of breast cancer diagnosis to inform their treatment choices (Wevers et al., 
2014).   
 
At the outset of this study the potential population, having results that identified no 
BRCA1/2 gene mutation or a BRCA1/2 variant of uncertain significance, are: 
 Category A: up to 90 participants  
 Category B: up to 8 participants. 
Sampling aimed to contact participants in equal numbers from Category A and B 
until all Category B potential participants had been contacted, thereafter potential 
participants were contacted from Category A.  Additionally patients with the most 
recently conducted genetic test would be contacted first.  It was proposed that a 
minimum of 10 new interviews be conducted and analysed.  Ongoing analysis and 
data collection occurred until theoretical saturation was reached. 
 
A major limitation in the previous study (09/S1401/25) is that of the 16 participants 
with an identified BRCA1/2 gene mutation; 15 fit Category A and 1 fits Category B.  
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In 2012 clinical practice had changed (since 2009-10) and a small group of patients 
had received genetic testing around the time of breast cancer diagnosis (Category 
B); these new potential participants were invited to participate.  Additionally the 
Clinical Genetics team alerted the research team if / when any new potential 
participants were identified. Genetic testing at the time of breast cancer diagnosis 
was carried out more frequently in 2012 than in 2009 however was (and is still) 
relatively uncommon. 
 
Eligible participants 
Eligibility criteria are detailed in Figure 8. Potential participants had a diagnosis and 
family history of breast cancer.   These patients have a significantly increased risk of 
carrying a BRCA1/2 gene mutation (Malone et al., 1998, Chappuis et al., 1999).   
 
All participants in the population had undergone gene analysis for the BRCA1/2 
gene.  The study sample corresponds with the high-risk population who it is 
anticipated that in the near future will benefit from early BRCA1/2 gene analysis at 
the time of breast cancer diagnosis to inform their treatment choices (Wevers et al., 
2014).   
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Figure 8: Eligibility 
 
 
 
In Tayside women with a family history of breast cancer commonly attend the Family 
History Breast Cancer Clinic (FHBCC), receiving annual review and screening for 
breast cancer. However it was anticipated that the study population would include 
women who had not known their family history at the outset.  For these women, 
family history is established after breast cancer diagnosis, often in response to age 
of diagnosis and / or tumour characteristics.  However family history may be 
identified in response ambiguous breast and / or ovarian cancer histories25.  In such 
cases, where high risk genetic family history is suspected, clinical and genetic 
investigation can confirm HBOC diagnosis.  Including these women in the population 
was considered essential, this phenomenon is not uncommon and the experience 
and impact of genetic testing for this population is different from those who receive 
routine reviews via the NHS Tayside Family History Breast Screening Clinic.  
                                            
25 Ovarian cancer increases the risk for developing breast cancer CLAUS, E. B., SCHILDKRAUT, J. 
M., THOMPSON, W. D. & RISCH, N. J. 1996. The genetic attributable risk of breast and ovarian 
cancer. Cancer, 77, 2318. 
Eligibility 
Criteria
Female
With a family history of breast cancer
Have / have had a breast cancer diagnosis
Received HBOC Counselling by NHS Tayside 
Clincial Genetics
Have undergone BRCA1/2 analysis
Willing to give consent & participate in the study
Currently live in Tayside
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Exploring the perspective from these women would add alternative and equally valid 
experience and opinions26. 
 
Secondary data analysis of anonymised and complete data from the previous 
research (Ref: 09/S1402/25) supplemented the interviews conducted in this 
research.  Eligibility for the previous research required gene analysis before or 
during breast cancer treatment that identified BRCA1/2 gene mutation.   
 
Potential participants would be selected from a Convenience Sample of 
approximately 135 eligible patients who were under the care of NHS Tayside Clinical 
Genetics Department. Theoretical Sampling, an ongoing process, would stop when: 
Theoretical Saturation occurred (Carter and Henderson, 2005, Strauss and 
Corbin, 1998)  
OR 
20 interviews had been conducted, transcribed and analysed 
AND / OR 
16 previous study (09/S1401/25) anonymised interviews had been analysed.   
 
The previous study (09/S1402/25) population did not include patients who had 
undergone BRCA1/2 gene analysis with results of no BRCA1/2 gene detected or 
variation of uncertain significance.  This population have been included in this 
research and sampling has targeted patients who received BRCA gene testing after 
                                            
26 Women who had received gene testing but did not have a breast cancer diagnosis were not 
included in the study population.  It was determined that the experience of these women would have 
differed from the population with a breast cancer diagnosis.  While women with no breast cancer 
experience similar gene testing processes the impact of the result will not be the same, i.e. decision 
making does not involve breast cancer treatment choices. 
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2000.  Furthermore the previous study had invited all women with an identified a 
BRCA1/2 mutation who had undertaken BRCA testing prior to 201027. Therefore 
sampling targeted patients with an identified BRCA1/2 gene mutation, who 
undertook testing after 2010. 
 
The sampling plan proposed that potential participants from the NHS Tayside 
Clinical Genetics eligible population were contacted with an invite to participate and 
where possible this would be sent close to the time that their genetic test was 
conducted. It was predicted that this would have a positive effect on recruitment: 
where genetic testing was a recent event potential participants may be more willing 
to participate additionally it was anticipated that recall of events would be greater. 
 
7.5 Setting  
The study has been conducted in an NHS Scotland location: NHS Tayside where 
approximately 300 new breast cancer diagnosis are made per year (NHSTayside, 
2009).  In NHS Tayside breast cancer can be diagnosed at one of three clinics: 
 Family History Breast Cancer Clinic 
 One Stop Breast Clinic 
 Scottish Breast Screening Program Clinic28. 
While most women were diagnosed by the Family History Clinic not all women were 
aware of their family history at the time of their diagnosis29; in such cases family 
history was identified shortly after diagnosis. 
                                            
27 Recruitment for the previous research took place in 2009 and concluded in 2010.   
28 The patient’s diagnostic experience will vary depending on which clinic the woman has presented at 
however the procedures, investigations and standards of care will be the same across the three 
clinics. 
29 Diagnosis occurred at the One Stop or Screening Program Clinic. 
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All patients diagnosed with breast cancer by NHS Tayside are cared for by a multi-
disciplinary team (MDT); clinicians and health care professionals are responsible 
from first referral to diagnosis, treatment planning and ongoing patient care.  The 
MDT comprises of Breast Specialist Doctors (including surgeons, medics, 
radiologists, pathologists, oncologists and geneticists), breast care nurses, genetic 
counsellors and radiographers.  The MDT format is common across breast care 
facilities within NHS Trusts in the UK and similar teams exist abroad30.  Within the 
NHS Tayside MDT one breast surgeon has specific responsibility for family history 
patients and close liaison with the Clinical Genetics Department; the role of this one 
surgeon is noteworthy and may not be replicated across other NHS Trusts.   
 
7.6 Recruitment 
Required approvals were obtained prior to commencing recruitment / patient 
activities see Table 5 for details. 
 
Table 5: Approvals Summary 
Organisation Role & Reference Approved 
University of Dundee 
& NHS Tayside 
Sponsor 
Ref: 2012GE01 
March 2012 
Tayside Committee for Medical 
Research Ethics Committee REC 1 
Ethics 
Ref: 12/ES/0038 
June 2012 
NHS Tayside 
R&D 
Ref: 2102GE01 
June 2012 
                                            
30 The stimulus for implementing the MDT in the UK was as a result of the NHS Breast Screening 
Programme in 1998.  Initial up take was slow however Department of Health guidance for improving 
clinical for breast cancer in 1996 TAYLOR, C., MUNRO, A. J., GLYNNE-JONES, R., GRIFFITH, C., 
TREVATT, P., RICHARDS, M. & RAMIREZ, A. J. 2010. Multidisciplinary team working in cancer: what 
is the evidence? BMJ (Clinical Research Ed.), 340, c951-c951. This saw a notable increase in the 
acceptance and uptake of the MDT format for teams and improved working practice relating to breast 
cancer care. 
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It was anticipated that recruitment would be completed within 12 months, by end of 
June 2013. In-line with recruitment in the previous study we anticipated that 50% of 
participants contacted would be recruited.  Potential participants have been be 
contacted in blocks of 10.  To reduce potential drop-outs the researcher aimed for a 
short period of time, up to 8 weeks, between first contact and recruitment (completed 
interview).  It was predicted that a minimum of 10 and a maximum of 20 participants 
would be recruited.    
 
Potential participants were identified and contacted by NHS Tayside Clinical 
Genetics Department with a postal Invitation Letter, Reply Slip and Participant 
Information Sheet (Appendices H, I & K). Participant documents were created with 
input from the NHS Tayside Breast Support Group: Perth Branch.  Throughout the 
recruitment period the NHS Tayside Clinical Genetics Counsellor, who was a 
member of the research team, conducted ongoing clinical / patient database 
searches for eligible potential participants.  Prior to closing recruitment the NHS 
Tayside Clinical Genetics Counsellor ran a final search of the clinical database to 
ensure that no potential participants had been omitted; confirming that all potential 
participants had received an invitation to participate. 
 
Participants received written and verbal study information.  The Participant 
Information Sheet (PIS) was provided by post and at the interview session.  Verbal 
information was provided when a potential participant wished to discuss the study 
(prior to arranging an interview) and / or when the participant was contacted to 
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arrange the interview and again at the interview prior to obtaining written informed 
consent31.   
 
Each participant was given every opportunity to clarify any points they did not 
understand and, if necessary, more information provided where required.  
Participants were given a minimum of 24 hours to consider the information provided.  
It was emphasised that the participant may withdraw their consent at any time and 
without loss of benefits to which they otherwise would be entitled.  The Informed 
Consent Form (ICF) (Appendix L) was provided and completed at the arranged 
interview session. Informed consent was obtained by the Principal Investigator (PI) 
prior to conducting any protocol specific procedure.  The PI is an experienced 
researcher with current Good Clinical Practice (GCP) and informed consent training. 
The PI and the participant signed and dated the ICF to confirm that consent had 
been obtained.  In line with local procedures the participant retained one original ICF, 
the other original was filed in the Clinical Genetics Patient Record and copy stored in 
the Investigator Site File.   
 
Specific consent has been obtained to: 
 conduct audio recording of the interview 
 use anonymised quotes 
 collect clinical information from medical records. 
Optional consent has been obtained for the use of: 
 audio recorded interview, transcription and data in future research  
                                            
31 The verbal explanation of the study covered all the elements specified in the PIS and ICF.   
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 3-4 digits of postcode for deprivation score calculation32.     
 
Participants were advised that they could / can inform a member of the research 
team or Clinical Genetics team at any time should they wish to have their interview 
recording and / or transcription and / or supporting clinical data to be destroyed.  
Destruction would / will be recorded on Enrolment Log.  To date no participants have 
withdrawn.  
 
7.7 Ethical Issues & Measures Taken 
At the time of this study all participants were under the care of the NHS Tayside 
Clinical Genetics Team.  The clinical team conducted a study eligibility and clinical 
appropriateness check prior to sending invitations.   No invitations were sent to 
patients who had recently received an unconnected clinical diagnosis. 
 
Perceived risks for participants were minor although did include possible distress. To 
minimise this participants were informed that the interview would explore topics 
relating to breast cancer and genetic testing.   
 
Informed consent was sought through the provision of a Participant Information 
Sheet (PIS) and detailed discussion relating to study participation. The PIS was 
provided by post, thereafter a reply slip was returned by post and follow-up 
telephone contact with those who express an interest in taking part.  Completion of 
                                            
32 Discussion with the Ethics Committee specified that only the first 3-4 postcode digits could be 
collected.  However deprivation score calculation requires a full postcode therefore this was not carried 
out SCOTTISHGOVERNMENT 2012b. Scottish Index of Multiple Deprivations. Edinburgh.   
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written informed consent took place prior to conducting the interview. Participants 
provided specific consent for the interview being recorded using digital audio 
equipment. The researcher obtaining informed consent recently undertook Good 
Clinical Practice and is experienced in obtaining informed consent for research.  The 
TASC Informed Consent SOP was followed. 
 
Interview discussions included participant thoughts and feelings, based on their 
experiences of genetic testing following the diagnosis of breast cancer. It was 
anticipated that topics such as coping with cancer diagnosis, fears (such as pain, 
death, etc.), body image, sexuality, relationships, lifestyle and financial aspects could 
be discussed. Participants were invited to express their views but were informed that 
they did not have to discuss or reveal anything that they were uncomfortable with. 
Furthermore participants were informed that the researcher is a registered nurse.  
Interviews were conducted in a private room. Participants were advised that the 
interview could be stopped at any time.  
 
The research team included genetic counsellors who were / are available should 
participants wish to discuss anything further.  NHS Tayside Clinical Genetics 
Department operates an open access policy for further appointments and advice.  
Participants were reminded of this policy at the time of informed consent. 
 
Had a participant revealed a medical issue to the researcher or had the researcher 
considered that a participant had a medical issue this would be discussed with them 
at an appropriate time (either during or at the end of the interview). Furthermore the 
patient would be advised to seek advice from their General Practitioner or relevant 
108 
Health Care Professional (for example their Breast Care Nurse).  Clinical oversight 
was provided by the Chief Investigator and the NHS Tayside Clinical Genetics 
Department.  
 
Participants were advised that while there may be no direct benefit to their 
participation, the findings may inform more research and / or may change the way 
that genetic services are provided in the future.  The process of talking about an 
experience that evokes emotion may have cathartic effects.  While this effect was 
not anticipated a beneficial effect was reported by a number of participants who 
stated that they had previously not considered or talked about their genetic testing 
experience in such depth.   
 
Where possible invitations to participate were be sent close to the time that a 
potential participant’s genetic test was conducted. It was predicted that this would 
have a positive effect on recruitment: where genetic testing was a recent event 
potential participants may be more willing to participate additionally it was anticipated 
that recall of events would be greater.  
 
Participation was entirely voluntary and did not affect any medical care received at 
the time of participation or in the future.  In order to minimise inconvenience 
interviews were scheduled at a time and place that suited the participant. Interviews 
were conducted in a private room with only the researcher and participant (and close 
relative if desired) present. 
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All Investigators and study site staff involved with this study comply with the 
requirement of the Data Protection Act 1998 with regard to the collection, storage, 
processing and disclosure of personal information and uphold the Act’s core 
principles.  Information about and gained from participants has been treated in 
confidence and will remain confidential. Only named and delegated researchers 
have access to this information for research purposes.  All study data, paper and 
electronic, will be stored and archived by NHS Tayside for 5 years thereafter they will 
be destroyed.  The TASC archiving SOP will be followed. 
 
Computers used to collate and store the data have limited access measures via user 
names and passwords and are subject to backup. Computers are located in a locked 
office in the Clinical Genetics Department on a password protected secure NHS or 
University of Dundee computer system.  Where laptops are used no patient 
identifiable data is used or stored.  Table 6 summarises data storage systems that 
are in use. 
 
Study data are anonymised; to maintain participant confidentiality they contain no 
participant name or patient identifiers:  
 Participants are identified by a two digit study number 
 Anonymised data is identified by a two digit study number (as per the 
previous study) and prefixed by the letter ‘R’. 
Published results will not contain any personal data that could allow identification of 
individual participants.   
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Table 6: Data Storage 
 Paper 
Site File 
Word Document Excel 
Spreadsheet 
Digital File 
Invitation Log X n=1 X n=1   
Participant Log X n=1 X n=1   
Identifiable 
Information Log 
X n=1   X n=1  
Interview Recording    X n=17 
Transcription X n=17 X n=17   
Highlighted 
Transcription 
X n=17 X n=17   
Data Familiarisation   X n=1  
Topics  X n=1 X n=1  
BRCA Test Analysis 
Categories   X n=1  
 
 
Electronic and paper records containing participant’s personal identifiable data are 
held confidentially and securely in the NHS Tayside Department of Clinical Genetics. 
Personal identifiable data is stored separately from the study data on the Identifiable 
Information log.  This log contains each participant name, address, telephone 
number, NHS Tayside Clinical Genetics identifier and two digit participant number.  
Additional anonymised recruitment logs provide the following: 
 Invitation log = anonymised record of study contacts / potential participants   
 Participant log = anonymised record of recruited study participants. 
 
Permissions may be requested / obtained from the Chief Investigator for use of the 
anonymised digital interview recordings, transcriptions and supporting clinical data 
for secondary data analysis. 
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The majority of interviews (10/12) were conducted in a TASC clinical research facility 
(CRF).  The remaining 2 interviews were conducted at the participant’s home.  The 
protocol and relevant NHS Tayside Procedures were followed. 
 
No incentives or reimbursements were available, participants were informed of this 
via the PIS.  Free parking was available and provided for interview appointments 
conducted at NHS Tayside facilities. 
 
If any participant believes that they have been harmed in any way by taking part in 
this study, they have the right to pursue a complaint and seek any resulting 
compensation through the University of Dundee and NHS Tayside, the research 
sponsor.  Additionally, as a patient of the NHS, they have the right to pursue a 
complaint through the usual NHS process. The NHS has no legal liability for non-
negligent harm. However, if a participant is harmed and this is due to someone’s 
negligence, they have grounds for a legal action against NHS Tayside but they may 
have to pay their own legal costs.  No physical pain or changes to lifestyle were 
anticipated. No complaints or harm have been reported. 
 
7.8 Data Collection 
Recruitment, interviews and early analysis have been conducted concurrently.   
 
August 2012 – March 2013 
Date collection commenced in August 2012.  The initial assessment for Saturation of 
Themes took place late February 2013, as scheduled and following the completion of 
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10 interviews and interview transcripts33.  By March 2013 it was identified that 
saturation had been reached for eight coding topics34 for the sub-group / category of 
participant: test after breast cancer treatment / identified no mutation in BRCA1/2 
genes. Nine participants had been recruited (see Table 7 – shaded blue).  
Furthermore saturation for a significant proportion of the sub-themes had been 
reached for this sub-group/category.  No further potential participants for this sub-
group / category were contacted after March 2013 although one additional 
participant was subsequently recruited, this followed a February 2013 invitation to 
participate. 
 
Table 7: Participants & Targeted Recruitment Plan March 2013 
 Test (by 
Category) 
Totals 
Participants with 
identified  mutation 
in BRCA1/2 genes 
Participants with 
detected no 
mutation in 
BRCA1/2 genes 
Participants with 
detected  BRCA1/2 
variant of uncertain  
significance 
Test Result Totals  
(by Sub-group) 
16 (11 + 5) 5 10 1 
Tested after breast 
cancer treatment 
(Category A) 
12 (9 + 3) 3 9 0 
Tested before or 
during  breast cancer 
treatment  
(Category B) 
4 (2 + 2) 2 1 1 
Table Code:   Participants     Anonymised data 
Recruitment Plan   
 
                                            
33 The tenth participant was recruited in November 2012, complete interview transcription and data 
familiarisation for this participant’s data occurred by February 2013.   
 
34 The eight coding topics were later developed into the four key themes: 
 Genetic Testing 
 Impact of Test and Results 
 Early Genetic Testing 
 Hereditary Cancer. 
 
Further Participants Required No Further Participants Required 
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March 2013 – August 2013 
For the remaining 5 sub-groups / categories saturation of themes had not been 
reached by March 2013 (Table 7: Participants & Targeted Recruitment Plan March 
2013 – shaded grey) therefore additional participants were invited / recruited from 
those sub-groups and categories35. Targeted recruitment continued from March until 
August 2013.  However no potential participants were available36.  In addition the 
previous study (09/S1401/25) did not provide further anonymised data.   
 
Early Analysis 
Data familiarisation, identification of common topics / data categories and 
assessment for saturation of themes occurred prior to conducting in-depth analysis; 
this provided flexibility to adapt interview topics should new subjects, previously not 
considered, become apparent and recruitment37. 
 
Anonymous interviews, transcriptions, supporting clinical data and reflective notes 
have been examined using structured qualitative analysis methods for emerging 
                                            
35 Participants with:  
 no mutation detected in the BRCA1/2 genes tested before or during breast cancer treatment  
 identified a mutation in the BRCA1/2 genes: both before or during breast cancer treatment  
 detected BRCA1/2 variant of uncertain significance: both before or during breast cancer 
treatment.  
 
36 i.e. no patients underwent genetic testing before or during cancer treatment (whose test identified 
mutation, no mutation or variant of uncertain significance in BRCA1/2 genes) and no patients 
underwent gene testing after cancer treatment with an identified BRCA1/2 mutation or BRCA1/2 
variant of uncertain significance. 
 
37 Recruitment would continue until theoretical saturation of themes occurred OR 20 participants had 
been recruited.   Assessment for saturation occurred after 10 participants have been recruited, 
interviews conducted, transcribed and early data analysis had been completed; thereafter 
assessment for theoretical saturation was ongoing.  Where complete data saturation was reached 
recruitment would stop. 
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themes.  Secondary data (09/S1401/25) has been analysed in the same way as the 
new data.   
Supplementary reflective notes were taken by the researcher following interviews, 
during transcription and throughout data familiarisation.  These notes add the 
researcher’s perspective and assisted the development of thematic analysis 
categories. 
 
Data familiarisation involved focused listening to interview recordings, reading 
transcriptions and reviewing clinical data. During this early process eight common 
coding topics were identified: BRCA Test, Family Impact, Diagnosis & Treatment, 
Hereditary Cancer, Information, Knowledge, Coping and Support.  These inter-
related coding topics are represented in Figure 9.  
 
Figure 9: Data Coding Topics 
 
Appendices M and O provide extracts from coded interview transcriptions and 
supporting clinical data and the BRCA Test coding matrix.   
 
BRCA 
Test
Hereditary
Cancer
Coping
& 
Support
Diagnosis 
& 
Treatment
Knowledge 
&
Information
Family 
Impact
For the purpose of this 
representation the following coding 
topics have been combined:  
 Knowledge & Information  
 Coping & Support. 
Within the data these topics are 
independent. 
Within the data Diagnosis & 
Treatment is a combined theme. 
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The final interview was completed in May 2013, with 12 participants enrolled and 5 
anonymised sets of data (interview, transcript and clinical data) obtained. Table 8, 
details recruitment by sub-group and category38.  Saturation of themes was reached 
for one sub-group / category (previously described).  While the four key themes are 
represented saturation of themes was not reached, within the study timeframe, for the 
remaining five sub-groups / categories: participants from the detected BRCA1/2 
mutation and variant of uncertain significance sub-groups and tested before or during 
breast cancer treatment. 
 
Table 8: Final Recruitment 
 Test (by 
Category)  
Totals 
Participants with 
identified  mutation 
in BRCA1/2 genes 
Participants with 
detected no 
mutation in 
BRCA1/2 genes 
Participants with 
detected  BRCA1/2 
variant of uncertain  
significance 
Test Result Totals  
(by Sub-group) 
12 / 5 5 11 1 
Tested after breast 
cancer treatment 
(Category A) 
10 / 3 3 10 0 
Tested before or 
during  breast cancer 
treatment  
(Category B) 
2 / 3 
 
2 1 1 
 Table Code:    Participants     Anonymised data 
 
The End of Study Declaration was submitted to Sponsor, REC and NHS Tayside in 
August 2013.  
 
                                            
38 Ten participants underwent genetic testing after breast cancer treatment all with the result of no 
mutation detected in BRCA1/2 genes.  Two participants were tested before or during cancer treatment, 
one with the gene test detecting no mutation in BRCA1/2 gene and one with the test detecting BRCA1/2 
variant of uncertain significance. 
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7.9 Data Interrogation & Analysis Approach 
The primary aim of this study has been to provide structured in-depth qualitative 
analysis of interview, transcription, supporting clinical and reflective data to 
investigate experiences and opinions, of women with a diagnosis and family history 
of breast cancer who undertook genetic testing for mutations in the BRCA1/2 gene, 
in order to answer the research questions. Figure 10 details the systematic data 
enquiry process that has been used in attempt to realise the aims of the study. 
 
Figure 10: Study Enquiry & Objectives 
 
 
The study data and anonymised data from the previous study (09/S1401/25) have 
been combined into a single dataset.  Anonymous interviews, transcriptions, 
supporting clinical data and reflective notes have been examined for emerging 
themes.   A substantive approach has been taken: the data provides a window onto 
the participant’s world. 
 
Identify factors influencing test & treatment decisions
Explore genetic test experience
Evaluate impact of test & BRCA1/2 results
Determine whether timing impacts the experience & 
treatment
Identify plausible and acceptable approaches to 
improve breast cancer management from a genetic 
perspective
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Secondary data obtained from the previously conducted study has been combined 
with the new data with the aim of expanding the findings from the previous study and 
to expose new viewpoints / themes. During analysis no distinction has been made 
between data source.   
 
Systematic in-depth qualitative analysis has been on-going, analytical and 
investigative.  Furthermore the data analysis process started close to conclusion of 
the interview when reflective notes were taken.  Thereafter data familiarisation 
commenced with detailed listening (to interview recording), reading (of interview 
transcriptions) and reflective note taking.  The process of transcribing the interview 
and creating coded transcriptions further underpinned data familiarisation and early 
analysis.    An interpretative framework has been adopted to provide understanding 
based on the participant’s experience and perspective relating to Genetic Testing 
and Breast Cancer.   Throughout analysis themes have been developed to provide 
knowledge of the patient experience of genetic testing for the purpose of informing 
breast cancer treatment.   
 
The Framework Approach has been utilized to summarise the data and assist 
synthesis using common topics and categories (identified early in analysis) and sub-
categories (developed later in the analysis process)39.    Data summaries, that retain 
their links to the participant, are key elements and benefits of implementing the 
Framework Approach (Ritchie and Spencer, 1994, Ritchie et al., 2014, Spencer et 
al., 2014)40 41.  
                                            
39 An extract from a coded transcriptions are presented in Appendix M. 
40 Appendix N provides extracts from a Coded Interview and the BRCA Test Theme Word Document. 
41 Appendix O provides an extract from the BRCA TEST Coding Matrix 
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Data management, or the process of making qualitative data manageable, required 
considerable sorting and labelling (Spencer et al., 2014).  Throughout the study, 
manual data management and coding methods were used (Ritchie and Spencer, 
1994)42.  Figure 11 details the 5 stages of data analysis.  
 
Figure 11: Data Analysis Process 
 
 
 Source / adapted from (Ritchie and Spencer, 1994) 
 
 
 
 
                                            
42 Consideration was given to the use of Computer Assisted Qualitative Analysis (CAQDAS) 
programs however following detailed enquiry that focused on 4 CAQDAS programs (NVivo8, 
MAXqda, ATLAS6 & DRS) and discussions with experienced qualitative researchers CAQDAS was 
considered to have limited use in this study.  Training time and cost to purchase a relevant CAQDAS 
program were the rationale that prohibited the use of this type of tool. 
 
Data 
familiarisation
Data coding 
to identify 
common 
topics 
Indexing Charting
Mapping & 
interpretation
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A key to successful manual data management is familiarity with the data:  during the 
familiarisation process the investigator immersed herself in interview dialogue, 
transcription text and clinical data. Following data familiarisation and early data 
analysis, colour codes were allocated to denote each of the common topics: 
Grey = BRCA Test    Yellow = Diagnosis & Treatment   
Red = Hereditary Cancer Green = Family Impact    Purple = Coping 
 Pink = Support  Dark Blue = Knowledge Blue = Information        
 
Transcription statements / text of interest were subsequently highlighted and colour- 
coded according to these 8 common topics, creating Highlighted Transcriptions 43 
(Appendix M and N).  Where dialogue related to one or more Topic the text block 
has been highlighted using all relevant colour codes44.  Highlighted, coded dialogue 
relevant to the BRCA Test topic was transferred, to the following documents which 
have been used to assist data analysis: 
 Microsoft Word documents, for each of these 8 topics.  These contains all 
text relevant to the topic, sub-divided by participant (Appendix N) 
 Microsoft Excel Topics spreadsheet  
 Microsoft Excel BRCA Test Topic spreadsheet (Appendix O).  
 
                                            
43 Highlighted transcriptions are stored electronically as Microsoft Word documents.  
 
44 For example, Participant 12 dialogue: 
when somebody tells you that it is a genetic thing, that is the first thing that you think of, you 
know is it going to affect the rest of my family I don’t think it is, I think you just deal with it.   
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Spreadsheets contain text extracts; quotes taken from transcripts and investigator 
comments/reflective notes.  These spreadsheets45 have been used to create 
thematic matrices to: 
 Summarise data to assist data management 
 Identify common topics   
 Identify analytic categories and sub-categories to assist data synthesis, 
whilst ensuring that data retain their links to the participant. 
 
Reflexive and reflective structured in-depth qualitative analysis has been carried out 
to investigate patient experience and opinions relating to the BRCA test. Analysis 
required: 
 In-depth interview recordings 
 Comprehensive interview transcripts 
 Supplementary:  
o Reflective notes of the interview, transcription and data familiarisation 
experience to enhance interview / transcription data   
o Clinical data  
 Thematic Matrices (Ritchie and Spencer, 1994, Spencer et al., 2014) 
(Appendix O) .     
This study investigated dialogue that has been coded to the BRCA Test topic; 
detailed qualitative analysis focused on this topic.  However where a coding topic 
(Figure 9: Data Coding Topics, see page 114) related to or closely impacted opinions 
                                            
45 Password protected to prevent unintended edits. 
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relating to the BRCA Test (or treatment choice) the associated dialogue was 
included in BRCA Test thematic analysis46.   
 
Inductive and deductive, cross-sectional and non-cross-sectional analysis methods 
have been used: 
 Cross-sectional analysis where data are comparable 
 Non cross-sectional analysis where data are not comparable47 
A bottom-up, inductive approach has been the primary analysis method.  Synthesis 
of thematically sorted verbatim data and summaries, using the Framework 
Approach, has generated concepts and themes.   This is a new area with little 
published research; early and interim literature reviews revealed no early genetic test 
theory.   However relevant predictive genetic test and breast cancer theories are 
acknowledged and have been utilised in deductive analysis; these theory has been 
applied (in the later stages of analysis) to corroborate inductively developed themes.  
Furthermore the literature review conducted after thematic development identified 
new early genetic test theory; correspondingly this was applied deductively to test 
and confirm inductively developed themes.  Where possible topics, categories and 
themes have been given the name or words that the participant/s used. 
 
As described previously (Sample Design, Section 7.4) the first assessment for 
Saturation of Themes occurred at a scheduled time-point: following the recruitment 
                                            
46 Although the majority of dialogue from these additional coding topics was not explored within the 
scope of the study, for example while diagnosis and treatment were identified topics, the investigation 
did not seek to explore these specific topics unless an experience or opinion related specifically to 
genetic testing or impacted choices relating to genetic testing. 
 
47 For example: To investigate whether there is a different experience and opinion that relates to the 
timing of the genetic test, data from Category A and Category B have been firstly analysed using 
cross-sectional analysis then meta-level cross-sectional analysis has been carried out, where unique 
cases are revealed non-cross sectional analysis has been employed.   
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of 10 participants and completion of interview and transcriptions (including early data 
familiarisation).  This assessment to identify new (and recurring) themes took a 
pragmatic, informal approach.  Predominantly within each coding topic two or three 
dominant responses occurred, although less commonly up to five have been 
identified.  Where no new themes have been identified, in the presence of data rich 
with recurring themes, this has been assessed as a Saturation of Themes48.   
 
Saturation occurred for participants from the largest sub group / category but due to 
the small sample size it has been assumed that this has not been reached for the 
remaining 5 sub-groups / categories for each of the 8 coding topics.  The ongoing 
assessment did identify new responses within the data, therefore saturation has not 
been reached within the study timeframe.  However rich data from the small 
representation of participants from 4 sub-groups / categories is provided.  
Recruitment and ongoing assessment for Saturation occurred until recruitment 
closed, after the 11 month recruitment period.  
 
Infrequently, data inconsistencies have been identified, and have occurred in 
response to a hypothetical question or less commonly as a result of poor recall. 
Triangulation methods (Denzin and Lincoln, 2005, Lewis et al., 2012, Silverman, 
2000) have been used to explore and interpret these differing perspectives; 
contradictory narratives have been explored, to confirm meaning. For example, 
where a participant contradicted themselves, triangulation has been employed to 
conduct detailed inquiry. This involved checking each relevant statement against the 
                                            
48 For example: the primary reason that participants cite for undertaking the test was either for 
themselves or their family.  At the time of the initial assessment these 2 distinct responses were 
equally represented by participants regardless of the timing or result of their test.  Saturation of this 
analytic sub-category was established. 
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other. Where a consistent or dominant opinion is revealed, this has been interpreted 
in favour of the contradictory opinion.  However where no dominant opinion is 
identified the participant’s uncertainty has been represented. 
 
The BRCA Test topic data has been organised using 4 analytic categories and 17 
associated sub-categories.  These categories and sub-categories have been 
developed from the data then utilised to assist systematic data synthesis.  Verbatim 
transcription data from each interview has been sorted and summarised using the 
analysis categories and sub-categories then scrutinised to further develop themes, 
the use of audio interview data assisted the analysis process. While the data has 
been summarised for the purpose of synthesis ready access to the source data has 
been retained.  Themes have been further refined during the writing of this report.   
Details of thematic analysis categories and sub-categories associated with the 
BRCA Test Topic are shown in Figure 12: BRCA Test Topic, Analytic Categories & 
Sub-Categories.  Dialogue relating to each analytic sub-category is not present in 
every interview (nor was it anticipated) however it is available for at least half of the 
participants.   
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Figure 12: BRCA Test Topic, Analytic Categories & Sub-Categories 
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7.10 Scope & Study Limitations 
This research is the work of a single researcher and whilst overseen by experts 
concurrent coding and analysis did not occur; analytic codes and categories have 
been developed by one researcher.  Study resourcing49 and (tiny) budget did not 
provide the additional researchers to conduct parallel coding.  This can be viewed 
both as a strength and a limitation. Potential researcher bias could have be reduced 
by using additional researchers to during coding and analysis (Miles and Huberman, 
1994). However in defence of this approach; the purpose of this work is a balance of 
academic pursuit and to investigate patient experience and opinion of early genetic 
testing. 
 
The study has been carried out with a clinical genetics focus. However the 
researcher is not a genetics counsellor.  Clinical understanding of genetic 
counselling has been acquired through observation of HBOC counselling sessions. 
Furthermore the researcher previously worked as a clinical research nurse within the 
Clinical Genetics and FHBCC teams.  This approach has enabled candid discussion 
and an independent view of the patient experience.   
 
The scope of this study is limited to a small number of women and a single site:  
participants had a diagnosis and family history of breast cancer and undertook 
genetic testing for high risk BRCA1/2 gene mutations, whilst under the care of NHS 
Tayside Clinical Genetics. It was acknowledged at the outset that sample limitations 
may result in some opinions, topics and themes not being captured however the 
                                            
49 The study team comprised of the Chief Investigator who supervised the study, the Principal 
Investigator who designed and conducted the research and analysis, and a Clinical Genetic 
Counsellor who assisted recruitment and provided post-interview support. 
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research is intended to provide a comprehensive cross-section of opinions within a 
short timeframe and limitations of the project.  There is representation for each of the 
key themes for five of the six participant sub-groups / categories however saturation 
of key themes occurred for only one of the six sub-groups / categories. 
  
The aim has been to capture a broad range of patient experiences and opinions.  
Furthermore we did not plan or attempt to standardise recruitment by matching the 
characteristics or number of participants by gene test result.  For recruitment and 
analysis purposes the study population has been divided into 3 sub-groups, by gene 
test result: 
 Identified mutation in BRCA1/2 genes 
 Detected no mutation in BRCA1/2 genes  
 Detected BRCA1/2 variant of uncertain significance. 
Equal distribution between these categories would / could not be achieved; this 
reflects gene test results where the majority of tests detect no mutation in BRCA1/2 
genes.   
 
At the outset the aim was to create a more evenly distributed sample than the 
previous study.   A major limitation in the previous study (09/S1401/25) is participant 
distribution.  While genetic testing at the time of breast cancer diagnosis is carried 
out more frequently than in 2009 it remains relatively uncommon in 2015.  Since the 
end of the previous study recruitment a small group of eligible patients had received 
genetic testing around the time of breast cancer diagnosis. These patients were 
invited to participate. In addition the Clinical Genetics team alerted the research 
team if / when there were any new potential participants for Category B.   
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An objective of this study has been to acquire data that illustrate patient experience 
and options associated with the timing of genetic testing:   
 Category A (tested after treatment)  
 Category B (tested before or during treatment).   
It was anticipated that the experiences and opinions from the two Categories would 
differ, the primary reason for the difference will relate to urgency50.   To reduce the 
impact of a potential study limitation caused by a greater number of Category A 
participants and to increase the scope of the study, Category A participants were 
asked to consider hypothetically what they would do rather than what they did in 
relation to genetic test at time of diagnosis.  The principle reason for this commonly 
participants undertook the test after diagnosis and future care aims to provide tests 
at diagnosis to inform treatment choice.  Results from the two categories may be 
generalised while reading the results, analysis and study conclusions although it 
should be borne in mind that the experiences and opinions of the study participants 
will differ from the experiences and opinions of future patients51. 
 
Saturation of Themes has been assessed pragmatically.  Saturation for the 4 
analysis categories has been reached for those participants who undertook testing 
after breast cancer treatment, with results that did not identify a BRCA1/2 mutation.  
However it has been assumed that Saturation has not been reached, due to the 
small representation, for women who undertook testing before or during treatment 
                                            
50 For example, urgency for results to inform treatment will be present in Category B and while 
urgency may be a feature in Category A it was anticipated that it may be a lower priority. 
 
51 The population for whom the research may benefit; i.e. results from this study may advise whether 
it is acceptable to move towards offering early genetic testing, for the high risk BRCA1/2 genes, at the 
time of diagnosis to inform treatment choices.    
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and those with results that identify a BRCA1/2 mutation or a variant of uncertain 
significance, regardless of test timing. 
  
As previously described the interview schedule was adopted from a previously 
conducted study.  While the schedule was assessed as appropriate to the current 
study aims, ethical approval (for this study) permitted (version controlled) 
amendments to the schedule.  This would occur in response to new topics or 
themes, revealed in during data familiarisation and early analysis. However no new 
topics or themes were identified, therefore the schedule did not change in response 
to early data analysis.  However later analysis did reveal a topic that had this been 
identified earlier the interview schedule would have been altered: the impact of the 
genetic test upon health behaviours.  However dialogue relating to health behaviours 
has commonly been provided by the participants; this was not prompted by the 
researcher.  
 
A significant limitation relates to the generalisability of results and while the findings 
are illustrative of participant experiences and opinions, a newly diagnosed hereditary 
breast cancer patient, for whom early genetic testing can now be proposed, should 
be anticipated as having a different experience52.  
 
It would be tempting to translate the findings into another area of genetic testing, for 
example:  
 Predictive testing for women with high risk family history and no cancer 
diagnosis  
                                            
52 For example no participant received results within the 3 week guideline time for an early test. 
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 Hereditary cancers where genes have been identified: ovarian and bowel 
cancer 
 Genetic conditions where acute genetic testing is available, for example 
Huntington’s Disease. 
It is advised that while similar genetic testing experiences may exist it is anticipated 
that opinions for the population studied will differ significantly compared to these 
groups, for example urgency for results may not be relevant, and for this reason the 
results should not be generalised. Specific research can be carried out in these 
fields. 
 
In addition it is acknowledged that the population who participated may differ from 
the wider population of patients from a high risk family history with a personal breast 
cancer diagnosis.  It is anticipated that the participants may be more research active, 
knowledgeable and willing to share their experiences, this may relate to personality 
or experience.  No inferences can be drawn for the population who were invited and 
chose not to participate however it may be anticipated that the women chose not to 
share their experiences.  Declining participation can relate to infinite factors for 
example personality type, social or family circumstance, however all are unknown 
and cannot be categorised or assumptions made. 
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8. RESULTS  
8.1 Recruitment & Participants Enrolled 
Recruitment commenced in July 2012 and concluded 11 months later in May 2013.  
NHS Tayside Clinical Genetics Department sent a total of 21 Invitation Letters 
(Appendix H) with accompanying Reply Slip (Appendix I) and Participant Information 
Sheet (Appendix K):  
 Twelve (57%) women were recruited 
 Eight (38%) responses were received within 3 weeks 
 Thirteen Reminder Letters (Appendix J) with a second Participant 
Information Sheet were sent. Ten responses were received within a further 
3 weeks.  
See Table 9 for recruitment breakdown. 
 
Table 9: Recruitment Rates 
Invitations Sent 21 
Responders 18 (86%) 
Recruited 12 (57%) 
Declined 6 (29%) 
Non-Responders 3 (14%) 
 
As described earlier (Section 7.4 Sample Design) participants have been 
categorised according to test timing and results.  A summary of these characteristics, 
for the potential participant’s to whom invitations were sent is shown in Table 10: 
Invitations Sent.  
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Table 10: Invitations Sent 
 Test (by 
Category) 
Totals 
Participants with 
identified  mutation 
in BRCA1/2 genes  
Participants with 
detected no 
mutation in 
BRCA1/2 genes 
Participants with 
detected BRCA1/2 
variant of uncertain  
significance 
Test Result Totals  
(by Sub-group) 
21  1 / 5 19 1 
Tested after breast 
cancer treatment 
(Category A) 
15* 1/ 3 14* 0 
Tested before or 
during  breast cancer 
treatment  
(Category B) 
6 0 / 2 5 1 
Code  Invitations Sent     Anonymised data 
 * includes 2 who declined test during treatment / deferred test 
 
Of the 21 invitations 1 potential participant had confirmation of mutation in BRCA1/2 
genes, 19 had results that detected no mutation and 1 received results that identified 
a BRCA1/2 variant of uncertain significance.  In line with current practice the majority 
of invitations, 15 (71%) were sent to potential participants who undertook testing 
after breast cancer treatment. However, of these, 2 had been offered and declined 
the test during treatment (deferring the test until after treatment).  The remaining 6 
(29%) invitations were sent to participants who were tested before or during their 
cancer treatment.  The previous study (09/S1401/25) provided anonymised data 
from 5 patients with identified BRCA1/2 mutation, 3 tested after treatment and 2 
tested before or during cancer treatment (shown in blue text on Table 10). 
 
Responses were sent using the Reply Slip (Appendix I) and postage paid return 
addresses envelope to the NHS Tayside Clinical Genetics Team, thereafter positive 
responses were provided to the research team.  The research team contacted 
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interested potential participants using the details they supplied, most often via 
telephone or email.  In total eighteen (86%) of the invited potential participants 
responded: 
 Twelve (57%) were willing to give consent and subsequently participated 
in the study: five responded after the first letter, seven responded after a 
follow-up reminder letter was sent 3 weeks later.  
Both response and recruitment exceeded the anticipated rates. 
 Six (29%) declined participation, one of whom was willing to participate but 
had moved out of Tayside 
 Three (14%) potential participants did not respond, despite a follow-up 
reminder letter being sent 3-4 weeks later. They were not re-contacted.   
 
Study participation was discussed and where relevant an appointment arranged at a 
suitable time and venue to complete written Informed Consent (Appendix L) and the 
study interview.  Enrolled participants are recorded on the Enrolment Log and 
Identifiable Information Log.   
 
Where there was no response or a decline to participate was received identifiable 
information was not given to the research team: only participant initials and dates of 
letters were provided for the purpose of completing the Screening Log. 
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8.2 Study Data 
The dataset comprises of recorded interviews, fully transcribed interviews and 
supporting clinical data53 from 17 women.  The interviews provide around 900 
minutes of recorded data and verbatim transcriptions amount to 130,000 words. 
With consent 12 participants were interviewed using the topics and in-depth format 
that were used in the previous study (Appendix G)54. Interviews lasted approximately 
1 hour were conducted by the PI at an agreed time and in a quiet and private 
location55.  Interviews were conducted in a 10 month period and anonymised data 
from 5 previously conducted interviews (Ethics Reference 09/S1401/25) were 
obtained, with permission from the Chief Investigator. Participant distribution reflects 
NHS Tayside clinical practice during recruitment where genetic testing at the time of 
diagnosis remains relatively uncommon (See Table 8: Final Recruitment, page 115 
for recruitment breakdown). 
   
The first interview was conducted within 2 months of sending initial invitations.  This 
was within the planned 8 weeks between first contact and interview completion 
however the first interview was rescheduled due to interviewer and participant 
holidays.  The final interview was due to be conducted in April 2013 this was 
rescheduled to May 2013 at the participant’s request.   Rescheduling occurred for 5 
(40%) of the 12 interviews.  This could have, but did not impact on recruitment rates; 
                                            
53 Obtained from NHS Tayside Clinical records 
 
54 The topics and format were subject to change and could be adapted if recurrent areas which had 
previously not been considered become apparent during analysis, a new version controlled Interview 
Guide would be produced should this occur.   However this did not occur. 
 
55 Tayside Medical Science Centre (TASC) Clinical Research Facility (CRF) or participant’s home.   
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the original interview appointment time was instead used to produce transcriptions, 
carry out data familiarisation or collect clinical data. 
 
Audio recording of each interview was conducted using an Olympus Digital Voice 
Recorder WS-81156.  Only one participant chose to halt a recording, for the purpose 
of an off-line discussion; the participant was happy to recommence with the interview 
and recording.  Interviews were fully transcribed to provide the full interview content, 
including subtleties of tone and inflections.  Reflective notes of the interview & 
transcription experience were taken to supplement the interview / transcription data.  
Anonymised interviews and transcribed data from the previous study (09/S1401/25) 
were used to create a full transcription of each interview. Reflective notes were taken 
to supplement the transcription data.   
 
Clinical data were collected from Clinical Genetic medical records within 4 weeks of 
enrolment: 
 Year of diagnosis  
 Age at diagnosis 
 Treatment received 
 Genetic testing: date of test and date of result 
 Further treatment received up to point of interview. 
Clinical data provided accuracy of dates, treatments and test results and have been 
used in addition to breast cancer experience data that was collected during the 
interview; these data supported analysis.  Additionally the Chief Investigator agreed 
to provide clinical data from the previous study (09/S1401/25), no new clinical data 
                                            
56 Participants were free to halt the recording at any time. 
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was collected for the anonymised data; this was analysed in the same way as the 
new data.   
 
8.3 Data Findings  
Assumptions 
Throughout this chapter the term patient will be used when describing an event 
which occurred prior to study participation.  The term participant will be used to 
describe events or opinions that were revealed in study.  Text presented in italic font 
are direct quotations from the participant’s narrative.   
 
The BRCA1/2 status and Test (timing) Categories apply only to this study population.  
While a similar distribution may be anticipated across NHS FHBCC and Clinical 
Genetics populations this has not been confirmed. 
 
Quantitative Discussion 
Details of age at diagnosis, the year of each participant’s test, time waited for 
definitive BRCA1/2 gene analysis results, BRCA1/2 status, elapsed time between 
genetic test and study participation are shown in Table 11: Test Category, Result, 
Times & Treatments (see page 138). 
 
Breast cancer diagnosis commonly occurred for the study population between age 
37 and 50.  Genetic testing for the study participants took place between 1997 and 
2012, with 12 of the 17 patients receiving test results in less than 1 year. However 
when considering the total study population, the elapsed time between blood 
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sampling and definitive test results ranged from 2 months to 4 years, excluding one 
(R15) with a 10 year processing time (this commenced in 1997).  Two patients (P8 & 
P10) waited 4 years for definitive results however both agreed to a request for a 
second sample after 2 years had elapsed, results for these second samples took 2 
years.   
 
A notable limitation worth mention (for clarity) is that test timing within the study 
population differs when compared with the newly diagnosed patient for whom early 
genetic testing may be proposed to inform treatment.  Furthermore no participant 
received results that matched the current clinical guideline time of 3 weeks, for an 
early genetic test to inform treatment.  Testing was most recently conducted in 
February 2012, this participant (P6) received a study invitation in July 2012 and 
participated in the study within 10 months of testing.  It is anticipated that when 
testing was undertaken close to study participation that recall will be superior.  It is 
notable that testing which took place after 2003 took less than 6 months for all but 2 
patients. For one, a patient (P8) in whom repeat blood samples were requested 2 
years after initial sampling; definitive results took 4 years from the first sample date 
in 2005.  The second (since 2003) that took more than 6 months occurred in 2010, 
this patient (P7) waited 11 months for results. 
 
Four participants (24%) (P3, P9, R15, R16) commenced BRCA1/2 gene testing 
before or during their cancer treatment. This group included the patient (R15) who 
waited 10 years for definitive results. 
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Thirteen participants (76%) undertook BRCA1/2 gene testing after primary breast 
cancer treatment to inform future risk for themselves and family. However two 
women (12%) (P5 & P12) were offered testing before / during treatment and chose 
to defer until after primary cancer treatment (further discussion follows).  One patient 
(P5) who deferred testing had provided a blood sample however chose to request 
storage of the sample for future testing.  Three of these patients (P5, P11 & P12) 
definitively undertook testing to inform prophylactic treatment. 
 
Five patients received results confirming a BRCA1/2 gene mutation.  One result (P3) 
revealed a BRCA2 variant of unknown significance.  Eleven patients received results 
confirming no BRCA1/2 gene mutation.   
 
BRCA Test Topic 
BRCA Test data has been sub-divided into 4 inter-related thematic analysis 
categories containing a total of 17 sub-categories.  Details of these are shown in  
 Figure 12: BRCA Test Topic, Analytic Categories & Sub-Categories (see page 124 -   
reference to this figure will assist the reader’s progress through these study findings). 
 
A comprehensive representation that exposes the breadth of opinions conveyed in 
relation to the study aims and objectives follows.  Thematic analysis categories and 
sub-categories have been used throughout to assist analysis and where possible 
these are used for data presentation purposes.  Each category section starts with 
key findings and themes, thereafter more detailed discussion, using sub-categories, 
follows. 
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Table 11: Test Category, Result, Times & Treatments 
 Table Key:  * Blood sample provided, patient deferred testing until after treatment  
  + Repeat sample provided 2 years after initial sample 
  ∞Triple negative  
Participant / 
Age @ 
Diagnosis 
 
Test  
Category 
Before / 
During or 
After BC 
Treatment 
BRCA1/2 
Status 
Test 
Year 
Time for 
Results 
 
(from first 
blood 
sample) 
Time 
from 
Test to 
Study  
Primary 
Treatment 
Risk Reducing 
& Subsequent 
Surgical 
Intervention 
P1 / 37 After No BRCA 2011 4 months 11 mths 
Mastectomy 
Chemotherapy 
 
P2 / 48 After No BRCA 2010 5 months 
2 years  
4 mths  
Lumpectomy  
Chemo  & 
Radiotherapy 
Mastectomy 
Reconstruction 
P3 / 45∞ Before 
BRCA 
Variant of 
Unknown 
Significance 
2011 2 months 9 mths  
Chemotherapy 
Lumpectomy 
 
P4 / 37 After No BRCA 2009 2 months 
3 years 
2 mths 
Lumpectomy 
Chemo & 
Radiotherapy 
Bilateral 
Mastectomy 
Reconstruction 
P5 / 42 
After 
(deferred)  
No BRCA 
2009 
(‘07*) 
4 months+ 
5 years  
1 month 
Chemotherapy 
Mastectomy & 
Reconstruction 
 
P6 / 47 After No BRCA 2012 2 months 9 mths Lumpectomy 
 
P7 / 45 After No BRCA 2010 
11 
months 
2 years  
8 mths    
Mastectomy 
 
P8 / 61&64 After No BRCA 
2005 
& ‘07 
4 years+ 
 
5 years  
4 mths  
Lumpectomy 
Mastectomy 
Reconstruction 
P9 / 43 Before No BRCA 2010 6 months 
2 years  
10 mths 
Bilateral 
Mastectomy  
Reconstruction 
Radiotherapy 
(Mastectomy) 
P10 / 42 After No BRCA 
2001 
& 
2003 
4 years 
11 years  
1 month 
Chemotherapy 
Mastectomy 
Radiotherapy 
Reconstruction 
P11 / 45 
After to 
inform 
No BRCA 2010 3 months 
2 years  
9 mths 
Chemotherapy 
Lumpectomy 
 
P12 / 50∞ 
After 
(deferred) 
No BRCA 2011 5 months 
1 year  
10 mths 
Chemotherapy 
Lumpectomy 
Radiotherapy 
 
R2 / 32 After BRCA 2003 
2 years  
11months 
6 years 
Bilateral 
Mastectomy 
Chemo and 
Radiotherapy 
(Mastectomy) 
R11 / 43 After BRCA 1998 
2 years  
7 months 
11 years 
Chemotherapy 
Mastectomy 
Radiotherapy 
Prophylactic 
Mastectomy 
R14 / 46 After BRCA 2002 6 months 8 years 
Bilateral 
Mastectomy 
(Mastectomy) 
R15 / 48 Before BRCA 1997 10 years 13 years 
Chemotherapy 
Bilateral 
Mastectomy 
(Mastectomy) 
R16 / 38 Before BRCA 2008 3 months 2 years 
Chemotherapy 
Mastectomy 
Radiotherapy 
Prophylactic 
Mastectomy 
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8.4 Genetic Testing 
Key Findings: Why Women Undertake Genetic Testing 
In this study population, the proposal for BRCA1/2 genetic testing is ordinarily made 
by a healthcare professional, although less commonly the patient requested the test. 
Participants consistently undertake the test with the aim of informing primary cancer 
treatment or risk-reduction interventions.  
 
Recurring throughout the Genetic Testing dialogue are the themes of maximising 
survival, fear, protection and responsibility.  These closely inter-related themes 
impact participant choice throughout genetic testing and treatment decisions.   
 
The dominant reason for women in this study undertaking the test is to inform 
treatment decisions.  Maximising survival is presented as the recurring theme that 
impacts the decision. A test undertaken close to diagnosis is consistently taken to 
inform primary treatment and subsequent prophylactic therapies. However tests 
carried out after primary treatment are typically initiated, by women in this study, to 
obtain genetic information to guide cancer risk-reduction decisions.   
 
Within this study population the coping style that is adopted by the patient, when the 
test is proposed, influences whether patients actively seeks genetic information or 
accepts a proposal for testing.  While it is understood from participant dialogue that 
coping style is not fixed, those who assume an information seeking style, at 
diagnosis or when testing is considered, commonly request the test. Conversely 
women who, at this time, adopt an avoiding coping style readily accept the proposal 
for testing and are less likely to seek out the test.   
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An important factor that influences the uptake of BRCA1/2 testing, particularly when 
undertaken after primary cancer treatment, is the provision of genetic information to 
inform and offer protection for at risk family members.  While not consistently related 
to treatment choices responsibility and family protection are important themes.  
However participants identify that early BRCA1/2 status information to inform 
treatment will be higher priority and importance than genetic information for the 
family. 
 
Specific themes that relate to the test and informing treatment are ‘just take it’, 
‘prepare for bigger surgery’, getting ‘the right treatment early’ and ‘quick preventative 
treatment’.  Timing of the test is considered less important when considering cancer 
risk-reduction, prophylactic interventions.   
 
Preparing for Results 
Participants describe anticipating extensive surgery, until genetic results are 
available to inform personalised treatment.  Overwhelming, within the study 
population, preference is afforded to minimising the number of surgeries and where 
possible carrying out risk-reducing prophylactic interventions at the same time as 
primary cancer treatment.  Where prophylactic therapy is indicated, in the presence 
of a BRCA1/2 mutation, participants choose to undertake treatments quickly, with the 
aim of avoiding cancer recurrence. 
 
Protection, for self and family, is a theme that relates to disclosing the decision to 
undertake testing, before results are available. Participants indicate that the main 
factor that influences withholding this decision is protecting family, from worry about 
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results.  An alternative proposal is that fear guides this choice; external opinions may 
alter their test decision and previously supportive relationships can be impacted by 
the test and genetic uncertainty.  Furthermore participants identify that healthcare 
support, for the patient and family, can assist decision making throughout the testing 
process. 
 
Impact of Genetic Results on Treatment Decisions 
Women who undertake early genetic testing to inform treatment and prophylactic 
decisions, welcome test results, even when a BRCA1/2 mutation is identified: 
R15 I was grateful that I knew and it confirmed what I needed doing. 
For these women genetic results that identify a mutation are commonly received with 
‘no surprise’:  
R16 it came back positive almost straight away … I had the mastectomy and partial 
reconstruction ... I’ve had my belts and braces radiotherapy … surgery, within the next three 
months (prophylactic mastectomy with reconstruction) … I’ve had the chemo. 
The results facilitate a clear decision and personalised treatment pathway. 
 
Conversely where no mutation is identified or a variant of uncertain significance is 
identified participants describe a range of responses.  However a false sense of 
security the dominant theme: 
P7 there wasn’t anything … maybe that’s a sort of false security. 
Correspondingly they describe uncertainty:  
P5 would have been better knowing, one way or the other … if they could have identified 
something. 
The results report no mutation. However commonly this result is not considered to be 
definitive, participants worry about a false negative result:  
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P9 it’s come back as nothing … I do think they have just not found it yet. 
Participants consistently describe disbelief, they describe having a genetic mutation 
that has not yet been identified, when their result identifies no mutation or a genetic 
variant of uncertain significance.  
 
In response to a test that detects no mutation or a variant of uncertain significance 
participants and surgeons can choose breast sparing procedures. However the 
dominant themes a false sense of security, worry about a false negative result and 
maximising survival are fundamental factors in determining treatment decisions for 
these women: 
R3 even though it was negative I still wanted to go ahead with it (double mastectomy) …  it 
was a relief knowing that, I don’t really know if it was a relief because I know it made it less 
likely …there could still be something … it wasn’t conclusive. 
Within the study population psychosocial factors, including family cancer experience 
and fear of recurrence, motivate patients to undertake larger surgery that when 
based on established genetic risk this decision may be unwarranted. For these 
women treatment decision conflict can be a response to a test that identifies no 
mutation or a mutation of uncertain significance.    
 
Coping style adopted at the time of treatment planning, is identified as a significant 
factor that influences treatment decisions. Participants who display an information 
seeking style are more accepting of the surgeon’s treatment proposal.  Conversely 
those with an avoiding coping style assume a more active role; for these women, 
psychosocial factors appear to play a greater role in treatment decisions. 
 
Overwhelmingly participants support early genetic testing to inform treatment: 
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R16 giving information is much more proactive… it’s a no brainer, that’s what you have to do. 
Furthermore they demonstrate acceptance of the purpose and function of early 
testing. 
 
 
 
 
A presentation of the Genetic Testing sub-categories and evolving themes follows. 
First mention of the BRCA test  
Throughout the narrative participant’s describe who first mentioned genetic testing or 
their initial thoughts about gene testing.  Responses are organised into 3 groups: 
family, health care professional and self.  The relationship between these groups is 
displayed in Figure 13.   
 
Figure 13: Gene Testing & the First Mention or Thoughts 
 
FHBCC 
Dr
Breast 
Surgeon
Oncology 
Registrar
Self
Family
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Health Care Professional 
Predominantly BRCA1/2 gene testing is proposed by a health care professional, this 
commonly precedes the patient’s consideration of genetic testing: 
P9 we’ve been discussing your case and we were looking at it all and we would like you to 
speak to genetics. (Breast Surgeon)  
Acceptance of genetic test proposals within the study population are high:  
R14 You sort of depend on the doctors leading you in the right direction hoping that they 
know what is the best course that you are going to take … if they say genetic testing, you 
would probably agree to get it done.   
Doctors and healthcare professionals are regarded for their role in promoting the 
best for the individual57.  Most commonly, individuals who do not actively seek 
information, those with an avoiding coping style, indicate a ready acceptance of a 
test proposal. 
 
Contrastingly participants describe surprise and depict taking action to include the 
genetic test discussion in treatment consultations: 
P9 if no-one had spoken to me about it … I would have brought it into a discussion at some 
point. 
At the time of diagnosis this participant predominantly displays an avoiding coping 
style although she describes action, more related to an information seeking style that 
would be adopted had she required58.  
  
                                            
57 Notably one doctor, a consultant breast surgeon and FHBCC consultant, is consistently described 
as recommending genetic testing.   Furthermore supporting data revealed that this doctor has 
regularly cared for members of the study population. However it could not be established whether she 
was involved in the genetic test proposal for each of her patients.    
 
58 However for this participant a breast surgeon proposed genetic testing in response to age of 
diagnosis and tumour characteristics; she was not compelled to request testing. 
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Self 
Less often participant’s describe that they had the first thought or were first to raise 
the topic of genetic testing to inform treatment decisions.  An information seeking 
response is displayed:    
P3 When I got my confirmed diagnosis … at that point I spoke about genetics… I’ve always 
thought about genetics … it was discussed straight away … within 2 days of my initial 
diagnosis … after a bit of research I realised that if it was genetic I would be more, it would be 
more suitable to have a double mastectomy. 
Participants who propose genetic testing typically display an increased awareness or 
knowledge of personalised medicine techniques: 
R15 I read about it, always taken interest in research because of family (history). 
An information seeking coping style is associated with these actions; seeking 
information to address the cancer risk.    
 
Family 
More exceptionally a family member may suggest that their relative, the patient 
requests genetic testing: 
P1 it was really my cousin on my dad’s side … they wanted to know, it had to start with me, 
I’m the one that’s had the cancer… it was her ' is it ok if you go & see a geneticist?'  'Aye, 
fine, no bother.'   
However it is anticipated that this request would have a lower priority for the patient 
had testing been carried out before primary cancer treatment. 
 
Reasons for BRCA test 
Similar to first mention of testing, the reasons presented for undertaking the 
BRCA1/2 genetic test fall into 2 groups displayed in Figure 14. However cross-over 
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occurs and multiple rationale are commonly presented in participant dialogue.  The 
participants identifying self, predominantly identify treatment decisions within their 
dialogue.  
 
Figure 14: Primary Reason for the BRCA Test59 
  
 
Self 
The dominant reason for participants proceeding with the BRCA1/2 test relates to 
the individual.  Maximising survival is the dominant theme: 
R2 I needed to know to protect my own self, for my future health … my first priority. 
Within dialogue relating to self-protection, participants emphasise the importance of 
survival, commonly this dialogue conveys strong emotion.   An information seeking 
coping style is attributed to patients who seek genetic information. Information helps 
these women to cope with their diagnosis.  
                                            
59 An unanticipated response (unrelated to treatment decisions) that was provided in addition to self or 
family reasons for the BRCA1/2 test, related to societal and scientific benefit.  Women reported that 
these extra factors were part of the motivation to undertake genetic testing: 
P2 anything that I can do to help other people. 
R14 Mostly for the doctors … or research … rather than my benefit … to see scientifically. 
A factor that may have contributed to this response is that NHS Tayside clinical facilities are research 
active and patients are regularly exposed to research trials.  Additionally the field of breast cancer is 
highly research driven.  Progress within the field of Clinical Genetics relies on knowledge, new 
techniques and technologies.  Genetic material can be used within research will increase scientific 
knowledge. 
 
Self
Family
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The survival theme is a widespread motivation for undertaking the test; it extends to 
cancer risk-reduction and risk-reduction interventions to improve prognosis:   
P5 I agreed to have the actual test done to try and help me make up my mind whether I 
should go through it all again to the other side (mastectomy). 
The importance of appropriate cancer risk-reduction, including prophylactic therapy, 
surveillance and health behaviours, in the presence of a BRCA1/2 mutation is well 
established. Conversely the confirmation that a mutation is not identified can provide 
reassurance that breast conserving surgery is appropriate.  Furthermore, continuing, 
or adopting, surveillance and health behaviours to reduce non-BRCA HBOC risk is 
appropriate for women where no mutation is identified.  
 
The focus on self is at times described as a selfish act:  
P3 the reason for me getting the genetic testing was 99% to do with what my treatment would 
be, nothing else …if they didn’t do the right treatment for myself I might not be here so that is 
not selfish because they (family) need me. 
However self-protection is later justified as survival with additional family protection 
benefit. 
 
Family 
Unsurprisingly, throughout the study, family is a recurring theme and is universally 
cited as a significant factor in undertaking the BRCA1/2 test; consistently participants 
provide family reasons within their narrative.  This is understood to relate to the self-
protection theme, from the perspective of getting the best treatment: 
P11 my children were so young, they were 4 and 2, my priority was staying alive as long as I 
possibly could. 
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Self-protection is further emphasised by participants who indicate having dependent 
children. 
 
Additionally BRCA1/2 status information for family-protection is a common response:  
R14 knowing what gene they had and what steps to take and what course of treatment would 
be more appropriate. 
However it is acknowledged that experiences and opinions of the study population 
may differ from an early genetic test patient group: 
R11 we can treat you different if we know it’s genetic … and if you’ve got any sisters or 
cousins you could pass on that information to them, then they have a choice. 
Participants who undertake testing after treatment identify that BRCA1/2 status 
information for the family will be lower priority, than early genetic information to 
inform their treatment. 
 
Inform treatment? 
Primary cancer 
Within this study population genetic testing to inform primary cancer treatment is less 
common. Results pertaining to primary cancer treatment are presented for 
participants who undertook testing before or during treatment. For two participants 
results were available to inform primary cancer treatment. Data relating to 
hypothetical primary cancer treatment questions are presented later in the chapter 
(Section 8.6 Early Genetic Testing).  Clarification of treatment undertaken is 
displayed on Table 11: Test Category, Result, Times & Treatments (see page 138). 
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Participants acknowledge that early genetic testing preformed in response to a 
treatment planning discussion provides information that can assist appropriate and 
personalised treatment: 
P3 it will influence consultants decisions, it’s not just your decision, they would have changed 
their mind … 'if you do get genetic tested and it comes back positive BRCA1 BRCA2 we 
would change our mind' (Surgeon / Oncologist / Radiologist). 
Reassuringly the narrative displays a relationship where the patient and surgeon 
decide the most appropriate treatment plan. Similarly when proposing genetic 
testing: 
P9 ‘we want you to speak to the genetics’ (Surgeon)… I think they wanted me to speak to 
genetics to talk me into having both my breasts off. 
Recurring throughout the data the health care professional is viewed as an advocate, 
promoting tailored treatment that offers maximum patient benefit and when this is 
based upon established genetic risk: 
P3 I don’t really think you have a choice. I think the choice is made for you unless you put up 
some reasons for it to change … they are qualified they have the (pause) expertise, I don’t. 
Coping style is identified as a significant factor when treatment decisions are made. 
Women who adopt an information seeking coping style, generally accept the 
surgeon’s treatment decision proposal.  Conversely women who adapt an avoiding 
style during treatment decision-making commonly propose, or adopt an active role in 
deciding, the surgical intervention. 
 
Consistently early genetic test results are welcomed:  
P3 it just made such a difference to me … even if it had come back positive gene it still would 
have made the massive difference … whole treatment would have been changed. 
A variant of uncertain significance result follows a similar treatment plan to a no 
mutation result. Dialogue displays that the result established clarity for treatment and 
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in response the BRCA1/2 result breast conserving treatment can be safely 
undertaken:  
P3 The decision, their thoughts were always to do a lumpectomy and in my eyes I would go 
along exactly with what they think … the only change it would have been is if it had come 
back positive. So there was no real discussion afterwards because to me it was black or 
white. If it came back positive … I’m going down one route and if it came back negative I 
would go down the other route … so the decision was made a long time before. 
The dialogue presents the surgeon’s chosen treatment plan, identified prior to 
testing, being implemented following the receipt of the BRCA1/2 result. An 
information seeking coping style is adopted by the patient at the time of treatment 
decision-making; the genetic result confirms for the surgeon and patient that the plan 
is appropriate. 
 
Contrastingly when a test identifies a BRCA1/2 mutation breast conserving surgery 
will not be proposed.   
R16 I had the mastectomy and partial reconstruction 
The result provided genetic cancer-risk clarity and a definitive, more extensive 
surgical treatment, including prophylactic treatment will typically be recommended.  
Furthermore, reconstruction incorporated with primary treatment is increasingly 
considered by surgeons and patients. : 
 
Within this study population results are not consistently available to inform primary 
cancer treatment.  Rarely testing commenced prior to the use of modern genetic 
techniques and while aware that the result would not be available to inform treatment 
this patient chose to pursue testing and wait for results: 
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R15 in my case it didn’t because it was such a long delay … that was something that I’d 
decided anyway (bilateral mastectomy) it didn’t bother me at the time, I knew it was the right 
decision 
While this 10 year wait for results is an extreme example, it emphasises the impact 
when results (that are required and anticipated) are not available to inform treatment. 
Support for genetic testing to inform / confirm treatment is however evident: 
R15 I was grateful that I knew and it confirmed what I needed doing even though I was doing 
it anyway … .the knowledge would help you to decide whether to have a mastectomy or not. 
Irrespective of the prolonged wait for results the value of early genetic information to 
inform treatment is defended by the participant.  This benefit was not afforded to this 
participant but can be anticipated for future HBOC patients. 
 
A more exceptional experience indicates that genetic testing is not be required to 
inform primary treatment: 
P9 I said ‘well can I have both breasts removed’  ... ‘absolutely and in that case you can have 
a, we can do an instant reconstruction’ (surgeon) … I didn’t go back to see (genetics) till 
later… I think we just … could … have cut out the middle man if you will excuse me referring 
to genetics like that... no urgency 'you’ve got enough to be dealing with, we’ll deal with this 
later on' (surgeon)  
The culture for early genetic testing was however new:   
P9 I was advised against doing it, against waiting, delaying … they were saying there is time, 
3 weeks waiting for a genetics test to come back … I was booked in …these huge hours in 
theatre were booked in well in advance.  
While this experience is not one of the oldest it is not considered to be in-line with 
current practice.  Results would have been available before surgery (4 weeks after 
diagnosis) and surgical scheduling whilst complex is today more adaptable. Notable 
throughout this participant’s narrative is her rationale for extensive treatment:   
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P9 it’s breast tissue … it is a bit of my body that you can cut off and chuck in a bin, I would 
rather it cut off and chucked in a bin than the chance of it recurring …  my sister’s experience 
definitely, and other people … we know who have had breast cancer and have had 
lumpectomies or single mastectomies and had the recurrence … I personally don’t 
understand why anybody ever keeps their breasts if you’ve got it and they can cut them off, 
take them off (expressive) … people keep dying  …that was completely my main reason… 
because of my family history I was very clear I wanted everything removed 
The strength of this dialogue may conceal a false sense of security and disbelief in 
response to the genetic test that identified no mutation. Correspondingly maximising 
survival and psychosocial responses to the result are identified as factors motivating 
treatment choice.  Alternative lesser surgeries were proposed: 
P9 a lumpectomy…I don’t want that … or a single mastectomy I didn’t want either … there is 
no (way), I would be lop-sided.  
It is not established, the participant does not indicate, whether an early test result 
that identified no mutation would have altered treatment choice: 
P9 I love the way all of mine worked and the way it has all gone and it is fabulous … I kinda 
do think at some point you will find something else. 
This treatment plan (double mastectomy and immediate reconstruction) was made 
and carried out before receiving the BRCA1/2 test result.  The extensive surgery 
undertaken offers a significant risk-reduction and acceptable cosmetic result 
although based on the established genetic risk it is thought to be unwarranted. 
  
Risk-reducing treatments 
Genetic testing within the study population is predominantly undertaken to inform 
cancer risk and identify subsequent risk-reducing interventions.   However when 
considering early testing and the potential impact of a BRCA1/2 mutation, identified 
close to diagnosis: 
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P1 I would like to have known at that time … make an informed decision, you could have the 
double mastectomy. 
The anticipation of undertaking extensive primary surgery that incorporates 
prophylactic interventions is a recurrent theme.  Consistently participants support the 
option for genetic information at the time of primary surgical treatment: 
P3 It would have been very hard having a lumpectomy and then being told that it was genetic 
… positive BRCA gene because then to make the decision to go back again and have more 
surgery is a big decision 
Genetic information facilitates appropriate treatment decision-making; this dialogue 
emphasises the recurring theme:  Participants overwhelmingly value the option for 
personalised treatment, undertaken early to reduce cancer risk and minimise the 
need for further interventions. 
 
Less commonly participants chose to store their sample and defer testing until after 
primary treatment.  Postponed testing occurred where primary treatment would be 
appropriate if a BRCA1/2 mutation was present:  
P5 I didn’t want that at the time, I thought ‘I’m doing the surgery anyway (mastectomy), I don’t 
need to know’. 
Genetic information to determine subsequent risk-reducing interventions is a 
common theme.  Regardless of timing, the test provides personal genetic and cancer 
risk information to assist risk-reduction decision making.  Significantly this 
participant, in response to a no mutation result, did not undertake additional risk-
reducing surgical interventions.  
 
Recollection of a consultation identifies the predominant response when no 
BRCA1/2 mutation is identified, after primary cancer treatment: 
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P1 ‘Well you’re fine’ (surgeon in response to result) … I was asking ‘should I have this breast 
off?’ … ‘No you don’t need to, it’s a massive surgery’ (surgeon’s response) ‘you‘ve got to think 
of … your body’. ‘You don’t need to tell me!’ (very expressive) I’ve been through it already 
(mastectomy).  So at the moment I’m keeping things at the moment. 
Emphasis placed on the impact of surgery and confirms that further risk-reducing 
surgery, commonly a prophylactic mastectomy, is clinically unwarranted when a 
results identifies no mutation or a genetic variant of uncertain significance. Clinical 
guidance may indicate breast conserving treatment, ongoing breast surveillance 
screening and positive health behaviours.  Prophylactic breast intervention will not 
usually be proposed.  However when breast conserving treatment is undertaken a 
false sense of security and treatment-decision conflict can ensue: 
P11 I would have felt more comfortable had they just removed the whole breast and I still 
have that kind of feeling … I was like ‘oh, mmm was that safe' … I still have this fear of not 
having the whole lot taken away … I would have been happier I know that sounds really 
bizarre nobody wants to have their breast removed but I would rather remove the offending 
item and get rid of it (cancer risk) completely. 
Despite disbelief and conflict this participant undertook no further risk reducing 
surgical interventions, the BRCA1/2 result informed treatment.   
 
Correspondingly for participants with no mutation, who subsequently choose to 
undertake prophylactic bilateral mastectomy, a false sense of security is considered 
to be a significant factor in the decision: 
P4 even though these results were negative It was still something that I quite strongly wanted 
… I still wanted to go ahead with it. 
The dominant themes, maximising survival and disbelief, are identified as 
fundamental in the decision to undertake prophylactic treatment when no mutation is 
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identified.  Associated factors include family history cancer experience and family 
protection. 
 
Conversely where testing identifies increased risk patients consistently undertake 
prophylactic therapies.  In response to an identified BRCA1/2 mutation, regardless of 
timing of the test, these women undertake prophylactic treatment as soon is feasible.  
Furthermore where clinically appropriate, this can be undertaken at the same time as 
primary cancer treatment, for example a bilateral mastectomy: 
R2 I was keen, have the 2nd breast removed at the same time. I just didn’t want to have to 
cope with it twice ... they were talking about radiotherapy & chemotherapy, the thought of 
going through an operation, going through all that treatment, getting out of that and then 
developing another breast lump and having to start again. I wanted to get on with my life, it 
was me pushing for that. 
However in response to a BRCA1/2 mutation identified before primary cancer 
treatment it may be appropriate that additional prophylactic interventions are 
undertaken after primary cancer treatment:  
R16 I’m programmed in for to have surgery, within the next three months for that (mastectomy 
with reconstruction). 
Cancer therapy considerations can impact treatment pathways; for example 
radiotherapy has a negative impact on certain types of breast reconstruction.  
 
Participants identify that the impact of cancer recurrence and additional treatment is 
considerable.  Women propose risk-reduction (for cancer recurrence) to minimise 
subsequent health and psychosocial effects that result from cancer diagnosis and 
treatment: maximising survival. A similar (but lesser) effect can be anticipated in 
response to prophylactic and reconstructive surgery, i.e. combine surgeries. 
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In the presence of HBOC women may have undertaken oophorectomy prior to their 
breast cancer diagnosis, based on family history and predicted genetic risk: 
P6 doctor … suggested getting your ovaries removed … (I) got that done. 
Similarly they consider prophylactic ovarian surgery before genetic testing:  
P2 I’d been talking about the ovarian cancer … (surgeon) suggested getting in touch with the 
counsellor to talk about it.   
Genetic results can inform the decision:   
P9 it’s good not to have the gene … the chances of ovarian cancer would be heavy (if 
BRCA1/2 identified) so it took away the option of having to think do I go through another 
operation … which I would have done (oophorectomy), beyond any doubt. 
The dialogue indicates intention to undertake prophylactic ovarian surgery.  However 
when results identify no mutation, ovarian surgery is not undertaken, demonstrating 
that the test results are used to inform treatment.  
 
In response to an identified BRCA1/2 mutation additional prophylactic ovarian 
surgery is considered: 
R16 I think I’ve got a wee bit longer to think about that … I don’t think that’s immediate … by 
about the time that I’m about 43 I’ve really got to think about that, before the menopause 
because my grandmother had ovarian (cancer). 
However oophorectomy is generally undertaken soon after a mutation is identified: 
R14 I then had to decide whether to have my ovaries taken out because of the genetic strain, 
so I decided to do that as well + get my ovaries taken out About 3 months (after genetic test 
result) 
Women who had undertaken oophorectomy prior to genetic testing, based on family 
history and predicted genetic risk, are reassured that undertaking the procedure was 
appropriate when a mutation is identified. 
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Reaction to BRCA test result 
Response to results and treatment responses correspond to 3 general groups which 
relate to the test result.  Within each group a range of reactions were reported, some 
are short-lived responses while others endure and impact treatment choices. Figure 
15 details the responses with dominant responses shown in bold. 
 
Figure 15: Response to Results 
    
 
No mutation detected 
Responses to this result ranged from acceptance to ecstasy and relief to surprise. 
The dominant theme within the group of participants who received a result that 
detected no mutation is a false sense of security.  Consistently women report that 
their mutation had not yet been identified and that the genetic mutation may be 
identified in the future as techniques improve.  Uncertainty, disbelief and worry about 
a false negative result are understood to impact the treatment choice for this group 
of participants.  
No mutation 
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• Relief
• Surprise
• False 
Security
• Disbelief
Uncertain 
significance
• Uncertainty
• Not yet found
BRCA1/2 
mutation 
• Unsurprised
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Additionally participants provide familial experience accounts of cancer recurrence, 
these are thought to be closely associated with this false sense of security.  This 
description is typical, displaying first relief then disbelief and worry about a false 
negative result:  
P2 It was a relief, in a way to know that they hadn’t found anything but you still have this 
doubt, everything is changing so quickly, you still wonder, maybe there is something, it is so 
strange that 4 of us have had that type of cancer (laugh), alarm bells start ringing. 
Patients receive counselling before the test and after receiving a result of no 
mutation detected to advise that current testing only identifies a BRCA1/2 mutation in 
around 20-25% of families with a strong history of breast or ovarian cancer (NHS 
Tayside Clinical Genetics).  Furthermore genetic blood samples are retained for 
future testing.  
 
A false sense of security and worry about a false negative results is therefore not 
unwarranted as patients with this result may have an unidentified inherited 
susceptibility.  An increase breast cancer risk is acknowledged and increased 
screening is provided for the individual and family members.  However participants 
frequently describe disbelief and consider the result as inconclusive, leaving them 
with uncertainty: 
P5 in hindsight maybe it would have been better knowing, one way or the other 
Fear of recurrence in response to treatment choice is reported: 
P11 I still have this fear of not having the whole lot taken away 
Uncommonly anger is described in relation to the potential uncertainty of a result that 
detects no mutation: 
P9 it annoyed me, ‘oh for goodness sake get it right ’ you know ‘you either have or you don’t’ 
(laughing) … I thought ‘oh god, you’re putting people through that & then you are still saying 
after that you still don’t know. 
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The variety of emotional responses associated with a result that identifies no 
mutation (see Figure 15: Response to Results, pg 157) are associated with 
uncertainty and fear.  Frequently the response is amplified by factors such as age, 
prior cancer experience, support, knowledge and coping style.  Each of these factors 
can impact treatment decisions.  
  
Variant of uncertain significance 
A range of emotional responses are presented in response to results of uncertain 
significance: 
P3 I don’t really know if it was a relief because I know it made it less likely… but I know there 
could still be something.  The fact that it wasn’t conclusive is making me like ‘ohh’! 
A false sense of security is dominant.  Patients with an uncertain significance result 
are informed by NHS Tayside Clinical Genetics to anticipate future developments 
and re-testing.   Such information may further confound a false sense of security. 
Treatment decisions in the presence of a mutation of uncertain significance are 
personalised and based on established tumour characteristics. 
 
Women with a genetic variant of uncertain significance may have a variant that is 
considered normal, one that is associated with an increased breast cancer risk or 
more simply a variant that is not known.    FHBCC screening and risk reduction 
health behaviour information will be offered however the response to uncertainty 
may be similar to a false sense of security.  Some will view the result in the same 
way as a BRCA1/2 mutation, with the associated increased risk.  However medical 
response to this result may not support an identified mutation treatment plan.  
 
160 
BRCA1/2 mutation identified 
Overwhelmingly the reaction to an identified mutation in BRCA1/2 genes is ‘no 
surprise’.  The following dialogue captures a common response: 
R11 being told that (BRCA mutation) wasn’t any great revelation. 
Anger is a widespread response to a BRCA mutation, albeit for a short time: 
R16 I did feel, five minutes angry. You can’t let it … I focused on getting the cancer sorted. 
The psychological process of coming to terms with the presence of a highly 
penetrant gene is at times emotionally charged.  A number of significant factors, 
including age, family cancer experience, knowledge, and coping style impact the 
process. However when faced with a cancer diagnosis around the time of receiving a 
genetic result, participants consistently focus on the cancer treatment and recovery, 
and not the genetic result: 
R16 you had to be so focused on getting the cancer treated, sorted. I focused on getting the 
cancer sorted…You know you accept things happen… there’s no point in me sitting there 
thinking ‘why the hell?’ That wouldn’t have got me better so I focused on that… I was grateful 
that I knew (BRCA1/2 status) and it confirmed what I needed doing even though I was doing it 
anyway (neo-adjuvant chemotherapy, mastectomy and subsequent prophylactic 
mastectomy). 
Within the dialogue, the participant identifies that confirmation of BRCA1/2 status 
provides reassurance, and that the treatment pathway can be personalised to 
maximise survival and prognosis.  This testing pathway (test before treatment) uses 
the model anticipated for newly diagnosed HBOC patients.  Maximum patient 
benefit, within future clinical care pathways, is anticipated when early BRCA1/2 
testing informs treatment.   
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Family experience and (when known) a relative’s BRCA status will affect the patients 
expectations.  If for example a first line relative has previously received a negative 
result and the patient receives a positive result their response may be unpredicted: 
R16 (for) a very, very short period … a wee bit angry that the letter we got 4 years previously 
from my mum hadn’t suggested that the test was a moving ...angry that I hadn’t had the 
chance to have the test, if I had known test was getting better, I would have asked. Anyone 
with similar circumstances who got a letter (previous negative result) … traced and contacted 
and told test much better than it was before … get them before they get cancer … if any other 
families could be caught, traced and told test getting better. 
A realistic expectation of the time that will be required for genetic analysis and the 
accuracy of current testing is now provided, in counselling and in writing, before and 
after the test (NHS Tayside Clinical Genetics). 
 
Support During & After Testing 
Support is considered to be important for the participant and / or family during the 
genetic testing process.  Family support is commonly viewed as relevant and 
important during the genetic testing process: 
R2 people react in different ways …it depends on the support you’ve got around you with 
family. 
It is not clear, within the study dialogue, however it is predicted that family support 
extends to assisting patient’s treatment choice. 
 
Support is consistently expressed in respect of health care professional provision for 
either the patient or the family during the testing process.  This type of support 
relates to the often complex genetic information that is provided before, during and 
after the test: 
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R11 speak to Macmillan nurse and go through everything again (genetic results). 
Support to assist treatment choice is a fundamental role of the Breast Care Team.   
 
However less frequently it is acknowledged that despite an open-door policy patients 
choose not to contact Clinical Genetics: 
P11 In the letter it says ‘always call me’… I don’t want to be a pest I would have liked to 
speak to genetics again. 
Within future clinical pathways the role the wider Breast Care Team in assisting 
treatment decisions will require robust policy to ensure that patients have the 
necessary support to make treatment decisions.  In response to a result that 
identifies no mutation or a mutation of uncertain significance additional follow-up 
genetic counselling support may be needed to explore responses, for example a 
false sense of security and disbelief, that participants reveal.  
 
Impact for family 
The decision to involve family members early in the testing process is not always 
easy.  Predominantly women in this study chose not to involve family members in the 
test decision.  Where early testing is undertaken to inform treatment comparable 
choice is anticipated.  
 
Not informing the extended family provides protection to the patient; their decision is 
not questioned or altered by external (relative’s) opinion. In this example a clear 
decision is reached at the time of testing however in later reflection the decision and 
familial impact are questioned:   
P9 I never sat down & gave anybody any options. Oh god, that’s maybe really selfish? 
163 
Self-protection is afforded when family opinions are not invited.  Fear that relative’s 
attitudes and opinions may alter the genetic test, and subsequent treatment, decision 
is an underlying assumption. The dialogue demonstrates that the BRCA1/2 test is 
taken to inform treatment decision and not to provide genetic information for the 
family.  
 
Additionally the decision not to inform safeguards the family; they have no 
knowledge of the wait for results or potential impact for their health.  Responsibility 
and protection are common features that motivate withholding information about the 
genetic test:   
P2 it’s like saying you’ve got cancer, carrying the cancer gene, so I don’t want to say that to 
them, alarming them 
The dialogue displays a widespread participant opinion: the process of undertaking 
the genetic test displays an increased risk for developing breast cancer.  Women do 
not wish to unduly worry relatives of a potential risk but would rather wait until the 
result is available to give a more definitive risk.  Responsibility for the family is a 
recurring theme relating the uptake of BRCA1/2 testing however it is not considered 
to impact treatment choices, except in relation to survival.   Familial relationships and 
roles adopted by the patient are considered fundamental factors that influence the 
decision to communicate information about an intention to undertake a genetic test.   
 
Less commonly the impact for the family starts when the genetic test is first 
considered and the family are involved in the BRCA test decision: 
P3 we are very close … it was discussed (BRCA testing) straight away … within 2 days of my 
initial diagnosis. 
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In response to this information relatives express concern regarding the potential 
impact of BRCA test (for them): 
P3 she (sister) immediately said that she would want tested. 
While disclosure occurred within a close relationship the patient risked exposure to 
additional psychosocial stress furthermore this previously supportive relationships 
may become strained.   
 
Throughout the dialogue little is found in relation to family members and treatment 
choice, except where a parent or sibling has a previous cancer diagnosis: 
P11 my sister had a mastectomy and my mum had a mastectomy... I was very much up for 
having the double mastectomy if it came back positive. 
In such situations a similar treatment choice, that undertaken by relatives, may be 
considered and is anticipated by the patient. 
 
Consistently familial consequences of genetic information are viewed in relation to 
significant life and health impacts and not the (patient’s) treatment decision.  
However the greatest impact is realised when a BRCA1/2 mutation is identified 
though infrequently this is in relation to the patient’s treatment.  However the process 
of informing family members can be difficult: 
R15 I’ve got two daughters and a son. It took me a few weeks to tell them … I was quite upset 
when I was telling them (BRCA result). 
Disclosing genetic information may gain greater familial understanding and 
appreciation of their hereditary cancer: 
R2 from my mum’s point of view… it has brought up a lot for her and we’ve learnt a lot about 
what she had to cope with … things fall into place for her as well now. 
Revisiting a relative’s cancer journey and treatment pathway however may impact 
treatment choices. 
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Siblings are infrequently mentioned in relation to treatment decisions.  However they 
are commonly the motivation for seeking BRCA1/2 status information and the 
presence of a confirmatory result amplifies the importance of testing a sibling: 
R16 my sister … we felt it was imperative that we get her checked. 
While the motivation for predictive testing is sound the psychosocial implications of 
predictive testing may not be fully considered by all concerned: 
R2 I know that from my sisters point of view, her getting tested for a gene put implications on 
her if she was wanting to re-mortgage her house and life insurances and things like that and if 
she had been diagnosed (identified BRCA gene mutation) with it that would affect her getting 
all these … I hadn’t really thought but from my position, because you definitely have the 
cancer, your priorities do change and you have to do the survival bit first and then deal with all 
the other things later. 
Additionally participants identify children in relation to treatment choice: 
P11 my daughter was 2 and I have a niece so for their sakes … my priority was staying alive. 
Maximising survival is the dominant theme when considering family and impact of 
the test on treatment decisions. 
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8.5 Test & Results 
Throughout this section results relate to the patient experience.  Subsequent data 
that relates to hypothetical questions is presented later in this chapter (Section 8.7 
Early Genetic Testing). 
 
Key Findings: The Impact of the Test & Results 
Waiting for Results 
The blood sampling process is overwhelmingly viewed, by participants, as 
acceptable.  Commonly the women make light of the process, although less typically 
a strong emotional reaction is reported.  This is understood to relate to establishing 
cancer risk and responsibility for self and family.  The importance of early sampling is 
recognised by participants; ensuring that cancer therapies do not compromise DNA 
quality.   
 
Reinforcement of reasons for undertaking the test recur throughout dialogue, that 
relates to waiting for results.  The ‘what will they do?’ theme indicates that patients 
recognise that genetic information increases bespoke treatment options, both when 
considering primary treatment and risk-reducing interventions.  Additionally, and in 
support of the decision to undertake BRCA1/2 testing, while ‘you don’t want to hear 
it’ participants propose that early testing is ‘a no brainer’ that is undertaken ‘so that 
you can get on with it’ then ‘get on with your life’.   
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Participants overwhelmingly propose a ‘don’t worry’ attitude when waiting for results.  
Similarly they accept the waiting time for ‘that’s the way it is’.  Persistently when tests 
are taken after cancer treatment there is no urgency to receive results60.   
 
Participants describe anticipating ‘the big surgery’ should a BRCA1/2 mutation be 
identified: 
P3 if it did come back positive I would want a double mastectomy and I would hope that the 
consultant would agree. 
Treatment options can be identified by participants and health care professionals 
prior to undertaking the genetic test and while waiting for results. However 
exceptionally the patient will propose extensive surgery prior to genetic testing: 
P9 I was really relieved when they said they would take off both my breasts because that was 
a wee bit of my panic that they were going to go ‘we’re going to do a lumpectomy’. 
Such a response is identified as maximising survival.  Additionally it is recognised 
that planning for a result that confirms a mutation, may enable patients to come to 
terms with larger surgery.  
 
When participants consider surgery commonly they describe less extensive, breast 
conserving surgery should no BRCA1/2 mutation be identified. This is understood 
typically occur when an information seeking coping style is adopted:   
P3 I was going down the line of just going for the lumpectomy unless it came back the other 
way (BRCA1/2 mutation identified). 
Similarly when tumour characteristics require a mastectomy (e.g. a large and 
extensive tumour) participants propose less radical surgery: 
                                            
60 Unusually within this study population ‘is it lost’ is a theme that recurs when results have taken 
several years.  However for these participants testing commonly commenced before modern genetic 
techniques were adopted.  Such events are not anticipated in an early genetic test patient group. 
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R16 (if BRCA1/2 mutation not identified) maybe I could have just had one mastectomy and 
not two mastectomies. 
This opinion is in contrast with the anticipation of ‘the big surgery’.  Alternating 
between coping style and treatment decisions may occur in response to the cancer 
diagnosis and the impending genetic status result.  This response may assist coping 
when genetic results are received. 
 
Participants indicate that they are advised how long results are estimated to take.  
Most commonly responses reveal support for the predicted waiting time.  More 
remarkably results are provided before this time:  
P3 my results came through so quickly … most things come through quickly when they are 
positive because the tests don’t have to go any further … so when they came through very 
quickly, prior to coming in to get the tests I kind of thought they were positive and so had my 
sister … so I was even more surprised to see that they were negative. 
Furthermore, a less expected result may amplify the patient’s response. 
 
The Impact of Results 
When considering treatment in the presence of a BRCA1/2 mutation the dominant 
theme is ‘get in and get it done’.  This opinion relates to bilateral mastectomy and 
where appropriate immediate reconstructive surgery.  Participants advise onco-
plastic surgery, for cosmetic and psychological results that ‘put you back together’.  
The uptake of risk-reducing surgery for the related ovarian cancer risk is similarly 
viewed with urgency. 
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Conversely a false sense of security, worry about a false negative result and 
uncommonly anger are described in relation to the perceived uncertainty of a result 
that detects no mutation or a genetic variant of uncertain significance: 
P9 it annoyed me, ‘oh for goodness sake get it right’ you know ‘you either have or you don’t’ 
(laughing) … I thought ‘oh god, you’re putting people through that & then you are still saying 
after that you still don’t know. 
Emotional responses to information that is perceived to be uncertain vary (see 
Figure 15: Response to Results, page 157) and frequently relate to factors such as 
prior cancer experience, support, knowledge and coping style.  Each of these factors 
can impact treatment decisions.  
 
The coping style adopted by the patient at the time results are received is 
understood to influence treatment and risk-reduction decision-making.  
 
Fear of recurrence is reported in relation to treatment choice, breast conserving 
surgery, when no mutation or a genetic variant of uncertain significance is identified: 
P11 I still have this fear of not having the whole lot taken away. 
This fear is associated with the false sense of security that participants report.  This 
theme, worry about a false negative result and treatment decision conflict are 
identified as the dominant reasons that participants, who have results of no mutation 
or a genetic variant of uncertain significance, choose to undertake extensive surgery: 
P4 even though my results were negative my mind was made-up before that I wanted to have 
this double mastectomy and reconstruction. 
Clinically such treatment may not be warranted when genetic status information is 
provided close to diagnosis. 
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Within the study population the uptake of risk reducing interventions including 
prophylactic therapies varies depending on BRCA status: urgent action is commonly 
taken when BRCA1/2 mutation is identified and participants report less urgent or no 
action when no mutation is located.   Furthermore coping style, assumed at the time, 
influences whether the patient adopts a more active or passive role in treatment 
decisions. 
 
 
 
 
A presentation of the Impact of the Test and Results sub-categories and evolving 
themes follows. 
Waiting, Timing & Blood Test 
Consistently participants recognise that their BRCA1/2 status will inform treatment 
decisions and correspondingly they accept the wait for results.  The genetic test 
experiences of this study population are varied and consequently a range of 
responses are presented61.  Further details of the time taken from blood sampling to 
receiving results are provided within the genetic test categories quantitative 
discussion and are shown in Table 11: Test Category, Result, Times & Treatments 
(see page 138).  For this theme responses have been clustered, correspondingly 
waiting responses have been presented by test timing category: before or during 
treatment and after primary breast cancer treatment; thereafter blood test responses 
(for both categories) follow.    
                                            
61 Within the study population the time taken to receive results span a remarkable range, from 2 
months to 10 years: 65% (11/17) < 6 months, 70% (12/17) < 1 year, 82% (14/17) < 3 years, 94% 
(16/17) < 4 years, 100% (17/17) < 10years. 
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Timing: before or during treatment 
Participants describe fast results: 
P3 When you are going through chemo you just take each day as it comes so yes it was very 
much in the back of my mind … my results came through so quickly  
During the wait they do not focus on the test or anticipated results.  However 
participants reveal that they prepare for bigger surgery then reconsider treatment 
choices when the genetic information is received. 
 
Early genetic testing undertaken for the HBOC patient aims to provide results to 
inform primary breast cancer treatment (surgery).  Dominantly within this group 
participants require neo-adjuvant (pre-surgery) chemotherapy and BRCA1/2 testing 
is initiated before chemotherapy. Furthermore test results, for these participants, 
were predominantly available before the anticipated surgery date: 
R16 just before the chemo was to start … (I) got my test done … it came back positively for 
the BRCA1 … almost straight away … I had 5 out of the 6 chemos … (the) 5cm tumour had 
been destroyed, I think they found something like 3mm on the inside (residual tumour)… the 
rest of it and the margins were safe and I had the mastectomy and partial reconstruction 
(laughs) … and removed all my lymph nodes and there’s been no evidence (cancer) at all 
Participants indicate that pre-surgical chemotherapy to reduce the tumour provides 
an ideal opportunity for genetic testing to inform treatment.  They identify that the 
available time can be used to consider the genetic test results and identify 
appropriate surgery including, when a BRCA1/2 mutation is identified, prophylactic 
surgery.   
 
Exceptionally waiting time exceeds the expected time that is advised by clinical 
genetics: 
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R15 I kept asking ‘any results?’… at least a year before I even got a letter…believe it or not it 
was ten years, almost to the day … finally got a letter from them saying that I had (BRCA). 
This testing commenced before current genetic techniques and the wait for results is 
prolonged.  Nevertheless this is an exceptional situation and results were received 7 
years after the 3 year anticipated time.  The response to the BRCA mutation result is 
justifiably more remarkable: 
R15 I was quite upset when I got that (BRCA result) because … over ten years I was getting 
the odd letter saying they can’t find anything I have to say that it was a shock to be told that. 
For this participant the impact of the wait did not have any effect on cancer treatment 
or prophylaxis, decisions were based on predicted genetic risk.  When results were 
received they confirmed the treatments that had been undertaken. 
 
Timing: after treatment  
The wait for results is not viewed with great significance by the population who 
undertook testing after primary cancer treatment.  Consistently this population 
require BRCA1/2 status to inform risk-reduction interventions.  Urgency is not a 
theme:  
P1 it was going to take a while … a couple of months. I just kind of forgot about it, it’s going to 
take however long it’s going to take, there is no point in … worrying about it. 
Similar to participants undertaking the test before or during treatment, participants do 
not focus on the test or anticipated results:  
P6 there’s no (not) really much you can do until … (you) get told whether (pause) you’ve got it 
or not. 
While waiting for results the theme of ‘not much you can do’ expands for these 
participants; they do not anticipate or plan for prophylactic interventions. 
Frustration over the wait is occasionally communicated:    
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P11 wait 3 months for genetics … wasn’t fantastic, that’s the way it was. 
The participant does not place great significance on, and accepts, the wait. It is 
anticipated that the current 3 week turnaround time would have a lesser impact. 
 
Within the study population participants describe concern that their sample or results 
are lost: 
P10 ‘did they loose it?’ … ‘I wonder what the lab is doing with that sample?’  
Notably this participant was required to provide a subsequent sample for further 
investigation.  Testing commenced in 2001 and results were provided 4 years after 
the initial sample.  It is anticipated that modern techniques ensure that results are 
available today within significantly less time and that such an experience will not 
occur when undertaking BRCA1/2 testing to inform treatment. 
 
The Blood Test 
The blood testing element of the test is overwhelmingly viewed, by participants, as 
acceptable. Consistently the women gave little regard to the blood sample and made 
light of the blood-test procedure:  
P1 ‘YES! Just take it!’ (laughing) … you have had so many needles in you what’s another 
thing of blood. 
Less commonly among the study population, when BRCA1/2 testing occurred before 
or during treatment, participants described issues with sample timing, for example to 
ensure that chemotherapy does not affect the genetic quality of the blood sample:  
R15 they said they had to take it before the chemo, cause the chemo would damage … DNA. 
For this study population the genetic testing occurred most commonly after initial 
cancer treatment.  
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Exceptionally an unexpected strong emotional response may be communicated 
where the blood taking process triggered the release of an overwhelming feeling of 
responsibility for self and family: 
P10 It’s quite a responsibility … I remember crying, I wasn’t expecting to be doing that, I don’t 
really do that. 
Responsibility is a theme that recurs throughout the data, in this dialogue the cancer-
risk implication related to the test may be accredited to this reaction.  Additionally it 
can be anticipated that this responsibility extends to family cancer-risk. 
 
Treatment decisions 
Participant experiences, results and opinions varied.  However BRCA1/2 status is 
identified as having the greatest impact on treatment decisions, therefore responses 
are categorised by test result and not timing of the test. It is similarly anticipated that 
a future HBOC patient population undertaking early testing treatment will be most 
influenced by BRCA1/2 result.  Treatments undertaken are detailed on Table 11: 
Test Category, Result, Times & Treatments (see page 138). 
 
No mutation or BRCA1/2 variant of uncertain significance 
The impact of test results for this population are divided by primary cancer treatment 
and prophylactic treatment responses. 
Primary cancer 
Dialogue reinforces the primary reason for undertaking genetic testing: 
P4 ‘will I have new options now I’m getting the testing?’… ‘what will they do?’ 
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Bespoke treatment options, including prophylactic interventions, with the goal of 
maximising survival are emphasised as the dominant reason that participants 
undertake the test. 
 
Within the population response to results are divided.  BRCA1/2 test results 
overwhelmingly inform treatment choice: 
P3 the decision … to do a lumpectomy … the only change it would have been is if it had 
come back positive. I would go along exactly with what they think. They are qualified they 
have the expertise, I don’t. So there was no real discussion afterwards because to me it was 
black or white. If it came back positive I’m going down one route (mastectomy) and if it came 
back negative I would go down the other route (breast conserving surgery). 
The coping style that the patient adopts when treatment decisions are made is 
identified as a significant factor affecting the process. Within this dialogue an 
information seeking style is identified: a passive role is adopted, the patient defers 
treatment decision-making to the surgeon. The initial surgical decision was based on 
tumour characteristics, subsequently the genetic result confirms appropriateness of 
the procedure. 
 
Conversely participants chose to continue with treatment decisions that were 
established before genetic information is available: 
 P9 I said ‘can I have a double mastectomy?’ … (surgeon) ‘absolutely and in that case you 
can have a, we can do an immediate reconstruction’, so that was so that was the decision 
While testing, proposed by the surgeon, is undertaken during treatment the surgical 
decision is taken before results are available.  Maximising survival is identified as a 
significant factor in the treatment decision: 
P9 cut whatever bits off me that you could … just as long as it meant that my odds were 
better and it did, they said it was 80% … decreased my chances by 80% of anything recurring 
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A false sense of security is not identified within the dialogue, the decision was made 
before genetic results were available.  This participant’s coping style is less clear; an 
avoiding style is evident when treatment is initially proposed (by the patient) then an 
information seeking style is adopted when deferring to the surgeon’s proposal.   
 
Similarly (and based on timing of the test) participants chose to continue with 
treatment decisions that were established before genetic information was available:  
P4 even though my results were negative… my mind was made-up before that … if they had 
offered me it (double mastectomy and reconstruction) I would have just took it … even without 
any genetic testing … it was always at the back of my mind … it was a grade 3. 
An avoiding coping style is identified in this dialogue; an active role in the treatment 
decision is adopted. 
 
Commonly within dialogue relating to no mutation, treatment decision is based on 
tumour characteristics and not established genetic risk.   
P4 I’m still guessing I’ve got some genetic link. I guess I’m in that category but what that 
actually means to me and will it come back? 
A false sense of security and disbelief are identified as significant factors in the 
response.  While this treatment choice is made before receiving the result (that 
identifies no mutation) the reaction impacts subsequent cancer risk-reduction 
decisions. 
Prophylactic treatments 
Contrasting the overwhelming opinion is that additional prophylactic surgeries would 
be considered should a mutation be identified: 
P6 gettin’ (getting) your breasts off, that’s a bit radical, but if they said ‘yeah, you had the high 
(risk)’ well then you would really have to consider (it). 
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More definitively surgery would be undertaken:  
P5 (BRCA mutation identified) then I would have definitely gone and done it … make it clear 
cut for me to have my surgery  … at higher risk and had to get it done or maybe I could leave 
it a little bit longer till I’d finished all treatment. 
The genetic result provides context and a timeframe for undertaking risk reduction 
interventions. An information seeking coping style is displayed; the participant is 
being guided or taking a more passive role in the treatment choice. Conversely in the 
presence of a confirmed BRCA mutation prophylactic treatment is undertaken 
rapidly.    
 
Within the data exceptions occur.  In one such situation genetic testing occurs in 
response to a third cancer.  Previous breast and ovarian cancer indicated a potential 
HBOC: 
P8 I never thought it would have happened the second time … (if tested the) first time they 
would be looking into my genealogy … say I did have the faulty gene, it would have been 
discovered earlier  …that would have … cleared things up… you could get on with the 
procedure.   
The dialogue indicates that early genetic testing, would have informed primary 
cancer and prophylactic treatment, thus preventing recurrence and the impact of 
additional surgery and cancer treatments.  These are reasons identified throughout 
the study dialogue as important motivators for undertaking early genetic testing; this 
example reinforces the rationale. 
 
Recurrently participants propose undertaking prophylactic ovarian surgery before 
genetic status is confirmed: 
P9 I would have had my ovaries removed … (doctor) explained the chances of ovarian cancer 
would be heavy 
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Where results do not identify a mutation:  
P9 it took away the option of having to think ‘do I go through another operation?’  
Genetic status personalises prophylactic treatment decisions. 
 
BRCA1/2 mutation identified 
Test results responses for this population are divided into primary treatment and 
prophylactic treatment. 
Primary cancer 
Women undertaking BRCA1/2 testing to inform primary cancer treatment use the 
BRCA1/2 test result to inform their surgery: 
R16 maybe I could have gone away and just had one mastectomy and not two mastectomies.  
The result provides a clear genetic risk which assist initial treatment decisions: 
R16 I had confirmation of my BRCA1 and I had to have my two mastectomies. 
With a confirmed BRCA1/2 mutation cancer treatment and prophylactic therapy are 
undertaken at the same time to reduce the need for further interventions: 
R16 At the end of the day it’s preventing you from getting cancer … so get in and get it done 
… from a prophylactic side of things, if you can achieve what …the plastic surgeons can do, 
I’ve dealt with it, they take you apart (laughs) but they can put you together…it’s a no brainer.  
Additionally breast reconstruction cosmetic results are presented in support of 
immediate bilateral reconstruction. 
Prophylactic treatments 
The genetic result is commonly viewed as confirmation that appropriate treatment 
has been undertaken and that no additional risk reducing intervention is required: 
R14 I knew that (because of) the family history, it would be a recurrent cancer, the best thing 
to do was to eliminate it completely … just get them both taken off at one time…double 
mastectomy with bilateral implant(s).  
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Similarly for the population with an identified mutation support for bilateral 
mastectomy is consistent: 
R2 the thought of going through an operation, going through all that treatment, getting out of 
that and then developing another breast lump and having to start again … I wanted to get on 
with my life. 
Participants overwhelmingly promote extensive surgery, including reconstruction, 
based on the aim of reducing risk, avoiding further cancer and treatments. 
Consistently concern about the link between breast and ovarian cancer this is 
presented as a significant factor in undertaking BRCA1/2 gene testing. BRCA1/2 
status is identified as having the greatest impact on ovarian prophylactic treatment 
choice.  Correspondingly responses have been categorised by test result (and not 
timing of the test). It is similarly anticipated that a future HBOC patient population 
undertaking early testing treatment will be guided by their BRCA1/2 result.   
 
Recurring throughout the study population, participants had previously undertaken 
ovarian surgery before their BRCA1/2 status was established: 
R11 as a precaution like with my aunty having ovarian cancer… I already had hysterectomy 
(and oophorectomy) when I went to get results (genetic test).  
Such decisions are commonly based on family history risk prediction calculations. 
Comparably but conversely participants describe needing to know their BRCA1/2 
status prior to making an ovarian surgical decision.  Where a mutation is identified: 
R14 (I) had to decide whether to have my ovaries taken out because of the genetic strain … 
so I decided to do that as well and get my ovaries taken out about 3 months (after genetic test 
result). 
For a younger participant with a BRCA1/2 mutation the decision for oophorectomy is 
less straightforward: 
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R16 we made a decision between us (patient and surgeon) that I was still at a reasonably low 
risk and if I wanted to I could go away, have children and then I could come back and 
reassess it in due course. 
Additional considerations for younger patients relate to childrearing decisions and an 
early onset menopause with the associated medical risks: 
R2  without having the results of the test it was difficult to get the gynaecology department to 
agree to it because of my young age … he wasn’t keen to do the hysterectomy and remove 
the ovaries because of my you age  … I was able to go along to him and say I’ve got this 
faulty gene with a high risk of me developing ovarian cancer … even I still had to fight with 
him a bit, cause he wasn’t keen to do it but I just had to dig my heels in and insist, and so he 
agreed to do it 
This participant portrays surprise, the BRCA1/2 mutation was not sufficient and 
further discussion was required for ovarian prophylactic surgical intervention. 
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8.6 Hereditary Cancer 
While dialogue relating to hereditary cancer does not relate specifically to treatment 
choice it is considered relevant to patient experience. Furthermore patient 
acceptance is identified as a significant factor that will influence the uptake of early 
BRCA1/2 testing.  Closely associated, awareness is identified as a factor influencing 
the uptake of genetic testing and personalised treatment decisions.  It is relevant to 
present patient experience and opinions to assist in the identification of plausible and 
acceptable approaches to improving the management of breast cancer, through 
early genetic testing. 
 
Key Findings: Hereditary Cancer  
Most commonly within the study population participants have an established 
hereditary breast and ovarian cancer history. These women attended FHBCC prior 
to their diagnosis and have established a rapport with key members of the breast 
MDT.  This relationship is identified as aiding their decision to undertake genetic 
testing.  Additionally the family experience of ‘growing up’ with cancer and attending 
FHBCC provides breast cancer information that a patient with an unestablished 
history is unlikely to access.  Correspondingly participants with significant family 
history indicate a high acceptance of early genetic testing. 
 
Less often family history is identified after breast cancer diagnosis.  Within the study 
population where family history is not established tumour characteristics or a young 
age at diagnosis can trigger a genetic referral. For these women in the study 
population BRA1/2 testing is more commonly offered later in the cancer journey and 
not at diagnosis. However they appreciate and support the relevance of testing.  
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Coping style is identified as influencing whether the patient or healthcare 
professional will initiate a genetic test discussion and timing of the test.  For 
example, participants who adopt an information seeking coping style at diagnosis are 
found to request genetic testing while those with an avoiding style will more 
commonly accept a test proposal.   
 
Participants describe health behaviours that are adopted to reduce cancer risk and 
improve prognosis. However they describe questioning the impact of these at 
diagnosis and when a mutation is identified.  Genetic counselling could be used to 
reinforce the effect of positive health behaviours for women with BRCA and non-
BRCA HBOC.  
 
Awareness 
Participants communicate a diverse range of HBOC knowledge.  Commonly they 
identify age as a significant HBOC risk factor. Associated with this they anticipate 
that a younger patient population will obtain maximum benefit early genetic testing. 
The maximising survival theme recurs throughout dialogue relating to this opinion.   
 
Most commonly within the study population a test reveals no mutation or a mutation 
of uncertain significance.  These participants have consented to future BRCA1/2 re-
testing.  While this process is overwhelmingly supported it may reinforce the false 
sense of security or disbelief when a test does not identify a mutation.  Furthermore 
participants indicate they would gain reassurance should a mutation be identified 
with re-testing. 
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Patient Preferences 
Participants overwhelmingly favour face-to-face discussion when early genetic 
testing is proposed.  Additionally written information is identified; participants 
consider that supplementary material that reinforces the purpose and benefit of early 
testing. Written information can assist their decision to undertake early genetic 
testing: 
P8 face-to-face is a good idea …. also writing … sit & ponder … re-read it … weigh up ‘is it 
too much to take in all at once?’  
Furthermore participants identify that relevant healthcare professionals require 
BRCA1/2 gene and early genetic test knowledge.  
 
 
 
 
A presentation of the Hereditary Cancer sub-categories and evolving themes follows. 
Family history  
Established family history 
Within the population family history HBOC details are commonly established prior to 
breast cancer diagnosis62: 
P9 (breast cancer) my mums sister, my grandmother and 2 of her daughters and then 2 of my 
mum’s daughters… my sister having cancer… and then (I) you have got breast cancer … one 
sister’s had twice, two primary breast cancers, 10 years apart… had lumpectomy …10 years 
                                            
62 In such cases patients will usually receive specialist breast care and surveillance through the NHS 
Tayside FHBCC. Furthermore FHBCC patients are exposed to knowledge of their family breast 
cancer history and individual breast cancer risk (calculated using Clinical Genetics techniques). A 
typical FHBCC pedigree will identify a significant number of first and second degree relatives with 
breast or ovarian cancer, including cancer recurrences. 
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later double mastectomy… mother bowel cancer, father lung cancer, grandmother had breast 
removed 1920s or 30s…quite a history in my family … from my mother, 8 half-sisters all in the 
same line, a lot of women in the family. 
Participants who report significant family history indicate a high acceptance of early 
genetic testing.  Correspondingly the uptake of early genetic testing to inform 
treatment should be anticipated to be high, where families have an extensive history.  
Participants report greater urgency for genetic testing when they have a significant 
family cancer experience.  BRCA1/2 status knowledge for the family is suggested as 
a significant secondary factor in such patient’s undertaking testing. 
 
Previously unestablished family history 
Less common within the population are participants who are unaware of the extent 
or relevance of their family history until their cancer diagnosis.  They report that 
family history of breast or ovarian cancer may be recent and involve few relatives.  
For women with a previously unestablished family history, participants indicate that 
knowledge and acceptance of HBOC and increased breast cancer risk may be 
poorer than those from families where history is expansive and women have ‘grown-
up’ with cancer.   
 
A young diagnosis (age 45) and triple negative tumour can trigger genetic enquiry.   
P3 I was diagnosed … with triple negative breast cancer … it’s 3 crosses … I have no family 
history on one side because my mother was adopted so you always kind of look down the 
negative thoughts and think well maybe there is something there. 
This dialogue, whilst atypical in the study data, identifies both a triple negative 
tumour and an unestablished family history.  Significantly an information seeking 
coping style is evident: 
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P3 after a bit of research I realised that if it was genetic … it would be more suitable to have a 
double mastectomy … I’ve always thought about genetics … my husband’s side of the family 
is riddled with breast cancer. 
Furthermore family history cancer experience is identified as a major factor 
influencing this patient’s search for information and decision to seek genetic testing.  
It is however exceptional and atypical that this family history experience and 
knowledge are from an unrelated bloodline.  Nevertheless for this participant, triple 
negative tumour characteristics together with an information seeking coping style 
ensured that early genetic testing was undertaken. Based on this patient experience, 
it is anticipated, that a patient who adopts an avoiding coping style at diagnosis, 
would not be offered early genetic testing.  Rather, testing would be proposed later in 
the cancer journey: 
P3 at that point I spoke about genetics and they said … that it would be looked at after all my 
… treatment.  
In contrast with this assumption, another participant (P12) with a triple negative 
tumour, and little family history (1 aunt diagnosed 6 months earlier), was offered 
genetic testing by the FHBCC breast surgeon.  Genetic counselling occurred 
however testing was deferred until primary cancer treatment was completed: 
P12 (at diagnosis) I don’t really think that I thought about the gene side of it … at that time 
because I was more concerned about whether I was getting to keep my breast or not … that 
was my main concern. 
An avoiding coping style has been identified throughout dialogue relating to 
diagnosis and the treatment decision; while the patient does not seek additional 
genetic information they assume an active role in the treatment decision. However 
had a BRCA1/2 fault been identified dialogue indicates an information seeking style; 
dialogue implies adoption of a passive role should risk reduction intervention be 
required.  These dialogue (P12) exemplify movement between coping styles: 
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P12 I would have done whatever they said, if they advised me ‘this is what you need to do’ I 
would have done it, you know you don’t want to put your life at risk. 
Exceptionally this participant would have undertaken additional interventions rather 
than favouring a combined approach, as is overwhelmingly favoured by the study 
population. 
 
Access screening? 
Overwhelmingly participants are aware of HBOC prior to their cancer diagnosis and 
FHBCC screening is commonly undertaken regardless of genetic test result.  These 
participants report attending FHBCC for screening every 12-24 months depending 
on risk63.  Consistently participants describe relief that they attend screening:  
R16 I’ve been visiting the family history clinic for a number of years …from my early 20’s… I 
have my annual check at the family history clinic.  
Patients attending annual FHBCC report forming supportive relationships with the 
clinical teams who provide HBOC care.  These relationships are considered 
important and for participants this supports their decision to undertake genetic 
testing and subsequent treatment decisions. 
 
Health Behaviours  
Risk-reducing health behaviours are presented in relation to diagnosis although in 
this study, seldom affect treatment interventions.  Where no mutation is identified: 
P2 I am healthy, you know (not) drinking too much alcohol, eating rubbish,  not taking 
exercise  I eat all my five or more my six portions of fruit and veg every day. 
                                            
63 This comprises of a review by Breast Specialist (Surgical or Medical Doctor), breast examination 
then dependent on age and risk mammography. 
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A negative BRCA1/2 result can leave the individual questioning why they have 
cancer. Correspondingly where a mutation is identified similar reference is made to 
health behaviours and risk: 
R15 it never came as a shock … I breastfed and I always played a lot of sport, I wasn’t 
overweight … I don’t really drink much, I’ve not ever been a drinker.   
While an extensive family history is identified as the most significant cancer-risk 
factor, positive health behaviours have been adopted in an attempt to reduce cancer 
risk.    Participants acknowledge the impact of healthy behaviours in association with 
risk and improving prognosis:   
R16 I was dealing with the cancer side of things, I was going for the (neo-adjuvant 
chemotherapy, mastectomy, radiotherapy and prophylactic mastectomy), I was doing 
everything I could possibly do. You know I drink very limitedly, I’m not a complete nutter,  I 
have the occasional, don’t get me wrong but I look after myself, I eat well, I do all the right 
things … I’ve never smoked, maybe I won’t get it (recurrence). I’ve always been doing my bit 
to keep myself healthy, which wasn’t obviously enough but maybe it was enough to cure me 
and to stop it from going further, I don’t know. 
It may be anticipated from this dialogue that genetic counselling can reinforce 
positive health behaviours, to reduce risk and improve prognosis. 
 
Genetic Knowledge  
Within the dialogue a range of responses relating to genetic, health and scientific 
knowledge are presented.  Knowledge is revealed as a factor that affects the uptake 
of genetic testing and treatment choices.  Patient knowledge has been obtained from 
a variety of sources; participants indicate FHBCC, their (and family member’s) 
occupation, the press and internet.  
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Participants propose that the uptake of early genetic testing can be anticipated to be 
higher for a younger patients:  
P10 for younger people it is worse for if they get a cancer, it could be fast growing kind … I 
know from 50 downwards you are of a higher risk of recurrence and also of genetic. 
Treatment decisions may be influenced by patient knowledge: 
P9 (scientific community) you know a lot about what you know but there is an awful lot more 
that … even with the knowledge it is not guaranteed that you are going to develop (breast 
cancer) 
This knowledge may contribute to this participant’s false sense of security that is 
indicated in response to a result that identified no BRCA mutation. 
 
Health care professionals 
Less often participants describe experiences that reveal genetic knowledge gaps 
within their health care team: 
P12 the nurses that looked after myself didn’t really discuss anything about genetics. I did say 
to the nurse mine was triple negative, she was like ‘oh, oh right’, she didn’t really discuss it 
and didn’t really know much about it … it would be good from their point of view and the 
patients to know more about genetics (nurse education). 
This uncommon dialogue highlights patient recognition of a need for genetic 
education. They indicate that where health care professionals are not informed the 
uptake of testing and treatment decisions may be compromised. 
 
Re-testing  
Future re-testing is relevant for participant’s whose test identifies no mutation or a 
mutation of uncertain significance.  Participants were asked if they had knowledge 
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that their sample would be retested.  Overwhelmingly participants confirmed that 
they were aware and happy for future re-examination. 
P2 things are changing all the time … they are storing the results and all (sample) … it’s fine, 
I’m quite happy about that. 
The dialogue indicates an appreciation of future scientific progress that may 
subsequently reveal a genetic mutation. Similarly participants anticipate that a 
mutation will be identified: 
P9 I think you will find something else … … I hope I am still in their files so that if anything 
pops up then I’ll be informed. 
P12 I would be quite relieved actually … the not knowing ‘is it genetic or just something that 
happened?’  ...  ‘oh yeah we’ve found a gene’ … I’d be quite relieved actually. 
The dialogue, a response to results that do not identify a BRCA1/2 mutation, 
provides further evidence of a false sense of security or belief that the results are a 
false negative.  While risk-reducing interventions may be required should a 
subsequent BRCA1/2 fault be identified participants indicate support for such 
intervention should it be required, at a later date. 
 
Patient Information 
Based on their genetic test experiences the study population propose a range of 
methods for disseminating information about the option for early genetic testing to 
inform treatment. Two broad groups were identified: discussions and written 
information. 
 
Face-to-face discussions 
Consistently face-to-face discussions are favoured by participants both for the initial 
proposal of early genetic testing and when providing extra information.   
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P3 appointments ... so informative, so helpful for both my husband and I. 
The proposal should include: 
P5 an explanation of why things are done, the time scales, having test would help decide 
what you get done, explaining it properly from the outset. 
However caution is advised: 
P8 face-to-face is a good idea … if not too mentally disturbed from (diagnosis). 
A recurring theme is whether people want to know their BRCA1/2 status:  
P9 some people don’t want to know … hugely individual.  
Contrastingly and based on experiences with other patients: 
R2 depend on the person’s nature … people that I’ve gotten to know through Macmillan and 
going through treatments … people who wanted knowledge and wanted to know what was 
going on … probably more to do with personalities and way they cope rather than knowledge 
... they wanted to know every little bit of detail, what word meant, looking everything up … I 
can see them benefiting from it (genetic test).  
Coping style should be anticipated as an important factor in the uptake of early 
genetic testing.  
 
Participants additionally identify long periods of time where they propose that genetic 
testing can be discussed, this is particularly relevant for patients undertaking neo-
adjuvant chemotherapy:  
P1 you can be there all day … talking to a nurse in a room while you are getting the drip in  
Participants indicate that such times can be anticipated as useful, for sharing extra 
information that will assist the patient to decide whether to undertake early genetic 
testing.  Although it has been (P12) previously indicated that staff training will be 
required to ensure equality of information. 
 
191 
Written Information: Leaflets, The Internet & Results Letters 
Supplementary written information is proposed assist decisions about early genetic 
testing: 
P8 also writing because you can sit and ponder a letter, you can re-read … you’ve got to 
weigh up … too much to take in all at once. 
Less frequently the function of providing information for the family while undertaking 
testing is described as an important role: 
R11 You think ‘I have to take all this information in’ … when I go back home all the family is 
going to be asking ... you’ve got to have some sort of answers or something about what’s going 
to be happening. 
Participants indicate that written information would assist where patients wish to 
discuss the option for genetic testing and the impact that BRCA1/2 results have on 
treatment decisions. 
A contrasting opinion that relates to the proposal for early genetic testing: 
P1 (at diagnosis) giving them a leaflet at that time … you can put it in your pile of stuff to read 
at some time and think about when you have read. … (during neo-adjuvant chemotherapy 
treatment) a leaflet or anything when you are sitting having chemo, cause you are sitting for 
some considerable time.   
This participant later indicates that such a proposal would require follow-up to ensure 
that the patient is aware of the relevance of early genetic testing and the impact that 
it can have on their treatment plan. 
 
The internet is presented as a significant source of genetic information:  
P12 I did go looking for information, there is so much on the internet (och sound) ‘I don’t really 
understand’ … most of it,  you didn’t really know where to start looking, I abandoned the 
search at that point … the internet there is just so much and it frightens you … find stuff on it, 
it makes you worse … if you don’t have information that is the first thing that you do, you go to 
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the internet and that’s a nightmare, it’s really scary (laugh) (other people's experiences) some 
are quite bad, you are thinking ‘is that going to happen to me? 
Participants recognise that caution is required, and that patients should be advised 
where to seek appropriate information.  They indicate that when sufficient 
information is provided at the outset, this can guide and inform patient decisions 
relating to early genetic testing and treatment. 
 
Participants universally support the use a letter, subsequent to face-to-face genetic 
counselling, to confirm genetic test results: 
P12 the letter was really useful because it explained the findings and also explained that 
although they hadn’t found anything, that there were more genes that they were looking for.  
P3 it was brilliant, pitched at the right level … understood it fully. 
Associated with the proposal for early genetic testing, participants recognise that 
appropriate systems and documentation will be required to assist the process for all 
involved.  
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8.7 Early Genetic Test 
Within the population a range of genetic testing experiences exist.  Details are 
provided in Table 11: Test Category, Result, Times & Treatments (see page 138) 
and throughout the study results64.  Specific data relating to participant experience of 
early genetic testing to inform treatment are found within the previous section65. 
Where an early genetic testing experience is not available the participant’s dialogue 
is either unguided or where required prompted by the use of hypothetical questions 
that provide an offer of testing at or close to diagnosis, with results available within 3 
weeks to inform treatment.    
 
Key Findings: Early Genetic Test 
Based on a hereditary breast cancer diagnosis and personal genetic testing 
experience, participants overwhelmingly indicate their support for early genetic 
testing to inform treatment decisions, for the newly diagnosed HBOC patient.  
Significant satisfaction and benefit is reported by participants, they favour having 
‘genetics to back you up’ to help choose the right treatment.  While all participants 
support early testing those who undertook early genetic testing to inform their 
primary cancer treatment indicate the highest levels of support. 
 
Dominant themes that relate to patient satisfaction, following the provision of early 
BRCA1/2 testing to inform ‘tailored treatment’ or prophylactic decisions.  Participants 
describe that ‘it makes sense’ to ‘have it done’ early to gain personalised genetic 
information for risk-based treatment decisions with the ultimate goal of ‘tailoring 
                                            
64 Most relevant are Sections 8.4 Genetic Testing and 8.5 Test Results. 
65 Section 8.4 Genetic Testing: Inform Treatment? 
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treatment’ and maximising survival.  Coping style is identified as a factor that impacts 
test and treatment decisions.  Nevertheless participants indicate that treatment 
decisions will be informed by early BRCA1/2 testing. 
 
Urgency is a recurring theme; participants seek and require genetic information 
quickly.  However genetic information is considered to be something that ‘you don’t 
want’ but ‘need to know’. Participants state that there is ‘not really a good time’ to 
discuss early genetic testing and propose that testing should be ‘part of the 
package’, integral with diagnosis and treatment planning.  A ‘get it over with’ opinion 
is consistently voiced by participants; they support an early test proposal and 
subsequent BRCA1/2 testing at diagnosis or as soon as possible.  Nevertheless it is 
recognised by participants, that for some, diagnosis can bring too much information, 
‘all things you don’t know about’ and emotional overload.  Participants identify that 
early testing may not be suitable or appropriate for all patients. However they favour 
patient choice; an early proposal for testing and allowing the patient to undertake 
testing when they are ready.  Furthermore they state that the proposal should clearly 
indicate the benefit of early personal genetic risk information to inform treatment.  
Consistently participants report that treatment can be personalised at primary 
intervention or later if risk-reducing interventions are required. 
 
Participants identify that the offer of early genetic testing will be best received when 
a knowledgeable member of the genetics team makes the proposal and is available 
to promptly respond to questions.  This will ensure that the decision to undertake 
testing does not delay primary cancer treatment.  Furthermore this may have 
additional relevance where family history is not established at the time of diagnosis. 
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When early testing is indicated participants propose, that a clear timescale, 
specifying the wait for results, is required by the patient.  While the potential 3 week 
wait for results is consistently viewed with little consequence participants indicate 
that this timescale should, for each patient, be approved by the surgeon; importantly 
they state that testing should not delay treatment.  However where concerns exist 
participants indicate that intervention planning with ‘pencilling-in’ for big surgery 
could prevent any treatment delay.  They propose that the scheduled surgical plan 
can subsequently be altered when the final treatment decision, informed by genetic 
status, is taken.   
 
Participants propose that waiting for genetic results can occur during the time 
between diagnosis and treatment.  They describe that this as a busy time; when 
commonly patients start coming to terms with their cancer diagnosis, attend 
treatment-planning appointments and arrange support to assist the family to during 
their cancer treatment. 
 
Within dialogue relating to early genetic testing participants provide additional 
reasons and rationale for undertaking an early test; these fit with the maximising 
survival theme. Furthermore it is identified that fear of recurrence is a significant 
factor motivating support and uptake of an early test.  Significantly participants 
indicate that a younger patient population should be anticipated to gain the greatest 
benefit from an early genetic test.  This finding may relate to the study population 
experience, where commonly diagnosis occurred between the ages of 37 and 50 
years.  Similarly participants predict maximum psychosocial benefit, for younger 
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patients, when immediate reconstructive procedures are undertaken should 
mastectomy be indicated. 
 
 
 
 
A presentation of the Early Genetic Testing sub-categories and evolving themes 
follows. 
Inform treatment 
Participants indicate that early genetic information, close to diagnosis, is essential for 
the high risk HBOC patient: 
R14 it’s something you have to do, it’s not something that you want to do. 
The results provide personalised risk information: 
P1 you are better to know what is going on. 
Early BRCA1/2 results bring clarity and inform appropriate risk-based treatment 
decisions:  
P10 if it was all done at the beginning then it would be like ‘well this is what I’m doing’… I 
would have gone with it … I wouldn’t mmm hesitate at all … you should do it sooner, than 
later … you might not need to have a mastectomy because of that (result) … without all the 
information how do you know that you have had the right thing done. 
Participants recognise that treatment options are associated with improvements and 
personalised care: 
P5 I would want to know everything … to help make a decision … (it’s) got to be a good thing, 
having the choices.  
Within the population an event recurs; proposed surgical procedures based upon 
predicted risk, using genetic / family tree risk predictions:  
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P11 the decision (surgeon)… their thoughts were always to do a lumpectomy. 
However participants indicate that patients do not always endorse a proposed plan 
and indicate undertaking more extensive surgery to maximise survival.  Coping style 
adopted at the time of diagnosis is identified as a factor can impact whether a test is 
proposed by the patient or healthcare professional:   
P9 If I needed genetics to back me up … push my case to have both my boobs removed then 
yes I would want them in the room. 
Survival factors that motivate the preference for mastectomy include family breast 
cancer experience (and treatments) and dependent children: 
P11 high risk (family history) … my mother when she was … early 40s had a mastectomy for 
breast cancer.  My sister 3 years previously had the same diagnosis … exactly the same 
ages … my children were 4 and 2, I was in my 40s … my priority was staying alive as long as 
I possibly could. 
While patient preference may be based upon coping style and psychosocial 
response the surgeon can agree to perform extensive surgeries, such as bilateral 
mastectomies. However: 
P11 I was quite disappointed when she said they would ‘if that’s what you want to do fine, but 
we wouldn’t certainly recommend it from a genetic point of view' (surgeon)  
This exceptional narrative indicates that the patient expected to be challenged about 
her preferred surgical choice.  The recommendation to undertake BRCA1/2 genetic 
testing was proposed by the surgeon in response to this discussion and 
subsequently the participant undertook breast conserving treatment based on her 
personal genetic risk.   
 
Participants indicate that treatment will be altered in response to genetic information, 
and when no BRCA1/2 mutation is identified surgery can incorporate less extensive 
procedures:  
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P4 if it had come back negative at that point (pause) … it would help me make up my mind 
and no there wasn’t a family (genetic link), get the lump out (lumpectomy) … I probably 
wouldn’t have considered it (double mastectomy)… if you’d tested me at that point I might 
have looked at my options differently.  
While the dialogue indicates that the participant undertook genetic testing after 
cancer treatment, support for early BRCA1/2 information to inform treatment is 
evident. 
 
Conversely and overwhelmingly participants identify that in response to the genetic 
test they prepare for a BRCA1/2 mutation:  
P3 unless it came back the other way… that would advise you (imaginary person) to having 
the prophylactic surgery as well as the mastectomy 
Larger surgical procedures including prophylactic treatment, either at the time or 
shortly after their cancer treatment, is advocated by participants, when a BRCA1/2 
mutation is identified:  
P10 (slowly) if it is a high risk I think you would go along with it (bilateral mastectomy) ‘cause 
why would you want to be living with the thought that you know, it could recur… if you had 
had the testing and it was yeah (BRCA mutation identified)… probably would have gone 
(quietly) (for prophylactic surgery). 
While the dialogue relates to a hypothetical question the participant exposes an 
information seeking coping style.  Correspondingly coping style can be anticipated 
as a factor that will impact treatment choices when early testing is provided. An 
alternative response may be expected where patients adopt an avoiding style; a less 
accepting and a more active role can be assumed.   
 
Participants indicate that results will alter treatment decisions, particularly when 
extensive surgery is anticipated: 
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P3 the people that were thinking … of taking everything away, the big surgery, might be 
persuaded to then have the lumpectomy if you found out it wasn’t the BRCA genes, yes I 
think these people would be more likely to change their mind. 
This dialogue proposes that HBOC women who adopt an avoiding coping style, and 
are active in treatment decision-making, may gain most benefit from early genetic 
testing. 
  
More extensive and / or risk-reducing prophylactic surgery that is indicated when a 
BRCA1/2 mutation is identified may nevertheless present a difficult decision: 
P7 having my other breast removed, I think I would have done that … it would be a very hard 
decision I mean I honestly feel, even at this stage of my life … I am sure I would … I just put 
so much stock on my family, I just want to be there for them … I think even if they said to me.  
However a recurring theme is the need to minimise risk and the number of 
procedures that are required: 
P8 save (your) body having to go through it (cancer and treatment) a second time…harder it 
is for (the) body each time to recover, some of us have a very bad time 
The survival theme prevails when prophylactic treatment decisions are required: 
P9 some women have a huge problem with having their breast removed … seriously was a 
no brainer for me … I would have had my other breast removed because I want to give myself 
the best chance.  I would have had my ovaries removed.  
P6 people should get tested earlier … doctor said ‘this is the best option fur (for) ye’ (you)… 
then you would go, I would go with the advice… of the doctor (mastectomy), you can always 
get (pause) reconstruction (quiet). 
Cosmetic results will be considered when reconstructive surgery is appropriate: 
P9 if they hadn’t given me immediate reconstruction I don’t know that I would have even 
come in for reconstruction … I love the way mine worked and the way it has all gone, it is 
fabulous. 
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However the physical and psychosocial impact of large reconstructive surgery is 
acknowledged: 
P9 big surgeries… truly don’t know that I would have come back for reconstructions. I don’t 
know that I’d have come back … such a huge thing for my kids, for my husband, for my life. 
This dialogue further supports the theme of minimising or combining procedures. 
 
Await results 
Commonly participants consider that the 3 week guideline time for early genetic test 
results is acceptable. Opinions fall into two broad categories: Overwhelming support 
and Concern.  Notably, within dialogue that supports the 3 week wait for results, 
participants reinforce the main reasons for undertaking the test and present new 
rationale. 
 
When a 3 week wait for results is presented with an early genetic test proposal, 
overwhelming support is demonstrated, dialogue includes: 
P3 perfect, P7 marvellous, P10 oh, wow! and R15 wonderful … great, super. 
 Waiting 3 weeks after diagnosis, and the genetic blood sample, is regarded with little 
consequence and as a short time: 
P8 I don’t think that would endanger your life …waiting such a little time. 
P12 I would think in the life of cancer three weeks is not going to make much difference. 
Participants acknowledge that patients experienced period of waiting between 
diagnosis and primary treatment:  
P11 that would be acceptable completely … I don’t think it is too long because (pause) you 
know between your diagnosis and your chemo you have got to wait anyway so I don’t, I mean 
3 weeks is not really a long time to wait, so I don’t think it would be that much of a problem. 
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This time is described as eventful; with appointments for treatment planning and 
arrangements for assisting the family to cope during their cancer treatment: 
P10 a busy time, getting all these things done (tests) … my feet just didn’t touch the ground at 
that time, which wasn’t a bad thing. You didn’t get time to really think too much about things. 
It is also recognised by participants that coming to terms with a cancer diagnosis and 
interventions takes time: 
P10 I don’t think that is too bad, you need some time. 
They propose that this emotional process can start in the time between diagnosis 
and results. 
 
The dominant opinion is that the benefit of personalised treatment outweighs any 
concern about a 3 week wait for results66: 
P1 I think probably the wait probably outweighs … it is probably beneficial …I think probably it 
is worth waiting the three weeks. 
P12 if it is going to be a better outcome then it might be worth it. 
However it is acknowledged that individuals will view the 3 wait for results differently: 
P7 it depends on the person … I honestly feel it would be up to the person themselves. 
Less commonly participants identify that, for some patients, any wait may create 
distress: 
P6 3 weeks is a long time (laughing) isn’t it when you’re worrying. 
Urgency for treatment is a recurring theme and concern regarding a 3 week wait is 
supported by more exceptional experiences: 
                                            
66 Reinforcement of the theme ‘getting the right treatment’ consistently recurs when participants justify 
the 3 week wait: 
P3 it would have been very hard having a lumpectomy and then being told that it was genetic … a positive BRCA 
gene because then to make the decision to go back again. 
Additionally avoiding unnecessary and extra surgical procedures is commonly described is support of 
the wait: 
P12 you could end up with surgery that you don’t really need to have if you had surgery and then said ‘oh you’ve got 
the high risk gene’ and then you would have to go back and have more surgery. 
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P9 (3 week wait) I think that would be too long (quietly)… I was wanting to wait and have a 
week (holiday) but they just said ‘no’ … ‘we want to turn this around as quickly as we can’ … 
huge urgency… I was advised against doing it (postponing surgery)… huge hours in theatre 
were booked in well in advance … guess there is always an urgency 
Nevertheless the 3 week wait potentially delaying primary cancer treatment is a 
concern. Participants commonly indicate that treatment should start immediately 
after diagnosis: 
P5 (emphasis) I was just desperate to get started … I don’t think I’d want to be delayed. 
R15 once you know you have cancer you want treatment straight away …it’s not something 
you want to put off at all … I came home from (holiday) two weeks early,  I just feel that if you 
know you have cancer you don’t want things delayed … I would think that most people would 
think that. 
Participants anticipate that treatment planning should ‘pencil-in’ procedures: 
P9 maybe book their theatre (for bigger surgery then) reduce it. 
Thereafter when genetic information is available they indicate that the treatment plan 
should be finalised, with no delay: 
 P5 I don’t think I’d want to be delayed. 
P12 you feel more at ease when the doctor has given you the treatment plan. 
Participants identify that when a treatment plan is identified pre-treatment worry is 
reduced. 
 
Participants do identify that early genetic testing may not be appropriate for all 
patients:   
P3 you would have to be able to … 99% guarantee that it would be back within 3 weeks … 
the consultant would have to agree that 3 weeks wasn’t too long to wait for surgery. 
Nevertheless participants propose that clear information detailing the time required 
for genetic analysis is provided to assist patients in their decision to undertake the 
test: 
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P11 I would rather you told me then I know what I am dealing with (3 week wait). 
P5 an explanation of why things are done … the time scales …explaining it properly from the 
outset. 
Importantly this information will help patients if they proceed and while they wait for 
results. 
 
Best time? 
Participant responses are categorised into 3 broad groups: ‘it makes sense’, ‘part of 
the package’ and ‘tailored treatment’.   
 
It makes sense 
Despite genetic testing representing an extra activity and psychological burden 
participants regard early testing as an intelligent choice: 
P2 I know it’s a lot to go through but it would make sense to have it all done … it would be 
good to have genetics there at diagnosis. 
P10 that makes sense, it is more sensible to do it at that time … it makes sense to do it right 
at the start.  
Additional confirmation is seen when participants compare their post-treatment 
testing experience with the proposal for early genetic testing: 
P10 at the very start … better time to do it … it would be better … get it over & done with, 
deal with it at that time. 
A commonly held opinion views the patient as an active participant in the treatment 
decision: 
R15 offering the test & giving information is much more proactive, so many people would like 
to get it right in their own brains to actually deal with it. 
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Coping style is understood from participant dialogue to influence whether the test is 
proposed by the patient or healthcare professional.  However within the study 
population coping style is not considered to impact uptake of the test.  Participants 
view the test as enabling an informed decision; furthermore, they recognise that this 
is beneficial. 
 
Part of the package 
Overwhelmingly participants identify that early genetic testing should occur close to 
diagnosis:  
P3 blood should be taken the minute you are diagnosed … the big thing to put across … (it is) 
for their treatment. 
It is acknowledged that there is no ideal time.  However participants favour allowing 
the patient the option to decide: 
R11 giving people the option, the choice … there’s not really a good time (laughs) 
P2 brought up at the diagnosis talk through but leave it up to them as to when and if they 
have it. 
When the BRCA1/2 test proposal is not achieved at or very close to diagnosis 
alternative times are proposed by participants.  These fit broadly into two categories: 
before surgery and after the cancer treatment. 
 
The option to carry out testing before surgery presents a variable timescale. When 
surgery is scheduled before chemotherapy: 
R2 after the first week (after diagnosis) but before you got your surgery. 
Similarly when neo-adjuvant chemotherapy is planned: 
P1 before then (chemo), get a test before all the chemo is in your body. 
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Within these dialogue participants identify that the patient may want time to come to 
terms with their cancer diagnosis or that fitting in the genetic consultation may not be 
feasible when the focus is pre-treatment procedures.   
P3 fit the genetics into there that is probably the place to do it … even with chemo there is still 
about a month between diagnosis & starting chemotherapy. 
Recurrent focus is placed on the urgency to obtain genetic information on which to 
base primary treatment decisions. 
 
When early genetic testing integral with diagnostic and treatment planning 
procedures participants anticipate, based on personal experience that the impact will 
be less that when testing is undertaken post-treatment:  
P10 I probably would have been more ready for it at that time because you would get 
everything else done as well …part of your package of what you are doing … better because 
you are carried along … it is a busy time, you are getting all these things done and I think it 
would be more acceptable, probably would have been for me…it should be during the 
process of going through all your surgicals (pre-operative tests), your chemos (pre-
chemotherapy rather than after… get it over with (laugh), get it over & done with, deal with it 
at that time. 
When testing is included with diagnostic and planning procedures high patient 
acceptance is anticipated by participants:   
R16 ‘get tested, get the results back, make decisions and treatment is a ton better’… this is 
the test, you’ve got it (BRCA), you’ve got breast tissue on both sides, it all needs to be got rid 
of. 
A recurring theme of identifying a clear, treatment pathway is commonly presented. 
 
An alternative option that is presented is to carry out genetic testing after breast 
cancer treatment.  Within the study population the dominant testing pathway is 
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undertaken after primary cancer treatment to inform prophylactic interventions.  A 
recurring theme is to first deal with the ‘lifesaving stuff’:  
P11 let’s just get over with the lifesaving stuff now. 
R2 the person doesn’t have to get the result until later you could still tailor the (prophylactic) 
treatments.  
Participants identify the impact of a cancer diagnosis and treatments: 
P5 get through this (diagnosis) and my treatment and then consider (genetic test). 
R15 you have enough to deal with. 
While it is anticipated that treatment and genetic test experiences of participants are 
significant factors, these opinions highlight that they support the offer of early genetic 
testing.  Furthermore they indicate that patients will themselves decide whether to 
undertake testing immediately or delay until after primary cancer treatment.  These 
participants recognise that genetic information obtained via either pathway increases 
treatment choice and patient outcomes. 
 
Closely associated with the option to propose genetic testing is the consideration of 
‘too much information’.  Participants describe an optimum mental state for the 
provision and receipt of genetic information: 
P4 are you going to be in the right frame of mind at the time? (pause) would it affect your 
choices? would it be too much? would you take it in at the time of diagnosis?  
A feeling of emotional overload can occur at diagnosis: 
P5 I don’t necessarily think that everyone would take that in at that time… there is a lot of 
information … you are bombarded with and it’s all things you don’t know about … I don’t just 
mean the genetics … suddenly thrown in … you walk in for a check-up and come out with this 
happening, you are like ‘bang, bang, bang’ (moving hands) ‘it’s this, this, this’ … just getting 
your head round everything. 
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However a commonly held alternative choice and opinion is to deal with genetic 
testing at the same time as diagnosis: 
P10 you are in shock anyway so get it over with (laugh). 
A similar view presents genetic information as something you may not wish to know 
but that should be dealt with: 
P7 it’s kind of like when somebody is dying and they’re needing (pause) kidneys or something 
and the approach (for organ donation) you’ve got this horrendous thing in one hand and you 
are getting hit with something else 
Presenting the BRCA1/2 test option and the benefit that genetic information can 
bring to treatment decisions is consistently suggested: 
P5 it would probably be better that they knew …  I don’t regret having that at the outset, at 
diagnosis … it’s a lot to take in and consider, all the treatments & everything (genetic) they 
are throwing at you. 
Participants propose that following the BRCA1/2 test option, even if it is initially 
considered an extra burden, patients will consider and discuss the test: 
P6 it’s a lot to take in at the time but when ye’ (you) think … get home an’ (and) then ye’ think, 
it sinks in (slowly). 
P8 go away and perhaps discuss it with their family … or best female friends … leave it for a 
few weeks and think about it. 
To offer a second appointment for further genetic discussion is recurs:  
P11 the door is not going to be shut, you can come back. 
Participants propose that personalised proposals for genetic testing will enable the 
patient to consider an early test or to delay the choice. Indicating that an 
individualised offer and discussion will enable patients to retain control and make 
active, informed treatment decisions.  
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Tailored treatment 
Personalised care is a dominant theme when participants consider hypothetical 
situations and reasons for undertaking early testing: 
R2 helping to protect me, treatment could be tailored towards whatever gene I had.  
Participants identify clear treatment options in response to established genetic risk: 
P4 discussing it at diagnosis could potentially make people deal with things differently. 
R14 knowing what gene they had and what steps to take and what course of treatment would 
be more appropriate … the doctors could assess what kind of surgery was more appropriate 
for the different strains. 
Support is widespread and irrespective of participant’s genetic test experience and 
BRCA1/2 status.  However for participants who undertook testing close to diagnosis 
support is accentuated. 
 
Additional consideration is given to the psychosocial factors associated with 
extensive surgery that is required when a BRCA1/2 mutation is identified: 
P8 it must be a great help (reconstruction) that it gives them more courage to face the surgery 
… you don’t have a choice, you know it’s serious and it’s got to be done, this can be done for 
you to help you look at yourself as you would normally think of yourself. 
Participants recognised that early testing to inform personalised treatment can 
promote the best care for the individual.  Furthermore they identify that when 
immediate reconstruction is appropriate this can be carried out for cosmetic and 
psychosocial benefit. 
 
The study population support early genetic testing for all newly diagnosed HBOC 
patients.  Breast cancer diagnosis for the study population is commonly received at a 
young age, between the age of 37 and 50 years.   This may account for their 
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overwhelming emphasis of younger patients, who are consistently identified, as 
gaining the greatest benefit from early genetic testing: 
R16 particularly a younger person, it’s a no brainer. 
Fear, relating to cancer-risk, may be a significant factor that motivates participants to 
promote early testing for the younger patient group. It is anticipated that this relates 
to maximising survival, reducing risk and treatment interventions.  Further support is 
presented within participant opinion: 
P8 especially younger women with young families late 30s & early 40s  … it makes complete 
common sense … offering it to them and maybe then if there was a faulty gene avoiding all of this 
and all the stress it causes for everyone around you. 
Furthermore within the dialogue surrounding this extract the participant referred to 
her experience of 3 cancer diagnoses, the impact of these and the associated 
treatment, for herself and family.  They propose that getting the right treatment early 
is a recurring reason for undertaking the test, particularly when the younger HBOC 
patient is considered. 
 
Participants identify that within the newly diagnosed patient population, not all have 
knowledge of their HBOC: 
P4 would that be offered somebody with first breast cancer in a family?  
They recognise that such patients may not consider genetics when their cancer is 
diagnosed: 
P10 it is a different kind of thing … I didn’t … but I think it is something that you really should 
know about. 
Where HBOC risk is clinically identified participants recognise the value of proposing 
early genetic testing. 
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Recommendations 
Throughout these interviews the participants actively considered and disclosed 
suggestions, for improving the evolving genetics and breast care services.  It is 
relevant to present the range of participant opinions to assist in the identification of 
plausible and acceptable approaches to improving the genetic test experience with a 
view to improving breast cancer management and patient outcomes.  The proposals 
fit into two categories: ‘Who should propose testing?’ and ‘It would be better if…’ 
 
Who should present genetic test option 
Overwhelmingly participants advise that a member of the Clinical Genetics team 
makes the first proposal for early genetic testing: 
P6 somebidy (somebody) from genetics they have more knowledge … if they (patient) had 
any questions, then they’d be able t’ (to) answer them. 
Increasing the presence of the genetics team within the FHBCC is recommended: 
P10 would make sense to have strong presence … I haven’t seen her in a long time, at a 
family history clinic … should be someone there especially for new (patients).  
The proposal may be more easily received when it is made by a healthcare 
professional with whom a relationship has been established. The suggestion to 
involve the MacMillan nurse: 
R2 continuity of a Macmillan nurse, the same Macmillan nurse made a big difference, she 
could appear at different places to support me at a visit protected you, stuck up for you, she 
could be there for genetic testing. 
Alternatively, the surgeon and genetics nurse or doctor could make the first proposal: 
P4 a joint clinic (surgeon and genetic) you don’t want to ask a question for them to go ‘well we 
are not sure, we’ll let you know’. 
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When considering these responses a multi-disciplinary team approach may be the 
most appropriate.  Participants identify that if questions cannot be answered during 
the early genetic test discussion, the decision to undertake early testing may be 
delayed until the patient is provided with sufficient information. Of fundamental 
importance, members of this team should have the ability to answer genetic 
questions to ensure that the decision to undertake testing does not delay primary 
cancer treatment. 
 
It would be better if… 
 Preparing patients for genetic involvement can ease the process of establishing 
family history: 
R14 prepare people before they came up  ... what questions …you need dates and times and 
what kind of cancers, I didn’t have that information. 
This proposal indicates that the patient experience could be improved by the 
provision of additional genetic information.  
 
 Participants living the furthest distance from the main hospital expressed concern 
about impact of extra genetic appointments and their impact: 
P1 fair enough if you are in P or D (cities) but if you are 30+ miles from the hospital) and you 
are travelling ... kill two birds with one stone  
P6 I stay (15 miles from hospital) an’ (and) if ye (you) had t’ (to) go back t’ (to) another 
(another) meetin’ (meeting) ye (you) have t’ (to) ask t’ (to) get time off yer (your) work … I 
would prefer it together 
This recurring suggestion to combine hospital appointments could minimise impact 
and promote uptake of genetic consultations for patient treatment and outcome 
benefit. 
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 Increase psychological support provision throughout the testing process: 
R2 overall, the whole situation, the medical side was very good but felt that very often the 
psychological side was lacking. 
Recurring throughout the data participants recommend that support for patients 
could improve the genetic test and treatment choice experience. 
 
 Where resources are limited: 
P3 if you can only do so many in the 3 week bracket that’s the people who should be targeted 
(greatest benefit). 
 P8 almost would save money throughout the NHS. 
Participants identify that NHS resources are limited and that intelligent allocation of 
services is required.   
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9. DISCUSSION 
Research is required to fully realise the benefits and impacts of Personalised 
Medicine.  This small study is relevant to two recent proposals for evidence based 
research. The recent NICE guideline for familial breast cancer recommends that 
research is undertaken to identify the benefits and risks of early genetic testing 
(NICE, 2013b).  It proposes patient experience, as one of 4 research areas, in which 
evidence is required to establish service delivery.  Similarly an international gap 
analysis identified a research agenda that includes individuals with a genetic 
predisposition for breast cancer (Eccles et al., 2013).  
 
The aim of this study has been to investigate experiences and opinions of genetic 
testing for the highly penetrant BRCA1/2 genes and the impact these have on 
treatment decisions.  This investigation has been conducted in a single NHS Clinical 
Genetics setting, with in-depth interviews occurring in during 2012 and 2013.  
Targeted sampling used a convenience group of women, who undertook BRCA1/2 
gene testing between the late 1990s and 2012, testing occurred close to the time of 
diagnosis or following primary breast cancer treatment.  
  
Study data has been analysed utilising qualitative methodology to compare and 
illustrate genetic test experiences, opinions and treatment decisions. The study 
population is small, correspondingly the findings are not intended to be 
representative of a wider HBOC population.  Understanding has been derived from 
narratives and interpretation of the data, not from published theory. However, where 
theory exist these have been applied to test the themes, only after they had evolved 
from the data.  While early and interim literature reviews revealed no early genetic 
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test theory, the review was conducted following analysis and thematic development 
revealed new early genetic test theory.  This was used to corroborate study findings, 
and assist deductive theory development.  
 
The researcher has adopted a neutral and reflexive stance throughout the study.  
While the study has a genetic counselling focus, the researcher is not a genetic 
counsellor.  This may be viewed as a limitation however neutrality permitted candid 
dialogue and investigation of the patient experience. 
 
The discussion that follows presents the study findings according to the objectives 
and using associated headings. Factors that influence patient decisions and 
plausible clinical approaches are woven throughout the text.  
 
The Genetic Test Experience: Why, Who, When & How? 
The dominant reason for, women in this study, undertaking early genetic testing is to 
maximise survival.  Conflicting earlier, and possibly out-dated, interpretation (Julian-
Reynier et al., 1998) identifies that women with a cancer diagnosis attend genetics 
clinics, to learn why they have cancer and to inform family members of their risks.  In 
contrast, Julian-Reynier (1998) reports that predictive testing is undertaken to 
establish cancer-risk.  Therefore if viewed from a current perspective, where early 
genetic testing is available, Julian-Reynier’s (1998) predictive test group, and not 
those with a cancer diagnosis, share characteristics with participants in this study 
who undertake early BRCA1/2 gene testing.   
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Participants indicate that maximum survival requires personalised cancer-risk 
knowledge, bespoke treatment and risk-reduction interventions based on genetic 
status. Correspondingly, maximising survival is reported by recent publications that 
identify this as a fundamental factor that motivates women, with hereditary breast 
cancer, to obtain BRCA1/2 genetic information (Wevers et al., 2014, Jeffers et al., 
2014).  In this study, the survival theme not only relates to extending life but to 
ensuring that quality of life is preserved. Similarly findings that support these results, 
are presented within a report that details 15 reasons for receiving rapid genetic 
counselling and testing (Wevers et al., 2012b).   
 
Closely associated with the need to maximise survival, is family protection, although 
self-responsibility is identified, in this study, as the central factor that influences 
uptake of BRCA1/2 testing. Comparably, when considering genetic responsibility, 
self is reported as the first of 3 aspects (Etchegary et al., 2009).  In corroboration 
with the Etchegary finding that identifies self-responsibility as a fundamental factor, 
participants in this study, convey that maximising survival and family protection are 
predominantly achieved by considering additional treatment options.  Furthermore 
undertaking the most appropriate treatment, even when extensive, is viewed by 
these women, as offering the greatest self-protection, and lowest personal and family 
impact.  In support of this opinion, a recent publication identifies that extensive 
surgery, including risk-reducing procedures, significantly improves 20-year mortality 
for women with a BRCA1/2 mutation (Metcalfe et al., 2014). Additionally participants 
in this study indicate that a younger patient group, may gain the greatest benefit from 
early testing. While this finding may be based on their personal experience; breast 
cancer diagnosis, for this study population, commonly occurred between 37 and 50 
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years of age.  Similarly an Australian study identifies that women under the age of 50 
want to be informed about treatment focused genetic testing (Meiser et al., 2012a) 
and relevantly, the risk of a hereditary breast cancer diagnosis is highest before the 
age of 50 (CGHFBG, 2001, Claus et al., 1996). 
 
Participants convey the importance of reducing cancer-risk and minimising the need 
for subsequent surgery or treatments.  Similarly, supporting this finding, researchers 
from The Netherlands have identified this phenomenon (Wevers et al., 2012b, 
Wevers et al., 2014). Furthermore additional family protection is anticipated, by 
participants, when genetic results can be shared with relatives.   Genetic status 
information to inform and protect relatives, though a factor that influences the uptake 
and acceptance of BRCA1/2 testing, is acknowledged by participants as being lower 
priority when compared with advising treatment and risk-reducing decisions.   
Comparably, Etchegary (2009) reports that genetic information for others is the 
lowest priority genetic responsibility. 
 
A hierarchy of needs that relate to the genetic test experience, summarising those 
reported by participants in this study, are presented in Figure 16: Hierarchy of 
Needs. 
 
Throughout this study, coping styles have been identified, as influencing whether an 
individual seeks genetic information.  Furthermore participants are identified as 
commonly alternating between styles, at different times in their cancer journey. 
Supporting this finding the GRACE tool (Phelps et al., 2010) indicates a range of 
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coping styles and mechanisms that can be anticipated throughout the genetic test 
process. 
 
Figure 16: Hierarchy of Needs 
 
 
 
In this study, it is understood that when participants adopt an information seeking 
style they commonly request genetic testing. They indicate information seeking 
behaviours to confront their fear of cancer recurrence, and to maximise survival. 
Conversely, within the study population, when individuals assume an avoiding style, 
they are less active in seeking personal genetic information, although they indicate 
ready acceptance of an offer for testing.   However the offer, for these participants, is 
commonly made after primary breast cancer treatment.  An established cancer-care 
model proposes patient information should take account of coping style (Miller, 
1995). Supporting the finding that coping style influences access to genetic testing, 
early genetic testing protocols and care pathways should be developed to ensure 
equality of access, regardless of coping style (Vig and Wang, 2012).  
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Within the study population, participants who have an established family history 
attend the FHBCC.  Correspondingly relationships with the multi-disciplinary team 
are established and HBOC information is shared; importantly acceptance of the 
BRCA1/2 test is high.  Support and information provided by the Breast MDT are 
recognised, by participants, as aiding the genetic test process. While similar 
functions, structures and relationships are anticipated within UK FHBCCs.   A 
remarkable finding worth mention is the frequency with which a particular FHBCC 
doctor is identified within dialogue relating to BRCA testing.  This finding indicates 
that an interested and informed clinician can play a significant role in influencing test 
and treatment decisions.  
 
Similarly, family cancer experience and cancer knowledge are identified as 
influencing the uptake of genetic testing.  Participants with a significant family history 
report the greatest urgency for obtaining personal genetic information; it is ‘a no 
brainer’.  Conversely, where family history is not established participants recognise 
that additional counselling and support may be required, to assist understanding of 
the relevance and uptake of early genetic testing. A study carried out in the 
Netherlands indicates that rapid testing should start within 5 days of a hereditary 
breast cancer diagnosis and provide results within 3 weeks (Wevers et al., 2014). 
Comparably, a proportion of the Dutch participants at diagnosis had an 
unestablished family history. Only one-third of their participants received results that 
contributed to primary cancer treatment decisions, however they report that rapid 
testing requires a complex clinical pathway.    
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The identification of a previously unknown or unrealised family history should be 
anticipated for a proportion of newly diagnosed breast cancer patients.  In this study 
the experience of women with a young diagnosis, high risk tumour characteristics 
and an unestablished family history, differs from those with a known history who 
attend FHBCC. For patients who had previously not realised a significant family 
history, genetic counselling and the offer of an early genetic test will require more 
careful discussion and consideration to assist uptake of testing to inform treatment 
decisions. However, based on patient experiences revealed in this study, it is 
identified that coping style has a significant impact on timing of the genetic test and 
treatment choice. Participants identify that the development of clinical care pathways 
should ensure that when a high-risk hereditary breast cancer is diagnosed testing 
can be accessed rapidly; access should not be impacted by a previously 
unestablished history.  Future research should explore treatment decisions and the 
genetic test experience for younger women with high risk tumour characteristics and 
a previously unestablished family history67.   Furthermore a process for expediting 
family history information (where it is previously unestablished) should be 
established, to assist the early genetic testing pathway.   
 
Participants in this study, indicate that patients should be appraised of the purpose of 
early testing; that the result can inform and optimise their treatment. Methods to 
improve the delivery and receipt, of early genetic testing patient information, have 
been proposed by participants in this study.   Overwhelmingly, these women identify 
that the proposal for BRCA1/2 testing and results are best received during a 
                                            
67 Dialogue from participants (P3 & P12) indicate triple negative tumour characteristics.  Tumour 
pathology data have not been collected (from medical notes) to verify the status; such activity is out-
with the scope of this study.  
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personalised face-to-face discussion with a clinical genetics health care professional.  
They state that this will facilitate the most beneficial dialogue; crucially questions can 
be answered and significantly, when considering early testing, time is not wasted 
waiting for answers.  This finding is in contrast with that of an Australian study; no 
clear preference was identified for which healthcare professional should first discuss 
early testing (Meiser et al., 2012b).  Notably the clinical geneticist role is not 
presented within the Australian study; this may indicate an alternative healthcare 
structure.  The clinical genetics role may be less well integrated than in the UK or 
that the role may be assumed by an existing team member.  To enhance the 
discussion that proposes testing, participants identify that supplementary written 
information can aid the decision to undertake early genetic testing.  Furthermore the 
Meiser (2012) study identifies patient preferences for information delivery, they 
emphasise the value of brief written information. Additionally results are awaited from 
a study that is currently being conducted to investigate how best to discuss early 
genetic testing (Watts et al., 2012).    
 
Participants identify that NHS resources are limited and have proposed a range of 
practical, and relatively low cost, solutions to assist the integration of early genetic 
testing within the current FHBCC structure.  Further research is indicated to identify 
methods for integrating genetic information and personalised medicine techniques 
with current clinical care.  Correspondingly information delivery methods that assist 
early genetic test decision-making should be investigated. Furthermore, tools and 
clinical pathways to assist the delivery of early genetic test information should be 
developed. 
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A recent publication concludes that treatment focused genetic testing will in the 
future be integrated with oncology (Burcher et al., 2013).  A finding of this study 
confirms the Burcher conclusion and identifies that the proposal to offer early genetic 
testing close to diagnosis, can be more readily attained when the Breast Care MDT 
is expanded to formally include the role of Clinical Genetics.  Participants identify 
that ‘it would make sense to have a strong presence at a family history clinic’.  
Increasing presence of Geneticists and MacMillan Genetics Counsellors within the 
FHBCC would ensure that the genetic element of HBOC is a focus for the healthcare 
team and patients.  This expanded MDT approach could facilitate participants’ 
proposals for combined clinics which streamline care and resources for healthcare 
and reducing hospital visits for patients. It is proposed that when patients are newly 
referred to the FHBCC a consultation with a member of the Clinical Genetics team 
will identify those with the highest risk68 and increase patient knowledge.  
Additionally participants recommend that genetics are present at diagnosis to ‘back 
you up’ to ensure personalised treatment.  Should an increased presence be 
adopted the integration of early genetic testing with diagnosis and cancer 
management can be achieved more readily.   
 
A significant element of the test experience is waiting for BRCA1/2 results.  
Participant experiences demonstrate an acceptance of waiting for results, particularly 
when at the outset the purpose for testing and a clear time scale are presented. The 
waiting time is accepted by participants for ‘that’s the way it is’. In support of early 
testing, participants describe that this time, between diagnosis and treatment, is 
when women start to accept their diagnosis and are typically busy with treatment 
                                            
68 Predictive testing may be indicated for those at greatest risk. 
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planning procedures. However when considering a 3 week wait for early test results 
urgency is identified, as a theme.  In order to inform treatment, study participants 
state that rapid results must be available within the 3 week period.  Furthermore 
where this is not possible it is proposed, by these women, that early genetic testing 
is not offered; primary cancer treatment should not be delayed by the test.  Still, 
participants state that the benefit of ‘tailored treatment’ outweighs any inconvenience 
associated with undertaking early genetic testing. Similar findings are reported by 
international research teams (Wevers et al., 2012b, Schlich-Bakker et al., 2007, 
Watts et al., 2012).  Overwhelmingly a ‘don’t worry’ attitude is proposed when they 
wait for results.  This and similar distraction coping strategies are indicated as 
appropriate in the GRACE tool, which can be adopted by the MDT to support genetic 
testing (Phelps et al., 2010).   
 
It is identified that participants in this study, choosing not to involve extended family 
in their decision to undertake genetic testing, are afforded self-protection. Their 
testing decision is not challenged or influenced by external views. Additionally family 
protection is identified as a factor that may guide their decision, to withhold 
information until a definitive result is available, participants indicate that they aim to 
prevent worry. Alternatively this choice may be guided by fear, that external opinions 
may alter the decision for BRCA1/2 testing.  Furthermore where relatives are 
involved, participants in this study reveal, that the individual undertaking testing may 
expose themselves to additional psychosocial stresses.  Correspondingly this can 
impact (previously) supportive relationships.  This finding conflicts with an earlier 
study that indicates support is gained when disclosing genetic information (Graceffa 
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et al., 2009).  However the Graceffa study does not provide theory that relates to 
support and the decision to undertake testing or during pre-result period.  
 
In this investigation, distress and loneliness have not been reported as responses to 
the genetic test.   Such psychosocial responses can be anticipated and are 
described in publications that relate to breast cancer genetic testing (Wevers et al., 
2011a, Valverde, 2006) although these reactions are not universally reported 
(Schlich-Bakker et al., 2007). However short-term anger has been described by 
participants in this study, although this is reported as a more exceptional reaction to 
the genetic testing experience. Anger, within participant dialogue, is identified as a 
response to a potential cancer-risk.  In support of this finding, anger is reported as a 
valid emotional reaction when genetic inheritance is considered (McDaniel, 2005).  
Nevertheless studies that report highest levels of genetic distress relate to predictive 
testing (Kenen et al., 2006).  Genetic testing carried out in response to a cancer 
diagnosis may diminish distress responses.  Reinforcing this proposal, participants 
report that their focus is dealing with the cancer, maximising survival, and that the 
test while providing important information has a lower priority.   
 
Participants identify that early genetic testing may not be appropriate for all newly 
diagnosed HBOC patients; where early genetic testing represents an added 
psychological burden testing they propose deferring testing until after primary cancer 
treatment.  A comparable conclusion is found within a large randomised trial 
publication (Wevers et al., 2012a).  Increased psychological support at diagnosis and 
during the genetic testing process have been identified, by participants in this study, 
as potential areas for clinical improvements.  To maximise patient acceptance 
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specific focus is proposed around the areas of cancer-specific distress and the early 
genetic test.   
 
It should be assumed that increased patient benefit is of principal importance.  
However enhancing professional awareness and knowledge of clinical genetics 
techniques, and their application, within the realm of Personalised Medicine is an 
added benefit that can be attained with integration.  Genetic knowledge should be 
acquired by the extended breast care team, to facilitate genetic discussion that 
presents a uniform message and patient support. Furthermore managing 
expectations, by fully informing patients of the test process and sensitivity may assist 
to reduce potential anxiety relating to the wait and the result. Subsequent to this 
study, research should be proposed to investigate the experience and opinions of 
relevant health care professionals prior to fully adopting this progression. 
 
Figure 17 summarises the inter-related factors that impact the genetic testing 
experience for these study participants. 
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Figure 17: Factors Impacting the BRCA Test Experience 
 
 
 
Widespread support, for early genetic testing to inform treatment decision making, is 
demonstrated by participants.  However the greatest endorsement is conveyed by 
younger participants and those who undertook early testing to inform their primary 
cancer treatment. 
 
BRCA1/2 Results & Treatment Decisions  
Participants in this study, have been recruited from a NHS Clinical Genetics Clinic 
convenience sample. While the study population is small, theoretical and purposive 
sampling techniques have been utilised with the aim of achieving proportional 
representation of patients with a BRCA mutation. Correspondingly, a BRCA mutation 
is identified in 30% (5/17) and no BRCA or a variant of uncertain significance in 70% 
(12/17) of the participants. Similar proportions can be expected within the HBOC 
population (Antoniou et al., 2003). 
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The BRCA1/2 result, in this study, is identified as the most significant factor 
influencing the treatment decision, informing women whether ‘the big surgery’ is 
needed. Where results identify a BRCA1/2 mutation the dominant response, from 
this population of HBOC patients, is ‘no surprise’.  Correspondingly women 
overwhelmingly choose to ‘get in and get it done’; they urgently undertake extensive 
surgery predominantly bilateral mastectomy, to maximise survival. While this 
intervention is not universally accepted by clinicians there is an increasing trend for 
this decision; an increased uptake of bilateral mastectomy at first surgery is reported 
in response to a BRCA1/2 mutation identified close to breast cancer diagnosis 
(Wevers et al., 2012b, Wevers et al., 2014, Metcalfe et al., 2014).  Furthermore, 
participants in this study support early breast reconstruction surgery to ‘put you back 
together’, they identify that it offers cosmetic and psychosocial benefits that assist 
coping with a significant health decision.  Recent publications also support a trend 
for immediate reconstruction within a BRCA1/2 patient population (Heemskerk-
Gerritsen et al., 2014).   
 
Coping style is identified as a significant factor that contributes to the individual’s role 
in treatment decision making.  Within the study population those who adopt an 
information seeking style at the time of treatment decision-making are more passive 
and depict acceptance of treatment proposals.  Conversely participants who, at this 
time, adopt an avoiding style reveal greater involvement with the decision and 
treatment planning. While coping style is understood to influence the decision 
process, for participants with a BRCA1/2 mutation, it does not impact the decision.  
 
227 
Participant responses to BRCA1/2 gene analysis that revealed no mutation or a 
mutation of uncertain significance are however less consistent.  Where a result does 
not identify a high risk BRCA1/2 mutation the dominant response, a ‘false sense of 
security’.  Worry about a false negative result is associated with less predictable 
treatment decisions and treatment decision conflict.  This reaction is not 
unwarranted, as women are informed that current genetic testing only identifies a 
BRCA1/2 mutation in approximately one quarter of HBOC patients.  Similarly non-
BRCA HBOC is also associated with increased cancer-risk, indicating that lifestyle 
factors and undiscovered genes may be responsible for the majority of HBOC.   
 
Typically treatment decisions, for women with no BRCA1/2 mutation, are based on 
tumour characteristics (NICE, 2013a, Smith and Isaacs, 2011) although in this study, 
it is identified that age, family cancer experience and psychosocial responses to the 
cancer diagnosis impact treatment decisions. Furthermore, when no mutation or a 
BRCA1/2 mutation of uncertain significance is identified, coping style is the 
fundamental factor influencing treatment decisions.  Participants who assumed an 
avoiding coping style, report being guided by the test result and medical advice. 
Most commonly, these women undertook breast conserving surgery, however 
treatment decision conflict is commonly reported, in association with disbelief and 
worry about a false result.  Conversely when an information seeking coping style is 
adopted participants portray being more active in the treatment decision commonly 
undertaking the most extensive procedure, bilateral mastectomy (often with 
reconstruction).  In such circumstances, the participant declares result disbelief and 
correspondingly they assume increased cancer-risk, subsequently this fundamental 
factor motivates the treatment choice.  A recent publication concludes that where no 
228 
mutation is identified, genetic status should guide treatment (Rhiem et al., 2012) and 
indicates that breast conserving surgery is most appropriate and not the extensive 
interventions commonly undertaken by those with an information seeking coping 
style.   However publications indicate a broad variation in surgical treatment choice 
and propose that additional research is required to guide treatment decisions for 
these patients (Culver et al., 2013, Murray et al., 2011, Huzarski et al., 2013).  
During the course of this study, the question of establishing the psychosocial impact 
of early genetic testing has recurred; most concerning is the ‘false sense of security’ 
or disbelief that participants report in response to a BRCA1/2 test that does not 
identify a high-risk mutation.  A comprehensive investigation of the patient response 
to a negative test is proposed to increase understanding and develop an appropriate 
clinical care approach for post-test genetic and treatment decision counselling. 
Furthermore it is proposed patient information delivery and treatment decision tools 
are developed to minimise result disbelief. In addition follow-up counselling may be 
indicated to determine whether treatment decision conflict occurs, and 
correspondingly address such a response.   
 
When considering the treatment plan participants in this study recommend that ‘the 
bigger surgery’ is ‘pencilled-in’ while BRCA1/2 test results are awaited.  They advise 
this to ensure that, should a BRCA1/2 mutation be identified, resources are in-place 
and the ‘tailored plan’ is not delayed.   Comparably, the Australian research team 
report logistical challenges when scheduling, and rescheduling, interventions 
(Wevers et al., 2014).  Evolving Personalised Medicine brings with it impacts for 
current clinical care systems that should not be underestimated, they require flexible 
patient management systems and progressive health care roles (McGowan et al., 
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2014, Joly et al., 2014).  Additionally when considering patient management or 
service planning challenges it should be recognised that the HBOC population is 
approximately 5-10% of the total breast cancer population and only 20-25% are 
anticipated to carry a fault in a BRCA1/2 gene; within a local health care population 
patient numbers are small. 
 
BRCA status, age, tumour characteristics and family history are identified as factors 
that influence the uptake of risk-reducing interventions.  In-keeping with the survival 
theme, more urgent action is required and taken, by participants, when a BRCA1/2 
mutation is identified.  Similar to primary cancer treatment decisions, when no 
mutation is identified choices are less predictable and coping style is a fundamental 
factor. Women identified as adopting an avoiding coping style express that they gain 
reassurance, correspondingly they do not require or undertake additional 
prophylactic procedures.  Conversely, participants who assume an information 
seeking style indicate that they are more likely to undertake risk-reducing 
prophylactic interventions.   
 
Within the study population the response to the BRCA test is commonly amplified by 
factors such as age, prior cancer experience, support, knowledge and coping style; 
each of these factors can impact treatment decisions. Participants identify that 
treatment decision-making should be supported and guided by the clinical team. 
However an important role of the Genetics Counsellor is to provide support and 
information that assist the patient, while taking account of coping style, to assimilate 
BRCA1/2 test results and their impact.  Current roles and knowledge should be fully 
explored prior to implementing appropriate clinical education, with expansion and 
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definition of roles that support treatment decisions informed by early BRCA1/2 test 
results. 
 
An overview of treatment decisions and coping styles identified in this study are 
provided in Figure 18.   
 
 
For participants with results that identify no high risk BRCA1/2 mutation, including 
those with a BRCA1/2 variant of uncertain significance, it is of particular relevance 
that genetic blood samples are retained for future testing.  Overwhelmingly 
participants in this study accept that current scientific techniques are not able to 
identify all of the possible faults on the BRCA genes, they acknowledge that future 
scientific advances may improve testing sensitivity.  Furthermore, women indicate 
hope and anticipate relief should a mutation be identified with (future) re-testing.  
Estimates report that BRCA1/2 mutations account for between 10-40% of familial 
breast cancer (Shuen and Foulkes, 2011),  suggesting that additional undiscovered 
genes and lifestyle factors are responsible for a high number of hereditary breast 
cancers.  Genetic and treatment counselling should take into account the role and 
impact of future re-testing.  Caution will be required, to avoid creating disbelief or 
worry about a false result. 
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Figure 18: Treatment Decisions in Response to Test Results & Coping Style 
 
 
Key * Tumour characteristics, age at diagnosis and family history / genetic risk prediction are 
also considered. 
 
 
 
 
When considering additional prophylactic surgery, for the associated ovarian cancer 
risk participant treatment decisions are less predictable.  A pilot study by a team from 
the Netherlands similarly found 46% of participants undertaking early genetic testing 
to obtain certainty for their ovarian cancer-risk (Wevers et al., 2012b).   
 
Understanding, taken from narratives, indicates that this relates to the absence of 
suitable ovarian surveillance procedures.  Within the study population, oophorectomy 
is commonly undertaken before genetic testing, and generally the decision is based 
on genetic risk prediction.  However where surgery had previously not been 
considered, BRCA1/2 status informs this risk-reducing decision, although the 
younger women, in this study, describe child-bearing as adding further complexity to 
the prophylactic ovarian surgery decision.  These findings are supported by a recent 
quality of life study that reports reduced cancer worry, in response to ovarian surgery 
when a BRCA1/2 mutation is identified (Finch et al., 2013).   
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Participants identify the impact of health behaviours on cancer-risk and prognosis 
although they question the impact of positive health behaviours at diagnosis and 
when test results are received.  It is not known if this response is typical though a 
similar response is seen in publication (Valverde, 2006).   Genetic results can be 
used to reinforce healthy behaviours (McBride et al., 2010) and risk-reduction 
strategies (Guinan et al., 2013a) to improve patient outcomes.  Participants identify 
that they are uncertain about the benefits of positive health behaviours when faced 
with both HBOC and a BRCA1/2 mutation. Correspondingly clear guidance, 
identifying health behaviours that provide the greatest benefit should be incorporated 
into hereditary breast cancer risk-reduction counselling to further improve prognosis. 
Furthermore, while many personalised interventions are require either increased 
healthcare resource or budgets health behaviour interventions can be relatively low-
cost.  Research to identify the most important health behaviours is proposed. 
 
Test Timing & Treatment Decisions 
Within the NHS Tayside Clinical Genetics service early genetic testing remained 
uncommon during study recruitment.  Following breast cancer diagnosis BRCA1/2 
testing was undertaken, by study participants, between 1997 and February 2012; 
predominantly testing occurred after primary cancer treatment.  Today cancer 
treatment for the majority of patients starts 3-4 weeks after diagnosis, although 
participants indicate a wider time range for the start of their treatment.  Purposive 
sampling has been used throughout recruitment to ensure representation from 
patients who undertook BRCA1/2 genetic testing close to breast cancer diagnosis.   
A higher proportion of patients today could be expected to undertake early genetic 
testing; this expectation relates to current clinical guidelines (NICE, 2013b).  National 
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clinical guidelines that provide clear early testing eligibility guidance should be 
anticipated.  
 
Within the study population a fundamental factor influencing the genetic test 
experience is the length of time taken to obtain results. However it is predicted that in 
light of modern testing techniques (Wevers et al., 2012b) and the 3 week guideline, 
for early test results, the consistent long wait experienced by these participants is 
now out-dated.  Today, the option to take a genetic blood sample close to diagnosis, 
and before or while pre-treatment tests are carried out, is not expected by clinicians 
to impact or delay primary cancer treatment. Furthermore, it is anticipated, in light of 
national clinical guidelines that early genetic testing will increasingly be proposed.  
Delivery of early BRCA1/2 testing from newly diagnosed hereditary breast cancer will 
requires an efficient process to ensure that results are available within the 3 week 
guideline; this carries significant resourcing implications.   However resourcing 
should also consider the small group of patients with particularly aggressive tumour 
characteristics (arguably those with greatest need for early genetic testing) who 
require rapid neo-adjuvant chemotherapy; testing may be required more urgently to 
maximise DNA quality.   
 
In attempt to rationalise the proportion of women undertaking testing after primary 
cancer treatment, participants report discussions with healthcare professionals that 
consider the ‘lifesaving stuff’ more important than early testing.   Personalised 
medicine is changing this culture.  Healthcare professionals now have a greater 
knowledge and acceptance of the value of BRCA1/2 gene testing within a HBOC to 
inform treatment (Burcher et al., 2013).  Correspondingly more women now have a 
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greater appreciation of the relevance and request personal genetic information 
(Meiser et al., 2012b).  
 
BRCA1/2 testing, and the associated implications, is proposed by study participants 
as something that ‘you don’t want to hear’.  However participants identify that early 
testing is ‘a no brainer’ and based on their experiences, they recommend that (you) 
‘get it over with’. In this study, it is identified that, the test provides important 
additional information ‘so that you can get on with it’, the most appropriate treatment 
and if necessary risk-reducing interventions, and then ‘get on with your life’. Study 
participants describe that the result enables patients (and their care team) to identify 
‘tailored treatment’ to reduce cancer risk and avoid further interventions. 
Similar results, supporting these findings, are found in a qualitative study 
investigating treatment focused genetic testing (Meiser et al., 2012b).  
 
A cancer diagnosis is life-changing and around the time of diagnosis patients can 
feel overwhelmed (Meiser et al., 2012a).  Participants concur, and identify that 
information, ‘all things you don’t know’, is provided during the diagnosis consultation.  
However they state that significant health and life decisions are required.  While 
participants recognise that there is ‘not really a good time’ to raise the option for 
early BRCA1/2 testing to inform treatment they recognise that early genetic testing 
can assist these significant treatment and risk reducing decisions.  Appropriate 
information and counselling for patients, who would benefit from early genetic 
testing, should be tailored to address such concerns. Correspondingly the Meiser 
(2012) study provides support for this finding. 
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Less commonly participants in this study chose to defer gene testing.  
Correspondingly participants identify that when testing is deferred subsequent 
‘tailored’ risk-reducing intervention, based on genetic risk, may be required. Probable 
explanations for deferring are that planned treatment (mastectomy) was based on 
predicted risk and family history was unestablished before diagnosis. Furthermore, 
relevance of testing is identified as the factors that pertain to the participants who 
deferred testing.  An earlier study (Schlich-Bakker et al., 2007) that investigated the 
reasons for withdrawal from genetic testing reports a higher proportion (30%), than 
this study (12%), of women declining or withdrawing. Corresponding with the factors, 
identified in this study, as relating to test deferral the Schlich-Bakker (2007) 
publication reports that immediate decliners do not consider the test to be relevant.   
Maximising survival is the fundamental theme, in this study, that influences uptake 
and participant support for early genetic testing.  Participant dialogue relates to 
responsibility for self and gaining certainty about cancer-risk, these themes are 
identified as foremost when patients choose to undertake early testing.  Similarly 
maximising survival, is considered by participants, to be more significant than any 
foreseen psychosocial distress that may be anticipated in response to genetic 
testing.  A recent literature review reports an overlap of cancer-specific and genetic 
psychosocial distresses when considering cancer genetic testing (Eijzenga et al., 
2014).  Results of a large randomised controlled trial investigating the psychosocial 
impact of early BRCA1/2 gene testing are currently awaited (Wevers et al., 2011a).   
 
Significantly, when an early test is undertaken, participant treatment decisions 
include risk-reducing prophylactic interventions.  Conversely a test taken after 
primary cancer treatment informs only risk-reduction. Hypothetical questions have 
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been used to explore early testing opinions where women undertook testing after 
primary cancer treatment, although it is understood that their responses are based 
on genetic test and breast cancer experiences. Regardless when their test was 
carried out these participants propose that early testing is ‘part of the package’ and 
integrated with diagnostic and cancer management procedures.  Correspondingly an 
Australian team identified that early testing should be incorporated with the routine 
clinical assessments (Meiser et al., 2012a). Furthermore women in this study identify 
that when early testing is an option it is ‘better to know at the start’ to avoid the need 
to ‘go back in’ for additional treatments. When participants who undertook testing 
after primary cancer treatment consider a hypothetical early test they indicate that 
‘not everyone will take it in’.  This is a less common opinion however associated with 
the view they describe that diagnosis may be overwhelming or that the relevance of 
early testing is not appreciated.  Correspondingly, although infrequently, participants 
advise caution; the offer should include choice and the opportunity to defer testing 
when primary cancer treatment ends.  A comparable proposal is found within an 
ongoing randomised controlled trial (Watts et al., 2012).  
 
The findings from this study, demonstrate patient support for an early BRCA1/2 test 
proposal, to inform treatment decisions.   
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10. CONCLUSIONS  
Early genetic testing can inform breast cancer treatment. This qualitative 
investigation provides new knowledge of the patient experience and acceptability.  
 
Why offer early genetic testing? 
BRCA1/2 mutations are by far the most common cause of hereditary breast cancer 
(Miki et al., 1994, Wooster et al., 1995).  Within a hereditary breast cancer population 
women who present with breast cancer, and a significant family history, are most 
likely have a fault in the highly penetrant BRCA1/2 genes (Eccles and Pichert, 2005). 
BRCA-related tumours are typically more aggressive and respond less predictably 
than sporadic cancers (Shuen and Foulkes, 2011). Studies indicate that early 
knowledge of BRCA1/2 status brings significant benefit; treatment decisions can be 
tailored to incorporate genetic status and the most clinically appropriate interventions 
(Trainer et al., 2010a, Wevers et al., 2014). For those women with a BRCA1/2 
mutation extensive interventions that include risk-reduction significantly improve 
prognosis (Metcalfe et al., 2014). 
 
Why do women seek early breast cancer genetic information? 
Women, participating in this small investigative study, indicate that maximising 
survival is fundamental when high-risk breast cancer is diagnosed. Correspondingly, 
this theme is associated with justifications for pursuing early BRCA1/2 testing.  
Significantly these women identify a responsibility for obtaining genetic information to 
afford self-protection.  They recognise that genetic information, obtained close to 
diagnosis, can inform treatment and risk-reducing interventions.  Furthermore, 
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participants identify that preserving length and quality of life affords family-protection.  
This factor motivates women to seek early genetic information, particularly when 
children are dependant.  The provision of genetic information for the family is 
acknowledged as an incentive for undertaking early testing however maximising 
survival, their main concern, has the greatest significance. 
 
In this study coping style, age, family cancer experience and cancer knowledge are 
identified as factors that influence why women seek genetic information (see Figure 
19: Coping Style & Genetic Testing). Most significantly coping style is understood to 
affect whether women, in this study, request the test. While women are recognised 
as alternating between coping styles, throughout their cancer journey, an information 
seeking style is associated with those who request early genetic testing.  
Conversely, women identified as adopting an avoiding style are less likely to actively 
seek genetic information.  However they reveal ready acceptance of a proposal for 
testing.  Clinical practice should account for these differences and provide equality of 
access to early genetic testing. 
 
Figure 19: Coping Style & Genetic Testing 
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While women commonly state that BRCA1/2 genetic information, and the associated 
cancer-risk implications, is not something they choose to seek they recognise that 
genetic information brings ‘clarity’ to treatment decisions and the option for ‘tailored 
treatment’ makes early testing ‘a no brainer’. Cancer diagnosis can be 
overwhelming.  Nevertheless participants support obtaining genetic information close 
to breast cancer diagnosis and indicate that these benefits outweigh any perceived 
burden.  
 
The patient experience: psychosocial burden? 
The genetic test is predominantly undertaken, by women in this study, after primary 
breast cancer treatment. However in response to their experience participants favour 
early BRCA1/2 testing to inform treatment, for women with a high-risk hereditary 
breast cancer diagnosis.  Additionally participants indicate accentuated benefit when 
diagnosis and early testing occur at a young age.  Furthermore, it is anticipated that 
the recent NICE clinical guidelines will result in a higher number of women 
undertaking early genetic testing.  
 
Commonly, for participants, family history is established before diagnosis, 
correspondingly increased breast surveillance and relationships with the breast care 
team are established. Participants indicate that ‘growing-up’ with cancer increases 
knowledge and acceptance of genetic testing. In contrast, where high-risk tumour 
characteristics or diagnosis at a young age indicates genetic enquiry, coping style is 
identified as a significant factor in BRCA1/2 test patient acceptance and uptake.  
Correspondingly, for these women additional genetic counselling may be indicated.  
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Furthermore future research should explore treatment decisions and the genetic test 
experience for younger women with high risk tumour characteristics. 
 
Concerns about the test adding unnecessary burden are not validated by this 
investigation, although participants identify that early testing is not always 
appropriate. Furthermore participants acknowledge that there is ‘not really a good 
time’ to discuss BRCA1/2 testing. Uncommonly within the study population a test is 
deferred when early testing has an uncertain relevance for the patient. However, 
overwhelmingly participants recognise that early genetic results can substantially 
assist the significant health decisions that may be required close to diagnosis. 
Correspondingly at this time, women focus on maximising survival and subsequently, 
in this study, early genetic testing appears to be associated with lower levels of 
distress than predictive testing.   
 
Participants recommend that early testing is undertaken within an integrated 
package of cancer diagnostic and intervention planning. An invitation for early 
genetic testing should state the benefit of ‘tailored treatment’ and provide an option 
to defer testing, after primary cancer treatment has concluded. When testing is 
undertaken close to diagnosis, participants affirm that results are required urgently 
and should not delay primary cancer treatment.  Furthermore, participants propose 
that extensive interventions are ‘pencilled-in’ to ensure that resources are in-place 
and treatment is not delayed.  Although when considering service planning 
challenges, small patient numbers can be anticipated, to require extensive 
interventions that are indicated when a BRCA1/2 mutation is identified. Further work 
is required to develop clinical roles and pathways that facilitate adaptable and 
241 
supportive treatment planning. Additionally it would be prudent to enhance 
professional education to gain maximum benefit from Clinical Genetic Personalised 
Medicine techniques. 
 
Participants recommend that the early test proposal and genetic discussion will be 
most effective when delivered during a face-to-face consultation. In this study, the 
role of an interested and informed clinician has been identified as providing 
significant benefit to patients. Preference is indicated, by participants, for a Clinical 
Genetics specialist undertaking this role, although with training a member of the 
breast care multi-disciplinary team could adopt the role.   Supplementary written 
information is proposed by these women, to reinforce the discussion and aid the 
decision to undertake early genetic testing.  Research is indicated to develop tools 
that assist effective patient communication. Furthermore it would be prudent to 
explore healthcare opinion prior to expanding current clinical roles or further 
integrate Clinical Genetics within the Breast Care Multi-Disciplinary Team.  
  
Does genetic information impact treatment decisions? 
The result, and not timing of the test, has greatest impact on treatment decisions.  
Early establishment of BRCA1/2 status provides personalised cancer risk information 
that can inform treatment and risk-reduction decisions.  Furthermore genetic 
information has the potential to reinforce positive health behaviours, improving 
cancer-risk and prognosis.   
 
Within a hereditary breast cancer population when a BRCA mutation is identified 
participants report feeling unsurprised.  When this knowledge is available prior to 
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primary cancer treatment, participants identify that extensive surgery and 
prophylactic interventions can combined at the initial procedure with the aim of 
increasing prognosis and avoiding further interventions (summarised in Figure 20).  
Furthermore, where appropriate, surgery can incorporate immediate breast 
reconstruction to ‘put you back together’. Participants regard extensive interventions 
as offering the greatest risk-reduction, while reducing the personal and family impact 
of cancer and interventions. In the presence of a BRCA1/2 mutation coping style is 
understood to influence the decision process, but not the decision.  
 
Figure 20: Response when a BRCA Mutation is Identified 
 
Most commonly within the study population no high-risk BRCA1/2 mutation is 
identified; this finding is representative of a hereditary breast cancer population. 
Correspondingly, for the majority, less extensive, breast-conserving procedures 
would be clinically indicated. Reassurance may be anticipated although typically 
women in this study population report a ‘false sense of security’ and disbelief.  This 
response is associated with less predictable treatment and risk-reduction decisions.   
It is understood that, for these women, the coping style adopted at the time of 
treatment-decision making significantly influences choice.  Furthermore where 
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disbelief endures treatment decision conflict can result (see Figure 21).  The clinical 
and psychosocial implications of a ‘false sense of security’, disbelief or worry about a 
false negative result should be fully investigated. This would assist the development 
of an appropriate clinical care approach for genetic and treatment-decision 
counselling.  
 
Figure 21: Responses in the Absence of a High Risk Mutation 
 
 
Clinical progression? 
Women in this small study who have undertaken genetic testing following a 
hereditary breast cancer diagnosis endorse and support the use of early genetic 
testing to provide BRCA1/2 status information that can assist treatment and risk-
reduction decision making. Participants overwhelmingly state that the benefit of early 
genetic testing and tailored treatment outweighs any inconvenience associated with 
the test and wait for results.   
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Regardless of when their test was carried out participants propose that ‘it makes 
sense’ to integrate testing with diagnostic and cancer management procedures and 
propose that testing should be ‘part of the package’.   Furthermore, the women in 
this study identify that it is ‘better to know BRCA status at the start’ to avoid the need 
to ‘go back’ for additional treatments (See Figure 22 for clinical recommendations).        
 
Figure 22: Clinical Recommendations 
 
 
 
 
Clinical integration should focus on developing early genetic testing protocols and 
that provides equality of access, regardless of coping style.  Hereditary breast 
cancer clinical pathways should ensure early access when high-risk breast cancer is 
diagnosed. Furthermore, access should not be impacted by a previously 
unestablished family history.  Future research should identify which roles within the 
extended breast care team are most appropriate for proposing and discussing the 
early genetic testing.  
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Adaptive cancer treatment planning systems will be required.  While early genetic 
testing will be indicated for only 5-10% of the total breast cancer population no more 
than 25% of these women should be anticipated as having a test that identifies a 
BRCA mutation.  Integrating adaptive systems will provide benefit to this small high 
risk group, who will subsequently benefit from personalised yet extensive 
interventions to maximise survival.     
 
Clinical adoption of early genetic testing to inform treatment for newly diagnosed 
hereditary breast cancer appears to be acceptable and feasible.  However the 
psychosocial implications of a ‘false sense of security’ or worry about a false 
negative result should be fully investigated to assist the development of an 
appropriate clinical care approach for genetic and treatment-decision counselling. 
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APPENDIX A. BREAST CANCER INCIDENCE 
Worldwide breast cancer is the most common female cancer (Ferlay et al., 2010, 
Servick, 2014).  Incidence has continued to rise since the 1970s.  In the United 
Kingdom (UK) breast cancer since 1991 has been the most frequently diagnosed  
female cancer and currently accounts for 30% of all cancer in UK women 
(CancerResearchUK, Feb 2011).  A woman in the general UK population carries a 1 
in 8 risk for developing breast cancer (CancerResearchUK, Feb 2011). 
 
UK and Scottish diagnosis rates for 2008 and 2011 are provided in Table 12. 
Significantly higher age-standardised rates were reported in 2011 for Scotland 
compared to England, Wales and Northern Ireland (CancerResearchUK, Feb 2011). 
Standardising diagnosis by age is appropriate when examining cancer rates because 
cancer diagnosis occurs more frequently in older age.  Higher age-standardised 
rates indicate that across all ages a higher percentage or incidence was reported for 
the Scottish population. Despite a higher incidence in Scotland (2011) breast cancer  
was not the most common cancer; lung cancer in Scotland overtook breast cancer 
for the first time since 1997 (CancerResearchUK, Feb 2011). 
 
Improving breast cancer outcomes with awareness and early diagnosis is a clinical 
priority for the UK (Richards, 2009) and Scottish Governments (NHSScotland, 2008, 
ScottishGovernment, 2012a).  
 
Table 12: UK Breast Cancer Diagnosis 
Year UK Scotland 
2008 47,693 4,232 
2011 49,936 5,578 
            Source (CancerResearchUK, Feb 2011) 
274 
Many scientific and health care advances have improved breast cancer detection 
and treatment since the 1970s furthermore  mortality has consistently fallen  since 
1989 (CancerResearchUK, 2014). As is the case for all cancers, survival rates for 
breast cancer in developed countries are more favourable than in the developing 
world (Ferlay et al., 2010, Servick, 2014).   
 
Regardless of survival rates death from breast cancer is still the most frequent cause 
of cancer death in women (Ferlay et al., 2010, Servick, 2014).  In Scotland the 
relative five-year survival rates for women diagnosed with breast cancer between 
2003 and 2007 reached 85.9% compared with only 65% twenty years earlier 
(NHSScotland, 2009, ScottishCancerRegistry, 2010) .  These improvements are 
mirrored in England; five-year relative survival rates reached 85.1% for women 
diagnosed with breast cancer in 2005-2009 compared with only 52% thirty years 
earlier (UK, Feb 2011, CancerResearchUK, 2013).  Despite survival rate 
improvements breast cancer remains the single most common cause of death 
among women aged 25-49 in the UK (CancerResearchUK, 2013).   
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APPENDIX B. BREAST CANCER SCREENING & DIAGNOSIS 
The Forrest Committee advised that a national breast screening programme should 
be introduced with the aim of reducing breast cancer mortality by 25% by the year 
2000 (Forrest, 1987). National Health Service Breast Screening Programme 
(NHSBSP) was initiated in 1988. The Scottish Breast Screening Programme 
(SBSP)69 was fully operational from 1991, with the first round of screening completed 
by 1994. 
 
Breast Screening Programmes aim to detect early breast cancer using 
mammograms and recommend for women: 
 in the general population three-yearly mammograms from the age of 50-70   
 with a moderate to high risk family history annual mammograms before age 
40 and / or Magnetic Resonance Imaging (MRI) screening via a Family 
History Breast Cancer Clinic (FHBCC).   
 
Patients presenting to their GP with breast symptoms such as a lump, skin puckering 
or nipple discharge will be referred to an NHS symptomatic breast clinic (SIGN, 
2005).  Breast Clinics70 aim to see patients within 2 weeks of receiving a referral 
(BreastCancerCare, 2014) and provide rapid assessment of symptoms and results 
by utilising the full range of breast investigation / diagnostic services including 
                                            
69 The Scottish Breast Screening Programme  invites all women aged 50 to 70 for mammogram 
screening approximately every 3 years: mammograms are the most effective method for detecting 
breast cancer in post-menopausal women with 8 out of 10 breast cancers being found in women over 
the age of 50NHSINFORM. Breast Screening [Online]. NHS Inform. Available: 
http://www.nhsinform.co.uk/Screening/breast..  Women aged over 70 years are not invited to attend 
however they remain at risk of developing breast cancer and can choose to attend for screening every 
3 years.  
 
70 Women with breast symptoms are referred to the NHS Tayside One Stop Breast Clinic. 
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specialist breast care teams, mammography, ultrasound and biopsy.  Results are 
usually available on the same day or within a day or two, however biopsy results 
may take up to 14 days (MacMillan, 2011).  
 
Breast cancer diagnosis and treatment planning is a multi-disciplinary activity 
requiring input from radiography, pathology, surgery, oncology and genetics services 
71 (NICE, 2009, SIGN, 2013).     
  
                                            
71 NHS Tayside has a core team of Breast Specialist Doctors, Breast Care Nurses, Radiographers 
and Radiologists and it is highly likely that patients attending any of the three clinics would see the 
same Health Care Professionals. 
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APPENDIX C: BRCA-RELATED BREAST CANCER 
CHARACTERISTICS 
All tumours are fundamentally unique as each evolves from a single genetic heritage 
however BRCA-related tumours have a common cellular repair mechanism defect 
(Shuen and Foulkes, 2011).  
 
Patients with a family history of breast cancer have a greater occurrence of bilateral 
breast cancer, lymph node involvement and abnormal looking cells, fast growing, 
aggressive or high grade poorly differentiated tumours (Veronesi et al., 2005).  
BRCA1 related breast cancer typically presents at a younger age and higher grade 
(Nilsson et al., 2014, Marcus et al., 1996, Lakhani, 1999, Stratton, 1997) and is more 
aggressive than a non-BRCA related cancer (Shuen and Foulkes, 2011).  
 
Recurrence is similarly higher.  Within 12 years of BRCA1/2 related breast cancer 
diagnosis and following breast conserving surgery and radiotherapy the risk of 
developing a new tumour in the same breast is reported to be 49% and in the 
contralateral breast 42% (Haffty, 2002).  The results of a  study presented in 2010 to 
the European Breast Cancer Consortium (Pierce et al., 2010) compared breast 
cancer recurrence in patients with a BRCA1/2 mutation following  breast conserving 
surgery and mastectomy: while local recurrence (same breast) was higher in the 
women treated with BC surgery contralateral recurrence occurred in around 40% of 
patients regardless of surgical technique.   
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APPENDIX D: BREAST CANCER TREATMENTS 
Treatment for breast cancer has progressed significant in the last 20 years.  Prior to 
this time treatment involved surgical procedures, radiotherapy and / or 
chemotherapy; the development of hormone and targeted therapies have improved 
breast cancer treatment (NHSScotland, 2008, SIGN, 2013).  
 
Cancer grading observes cell structure, rate of growth and spread, including lymph 
node involvement and hormone receptor status:   
 Low grade cells are slow growing, look similar to normal cells and are less 
likely to spread while high grade cells look abnormal and grow or spread 
aggressively 
 ER, PR and HER2 receptor status indicate cell sensitivity to oestrogen, 
progesterone and human epidermal growth factor hormones. 
 
Surgery 
Surgery remains the first-line and most effective treatment to remove cancer cells / 
tumour (Evans et al., 2013).  Surgical options: 
 Breast-conserving surgery or localised removal of tumour and / or any 
involved lymph nodes  (Haffty, 2002, Euhus, 2011) 
 Mastectomy with or without reconstruction (Evans et al., 2005) 
 Chemotherapy may be recommended prior to surgery for specific 
classifications of breast cancer. 
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Chemotherapy 
Chemotherapy impairs cell division.  The use of cytotoxic agents damage DNA and 
is a second-line treatment which is given before or after primary treatment:  
 Neoadjuvant chemotherapy aims to reduce the size of a large tumour prior 
to surgery 
 Adjuvant chemotherapy aims to remove any remaining cancer cells 
following surgery and / or radiotherapy. 
Treatment for breast cancer uses poly-chemotherapy regimens (EBCTCG, 1998, 
Mariotto et al., 2002, Mariotto et al., 2003, EBCTCG, 2012)  or chemo-endocrine 
therapy (chemotherapy combined with hormonal therapy) (EBCTCG, 2005a, SIGN, 
2013).  The duration of chemotherapy treatments ranges from 3 to 10 months 
depending upon choice of regimen (SIGN, 2013). 
 
Radiotherapy 
Radiotherapy uses beams of radiation to kill cancer cells and / or stop them from 
multiplying.  Post-surgery radiotherapy is a second-line treatment to remove any 
remaining cancer cells (Pierce et al., 2005, Pierce, 2000, Pierce et al., 2006).  The 
10 year international randomised trial EORTC reported enhanced local control but 
not improved survival rates for participants who received a radiotherapy boost dose, 
these results are not specific for BRCA-related breast cancer however the largest 
improvement was seen in patients aged below 40 years old  (Bartelink et al., 2007). 
 
Adjuvant therapies 
Advances in molecular medicine have seen the development of treatments that 
target intra-cellular receptors.  Tamoxifen, the first targeted breast cancer treatment 
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was initially tested in clinical trials in 1971 (Cole et al., 1971).  Today it is  the most 
widely used hormone therapy targeting ER positive breast cancer (Criscitiello et al., 
2010).  
   
SERMs (NationalCancerInstitute, 2012) including Tamoxifen and LHRH agonists 
(SIGN, 2013) including Goserelin can now being used as an adjuvant in highly 
specific, targeted manner however this relies upon the confirmed presence of 
specific biomarkers and gene status (EBCTCG, 2011).  
 
Advances in genetics (Sotiriou et al., 2003), oncology (Criscitiello et al., 2010) and 
clinical pathology (Rubinstein, 2008, Da Silva and Lakhani, 2010)  have resulted in 
refined tumour specific adjuvant breast cancer treatments. ER, PR and HER2 status 
are clinical indicators to the sensitivity of the tumour tissue to classifications of 
targeted treatments (Criscitiello et al., 2010, Rubinstein, 2008). Targeted treatments 
include: 
 hormone therapies SERMs and LHRH agonists (tamoxifen, goserelin) 
 AIs (anastrazole, letrazole, exemestane) 
 PARP inhibitors (olaparib) (Peasland et al., 2011) 
 biologic therapies / monoclonal antibodies (traztuzumab)  
 chemotherapies  
(MacMillan, 2013, SIGN, 2013, Euhus, 2011, NICE, 2013c, Farmer et al., 2005).   
 
Clinical management using adjuvant targeted treatment is complex; choice of 
agent/s depend upon tumour staging, lymph node involvement, menopausal status 
and molecular classification however resistance may develop following treatment 
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(Criscitiello et al., 2010, EBCTCG, 2011, EBCTCG, 2005a).   Online calculators such 
as Adjuvant! Online (Adjuvant!, 2003-2011) and National Clinical Guidelines are 
available to assist clinicians in their choice of adjuvant targeted treatment.  Table 13 
summarises SIGN and NICE clinical guidance (NICE, 2013b, SIGN, 2013, NICE, 
2013c), and is supplemented by data relating to triple negative receptor targeted 
treatment with Tamoxifen (Euhus, 2011).   
 
Table 13: Molecular Classification and Targeted Treatment 
Classification Status Endocrine Biological 
ER+ve 
Post-menopausal 
SERM: Tamoxifen 
AI: anastrozole or letrozole 
N/A 
ER+ve  
Pre-menopausal 
LHRH agonist: goserelin N/A 
ER –ve * SERM (Tamoxifen) N/A 
PR+ve 
 
SERM: Tamoxifen 
AI: anastrozole or letrozole 
N/A 
ER+ve  
Pre-menopausal 
LHRH agonist: goserelin N/A 
PR-ve * SERM (Tamoxifen) N/A 
HER2+ve N/A 
Trastuzumab 
(Herceptin) 
HER2-ve * SERM (Tamoxifen) 
Bevacizumab 
(Avastin) 
*Data shows improved survival irrespective of receptor status  
NA = not applicable for receptor, no guidance, no current licenced treatment. 
 
Sources (Foulkes et al., 2002, Cappelletti et al., 2003, Litwiniuk et al., 2008). 
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APPENDIX E: BRCA-RELATED BREAST CANCER TREATMENT 
Surgery 
Surgical options include breast conserving therapy (BCT), unilateral mastectomy or 
unilateral mastectomy with contralateral prophylactic or risk reducing mastectomy 
(CRRM).  For the majority of women with a diagnosis of breast cancer the treatment 
of choice is breast conserving surgery followed by radiotherapy (SIGN, 2013, NICE, 
2009, EBCTCG, 2005b).  Due to an approximately 40% risk of breast cancer 
recurrence within 10 years (Metcalfe et al., 2004) it is proposed that for women with 
a BRCA1/2 mutation CRRM is the most appropriate surgical intervention, however 
the procedure may be delayed if appropriate screening and chemo-prevention are 
initiated (Schwartz et al., 2008).  Furthermore reconstruction, incorporated with 
primary treatment is increasingly considered by surgeons and patients (Metcalfe et 
al., 2011, Heemskerk-Gerritsen et al., 2014) 
 
While the authors of the meta-analysis (Valachis et al., 2014) conclude that BCT is  a 
safe and appropriate treatment the two most recently published large scale studies 
which show improved survival following CRRM were not included in the analysis 
(Evans et al., 2013, Metcalfe et al., 2014).    Each of the three (Heemskerk-Gerritsen 
et al., 2014, Metcalfe et al., 2014, Evans et al., 2013) recent large studies that have 
been discussed propose that further large scale research is required to fully establish 
surgical protocols for BRCA related primary breast cancer. 
 
Bilateral mastectomy is supported in a study published in 2009 that investigated 
whether BCT is a safe option for BRCA-related breast cancer from the perspective of 
ipsilateral and contralateral recurrence. The authors reported a higher rate of 
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ipsilateral and contralateral recurrence in the BRCA-related breast cancer group and 
cautioned the use of BCT for BRCA-related breast cancer (Garcia-Etienne et al., 
2009); follow-up was for 4 years however patient numbers were relatively small with 
54 BRCA1/2 and 162 sporadic breast cancers.  Results from large studies report the 
average time for recurrence between 2.8 (Dent et al., 2007) and 5.7 years (Metcalfe 
et al., 2011). 
 
A recent meta-analysis proposes 3 main questions that should be answered to 
ensure that clinicians and patients make an informed surgical decision, (Valachis et 
al., 2014) management is summarised below in Table 14.  
 
Table 14: Surgical Management of Breast Cancer in BRCA-mutation carriers 
Question Meta-Analysis Findings / Conclusions 
Is the breast conserving therapy 
(BCT) option worse than unilateral 
mastectomy? 
 BCT does not increase risk for ipsilateral recurrence in 
patients with BRCA mutation compared with non-
mutation carriers  
 Radiotherapy is at least as effective as in non-carriers   
 Studies with long follow-up report increased recurrence; 
may relate to higher risk of BRCA mutation carriers 
developing new primary cancers i.e. mutation-related 
risk continues to affect residual breast tissue 
 Comparable recurrence and similar survival outcomes 
between carriers and non-carriers. 
Does bilateral mastectomy offer 
some additional advantages 
compared to BCT or unilateral 
mastectomy? 
 No survival difference found however relatively short 
follow-up  
 3 of the 23 studies presented survival data 
 Prospective RCT needed to provide definitive answer. 
Are there any risk factors that 
determine subgroups of patients 
that will gain more benefit with more 
aggressive surgical management? 
 BRCA mutation carriers have 3.5 fold increased risk for 
contralateral recurrence (compared with non-carriers).  
CRRM will prevent increased risk 
 BRCA1-mutation carriers had higher risk for 
contralateral breast cancer than BRCA2 carriers 
 Adjuvant chemotherapy declined 
 Tamoxifen treatment declined 
 Oophorectomy declined 
 Younger women 
 Tamoxifen or oophorectomy obtain stronger protective 
effect in BRCA2-mutation carriers compared to BRCA1-
mutation carriers (may be related to high incidence of 
BRCA-1 triple negative tumours). 
Source / Adapted from (Valachis et al., 2014) 
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In concluding the authors state that based on current evidence breast-conserving 
surgery is a reasonable option for BRCA-mutation carriers since it does not appear 
to increase ipsilateral recurrence however until clinical guidelines are available for 
the surgical management for breast cancer in BRCA1/2 mutation carriers 
individualised consultations and decision-making should include review and 
discussion  of: 
 Current evidence of the oncological safety of BCT 
 3.5-fold increased risk for contralateral recurrence in BRCA mutation carriers 
 Psychosocial aspects of procedures 
 Individual factors that alter risks of ipsilateral recurrence or contralateral 
breast cancer: tamoxifen, oophorectomy, chemotherapy  
Source / Adapted from (Valachis et al., 2014)    
  
Studies show that the decision for a woman with a BRCA mutation to undertake Risk 
Reducing Mastectomy (RRM) is influenced by numerous factors including having 
children (Lodder et al., 2002), previous breast cancer (van Dijk et al., 2008), previous 
mastectomy (van Dijk et al., 2003), family history (Metcalfe et al., 2008).  One study 
investigated how timing of RRM and reports that four groups of women with BRCA 
mutation were reported to need less time to decide to undergo RRM: under 50, those 
with a mother who had breast cancer, previous breast cancer and women who have 
undertaken mastectomy for breast cancer (van Driel et al., 2013). 
 
Chemotherapy 
Narod et al (Narod et al., 2013) summarise results of a study by Goodwin et al 
(Goodwin et al., 2012):  both papers state that women with a BRCA1/2 genetic 
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mutation when treated with chemotherapy have better survival than those not 
receiving chemotherapy. A limitation of the Goodwin paper is that chemotherapy 
regimens studied were those from 1995-2000 however in concluding Goodwin 
recommends that all women with invasive breast cancer and a BRCA1 mutation 
should be considered to be candidates for chemotherapy, particularly newer 
regimens. Similarly Euhus (2011) identifies BRCA-mutation status as an emerging 
predictive marker, that can be used in planning targeted treatment in a similar way  
to hormone receptor status (Euhus, 2011).   
 
An early clinical study conveys enhanced response to chemotherapy in BRCA1/2 
related breast cancer (Chappuis et al., 2002) and suggests that this may be as a 
result of the interaction of chemotherapy with the cellular functions of the BRCA 
proteins: DNA repair and cell death.  The authors question, whether these hereditary 
cancers are more sensitive to chemotherapy than sporadic breast cancers.  They 
conclude by proposing further large scale research to examine the efficacy of 
adjuvant chemotherapy and hormone therapy in BRCA1/2 related breast cancers.  
A study published in 2004 that examines the conflicting evidence regarding the 
outcome of hereditary cancers compared to sporadic breast cancers identified that 
BRCA1 patients received chemotherapy more frequently than patients who did not 
have a BRCA1 mutation (El-Tamer et al., 2004).  This related to a Stage 2 or higher 
tumours with nodal involvement at diagnosis, notably this presentation was reported 
in over 50% of BRCA1 patients in the study.  The study goes on to report in-vitro 
evidence for BRCA1 mutation-related tumour sensitivity and positive responses to 
doxorubicin and cisplatin but not to paclitaxel.   
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A small Dutch study (Hubert et al., 2009) proposes that chemo-resistance occurs in 
approximately a 1/3 of BRCA1 associated tumours.  They found 1/3 of BRCA1 
carriers did not respond to chemotherapy and 4/15 died within 5 years of diagnosis, 
despite higher clinical and pathological response rates to neo-adjuvant 
chemotherapy among the BRCA1 carriers than the BRCA2 carriers.   They conclude 
that new, effective chemotherapeutic agents, possibly platinum compounds, and the 
discovery of new molecular targets are required to treat these aggressive tumours.   
The authors state that results from recent clinical trials show promising results for the 
treatment of triple negative breast cancer with combined chemotherapy regimens 
using anthracyclines or taxanes and targeted therapies, for example PARP 
inhibitors.    
 
Knowledge of BRCA-mutation status before starting chemotherapy impacts choice of 
agent or agents and regimen.  Chemotherapy agents from the classes of 
anthracyclines, taxanes and clyclophosphamides are frequently used in the 
treatment of breast cancer.  Figure 23 summarises the five main classes of 
chemotherapy and BRCA-related breast cancer responses.   
 
A retrospective review of BRCA-related breast cancer responses to Neoadjuvant 
chemotherapy reported an 83% pathologic complete response to the platinum agent 
cisplatin compared with 15% response to the comparator chemotherapy (Byrski et 
al., 2010).  A later Phase II trial demonstrated high platinum agent (cisplatin) activity 
in BRCA-related breast cancer and reported that the agent is generally well tolerated 
(Byrski et al., 2012).   
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Figure 23: Chemotherapy Agents 
 
Sources / Adapted from (Chappuis, Goffin et al. 2002, Hubert, Mali et al. 2009(Euhus, 2011, 
Peters et al., 2000).  
 
Platinum agents exploit DNA repair mechanisms that are absent in BRCA-related 
cancer, consequently BRCA1/2 deficient cells are highly sensitive to platinum 
chemotherapy.  The results from Byrski (2012) are promising however scientific 
comment commands data from large scale prospective trials before a definitive 
BRCA targeted chemotherapy regimen can be recommended (Turner and Tutt, 
2012). 
 
Anthracyclines inhibit DNA production 
BRCA1 related breast cancer response is similar or greater than sporadic 
breast cancer 
BRCA2 related tumour response is variable 
Taxanes interfere with cell division
BRCA1-related tumours have low response or resistance to docetaxel
Cyclophosphamide damages DNA
BRCA-mutated tumours should be sensitive to cyclophosphamide agents
Anti-metabolites
Interfer with cell growth and division 
Platinum agents damage DNA (e.g. cisplatin)
Similar alkylating DNA damaging action (to cyclophosphamide) 
Laboratory studies show BRCA1-tumour pathological responses of up to 90% 
to cisplatin
PARP inhibitors inhibit cellular DNA repair
Early clinical trials showing promising response rates of 50% in BRCA1 
breast-cancer patients and with only 20% in BRCA2 related breast cancer
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The use of standard chemotherapy agents in combination with platinum based 
chemotherapy are proposed as highly effective tailored breast cancer treatment for 
BRCA-related breast cancers (Euhus, 2011, Ribnikar et al., 2015). BRCA 1 and 
BRCA 2 are integral in double-strand (DNA) cellular repair.  It is now recommended 
that chemotherapy is considered for all women with BRCA associated breast cancer, 
including stage 1 tumours (Narod et al., 2013).  
 
Recently published national guidelines by NICE (Familial Breast Cancer) and SIGN  
(Primary Breast Cancer) advises that knowledge of genetic status at diagnosis will in 
the future be used to determine first-line chemotherapy (NICE, 2013b, SIGN, 2013).  
The SIGN guideline references the same three large international studies as the 
EBCTCG (2012) paper for which results relating chemo-sensitivity are awaited.  
 
Radiotherapy 
Radiotherapy as an adjunct to breast conserving surgery has been reported as 
having the same overall survival rate for women with a breast cancer diagnosed 
under the age of 40 when compared with mastectomy (Kroman et al., 2004).  Given 
the high number of younger women with BRCA-related breast cancer this finding 
could be used to inform treatment planning.  However women with BRCA-related 
breast cancer have increased sensitivity to radiation therapy (Formenti and Preston-
Martin, 2000) this is concerning because radiotherapy may be indicated in the 
development of secondary tumours (Cooper et al., 2013).  However a recent large 
population-based study (n=52,536) reassuringly reports that BRCA1/2 mutation 
carriers were not found to be more susceptible to the carcinogenic effect of radiation 
when compared with sporadic breast cancer (Bernstein et al., 2013). 
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Radiotherapy has previously been proposed as offering a protective effect following 
BRCA-related breast conserving  surgery however this effect may reduce over time 
(El-Tamer et al., 2004).   
 
One study that examined the pre-operative radiotherapy and reported higher rates of 
breast-preservation in BRCA1/2 related tumours that non-mutated tumours.  The 
results suggest that the disturbed repair processes related to BRCA1/2 tumours do 
radio-sensitivity however induction radiotherapy can be used to improve surgical 
preservation (Fourquet et al., 2009). 
 
A 13 year follow-up study reported no difference in breast cancer recurrence 
following BCT and radiotherapy in BRCA1/2 related tumours compared to sporadic 
breast cancers.  The authors propose that increased BRCA1/2 related radio-
sensitivity makes BCT a feasible treatment option (Kirova et al., 2010) 
 
A review of BRCA-related radiotherapy studies, published in 2015, concludes that 
increased in-vitro radio-sensitivity found in BRCA1/2 mutation carriers does not 
translate into higher complication rates after radiotherapy nor does it increase the 
risk of radiation-induced cancers (Bernier and Poortmans, 2015).  These and other 
authors propose the use of discussion, counselling and treatment algorithms to 
assist these patients with their treatment decision-making (Bernier and Poortmans, 
2015, Cooper et al., 2013).  
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Adjuvant therapies 
Advances in genetics (Sotiriou et al., 2003), oncology (Criscitiello et al., 2010) and 
clinical pathology (Rubinstein, 2008, Da Silva and Lakhani, 2010)  have resulted in 
refined tumour specific adjuvant breast cancer treatments. Endocrine therapy, like 
the previously discussed therapies needs additional consideration in the presence of 
a BRCA1/2 mutation (Cooper et al., 2013).  
 
Knowledge of tumour receptor status (ER, PR, HER-2) is required for targeted 
adjuvant endocrine therapy. This is of particular relevance when considering that 
around 80% of BRCA1 related breast cancer is triple negative (Lakhani et al., 2002). 
 
Age and menopausal status are key determinants for the role of endocrine therapy. 
For post-menopausal women the role is established however for younger pre-
menopausal BRCA mutation carriers the role is less clear (Cooper et al., 2013).  For 
young women the use of many endocrine therapies are cautioned or contraindicated 
because of the effect of these agents on the ovaries: return of ovarian function with 
the risk of pregnancy even in absence of menstruation and chemotherapy induced 
amenorrhoea (Smith et al., 2006a).   
 
Tamoxifen, a SERM, does not provide effective treatment or prophylaxis for a 
general population ER negative tumour.  However publications from the early 2000s 
propose the use of tamoxifen as an adjuvant in BRCA-related breast cancer 
irrespective of ER status (Foulkes et al., 2002, Cappelletti et al., 2003).  Foulkes 
(2002) proposes that tumours lacking ER and BRCA respond differently to only ER 
negative tumours. 
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Aromatase Inhibitors, AIs were developed as an alternative therapy for post-
menopausal breast cancer.  Resistance to endocrine therapy can acquire following 
prolonged therapy (Criscitiello et al., 2010).  AIs and Luteinizing-Hormone Releasing 
Hormone (LHRH) Agonists modulate oestrogen receptors. 
 
Combination therapy using AIs and LHRH have been proposed for younger women 
for whom tamoxifen is contraindicated (Partridge et al., Pagani et al., 2014). When 
endocrine therapies are considered ovarian suppression or ablation therapy, as an 
alternative to oophorectomy, will be relevant for younger women with a BRCA1/2 
mutation (Christinat et al., 2013).  
 
The development of new biological therapies that target cellular repair pathways, e.g. 
PARP and AKT pathway, is anticipated to bring novel treatments that will be target 
BRCA-related tumours72 (Smith et al., 2014).   
 
PARP inhibitors, the newest of these drugs are biological agents. The action of these 
agents is described as ‘synthetic lethality’ (Farmer et al., 2005).    The enzyme PARP 
is essential in the repair of single-strand DNA repair.  PARP inhibitors impact cellular 
repair and this action is pronounced in BRCA1/2 related tumours which replicate 
more quickly than normal cells (Shuen and Foulkes, 2011).  A representation of 
synthetic lethality that results from PARP inhibition in BRCA-related cancer is shown 
in Image 2. 
 
 
                                            
72 Similar to the development of the agent traztuzumab (Herceptin) that targets HER-2 positive 
cancers TISCHKOWITZ, M. D. & FOULKES, W. D. 2006. The basal phenotype of BRCA1-related 
breast cancer: past, present and future. Cell Cycle (Georgetown, Tex.), 5, 963-967. 
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Image 2: PARP Inhibition Synthetic Lethality 
 
Source AstraZeneca (Smith et al., 2014) 
 
Early PARP inhibitor studies report few adverse events, such as those associated 
with traditional chemotherapy agents. In 2014 the first PARP inhibitor (Olaparib) 
received EU approval, while approval for UK-wide NHS use is pending national 
clinical body appraisals (Arney, 2014).  
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APPENDIX F: QUALTIATIVE METHODOLOGIES 
Table 15: Qualitative Methodologies - Advantages & Disadvantages 
Method Advantage Disadvantage 
Questionnaire Mail delivery 
Quick for researcher 
Closed questions easy to 
analyse 
Potential to send to a large 
number of participants 
Large amount of data can be 
yielded  
 
Long development process, 
requiring pilot and validation 
Responses rarely contain 
detailed data 
Rejection rate (postal) high 
Open-ended questions 
detailed responses are not 
guaranteed Revisiting / 
probing is not an option 
Difficult to analyse open-
ended responses 
Closed questions yield lack of 
detail. 
Focus Groups Discussion of shared 
experiences 
Discussion of differing 
experiences 
Discussions may yield novel 
responses and greater depth 
Many attendees 1 session 
Public, difficult for sensitive 
topics 
Scheduling & location for 
session particularly when live 
far apart. 
Structured & Semi-
structured Interview 
Fixed questions 
Same information collected 
from all participants 
Focused question schedule 
Shorter interview 
(potentially) 
Larger number of 
participants 
Straight forward analysis re 
same questions 
administered 
Fixed questions - less able to 
adapt and be reflexive. 
 
In-depth Interview In depth personal account 
Explore in depth & detail 
private, sensitive issues can 
be explored 
Adaptable 
Schedule & location to suit 
participant – reflexive 
Smaller number of 
participants required 
Time consuming data 
collection 
Time consuming data 
analysis 
Participant could steer 
interview off track. 
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APPENDIX G: INTERVIEW GUIDE  
1. Could you start by telling me about your experiences with breast cancer? 
 breast cancer journey 
 previous experience of breast cancer (knowledge of hereditary cancer) 
 feelings at diagnosis 
 
2. Knowledge/context of genetic testing? 
 own understanding 
 reasons for having the test  
 other family members 
 timing and influencing factors  
 how was the process of taking the test 
 feelings after hearing the result (anything changed from diagnosis) 
 
3. Impact of genetic testing on diagnosis? 
 Did you feel that your genetic test result played a part in / influenced your 
experience of breast cancer? 
 How was finding out at diagnosis / afterwards (depending on personal 
experience)? 
 
4. Any other comments? 
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APPENDIX H: INVITATION LETTER 
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APPENDIX I: REPLY SLIP 
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APPENDIX J: REMINDER LETTER 
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APPENDIX K: INFORMATION SHEET 
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APPENDIX L: CONSENT FORM 
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APPENDIX M: HIGHLIGHTED TRANSCRIPTION EXTRACTS 
   
P3 
When I got my confirmed diagnosis after the biopsy the 
following week, there was a breast care nurse there and a 
surgeon and at that point I spoke about genetics and they 
said if I remember correctly that it would be looked at 
after all my sort of treatment.  At that point I hadn’t 
researched it in any great detail, or more the type of 
breast cancer. But at that time they were speaking about 
doing a lumpectomy and after a bit of research I realised 
that if it was genetic I would be more, it would be more 
suitable to have a double mastectomy 
 
P9 
it was kindae broadening the knowledge of what I had, as 
I say because mine, because we don’t have the gene mm 
(pause, tut) cause I kind of thought with x (sister) having 
it twice and me once and as I say hers were 2 primary 
breast cancers mmm I kind of expected there would be 
something, you know because of our grandmother 
Mmm 
and because of whatever, so and then when it’s come 
back as nothing because its left me with a thing just 
saying, I do think they have just not found it yet, the the, 
it’s at some point and hopefully whatever information 
you gather from us will help  
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APPENDIX N: CODED INTERVIEW TRANSCRIPTION & BRCA 
TEST THEME WORD DOCUMENT 
Coded Interview Transcription 
 
 
BRCA Test Word Document 
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APPENDIX O: SUPPORTING DATA & CODING MATRIX 
Supporting Data
 
 
BRCA Test Coding Matrix 
 
